var title_f7_16_7424="Z-track technique";
var content_f7_16_7424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Z-track technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 529px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_16_7424=[""].join("\n");
var outline_f7_16_7424=null;
var title_f7_16_7425="Calculator: Ranson criteria for pancreatitis prognosis";
var content_f7_16_7425=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"RansonCriteria_form\" name=\"RansonCriteria_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Ranson criteria for pancreatitis prognosis",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Criteria present at 0 hours:",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"RansonCriteria_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Age &gt;55 years old (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"RansonCriteria_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           WBC &gt;16,000/mm(3) (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"RansonCriteria_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Glucose &gt;200 mg/dL (11.1 mmol/L) (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"RansonCriteria_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           LDH &gt;350 U/L (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"RansonCriteria_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           AST &gt;250 U/L (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Criteria present at 48 hours:",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"RansonCriteria_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Hematocrit fall of 10% or greater (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"RansonCriteria_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           BUN rise of 5 mg/dL or more (1.8 mmol/L) despite fluids (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"RansonCriteria_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Serum Calcium &lt;8 mg/dL (2 mmol/L) (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"RansonCriteria_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           pO2 &lt;60 mmHg (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc10\" onclick=\"RansonCriteria_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Base deficit &gt;4 meq/L (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc11\" onclick=\"RansonCriteria_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Fluid sequestration &gt;6000 mL (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"       <tr>",
"        <td bgcolor=\"#eeeeee\" width=\"1%\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <span class=\"medCalcFontTitleBox\">",
"          Ranson Score Interpretation",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"        <tr id=\"rr1_1\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           0-2 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Mortality 0-3 percent",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_2\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           3-5 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Mortality 11-15 percent",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_3\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           6-11 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Mortality &gt;=40 percent",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       Mortality increases with an increasing score.",
"      </li>",
"      <li>",
"       Please see appropriate UpToDate topic reviews for further information.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Ranson JH, Rifkind KM, Turner JW. Prognostic signs and nonoperative peritoneal lavage in acute pancreatitis.",
"        <i>",
"         Surg Gyne Ob",
"        </i>",
"        . 143:209, 1976.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"RansonCriteria_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_16_7425=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function RansonCriteria_fx() {",
"with(document.RansonCriteria_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1.checked){",
"Score = Score + 1;",
"}",
"if (cc2.checked){",
"Score = Score + 1;",
"}",
"if (cc3.checked){",
"Score = Score + 1;",
"}",
"if (cc4.checked){",
"Score = Score + 1;",
"}",
"if (cc5.checked){",
"Score = Score + 1;",
"}",
"if (cc6.checked){",
"Score = Score + 1;",
"}",
"if (cc7.checked){",
"Score = Score + 1;",
"}",
"if (cc8.checked){",
"Score = Score + 1;",
"}",
"if (cc9.checked){",
"Score = Score + 1;",
"}",
"if (cc10.checked){",
"Score = Score + 1;",
"}",
"if (cc11.checked){",
"Score = Score + 1;",
"}",
"cctotal.value = Score;",
"",
"if (doCalc){",
"rrclr();",
"if ((Score >= 0) && (Score <= 2)){ document.getElementById('rr1_1').bgColor = '#cccccc';",
"}",
"if ((Score >= 3) && (Score <= 5)){ document.getElementById('rr1_2').bgColor = '#cccccc';",
"}",
"if ((Score >= 6) && (Score <= 11)){ document.getElementById('rr1_3').bgColor = '#cccccc';",
"}",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f7_16_7425=null;
var title_f7_16_7426="Stage IIIA NSCLC";
var content_f7_16_7426=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Stage IIIA NSCLC",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 464px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts a stage IIIA cancer. In stage IIIA cancer, the tumor has spread to lymph nodes in the middle of the chest or it has spread into the structures in the middle of the chest like the main windpipe (called the trachea) or the swallowing tube (called the esophagus).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original, Anne Greene.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_16_7426=[""].join("\n");
var outline_f7_16_7426=null;
var title_f7_16_7427="Histology nevoid melanoma";
var content_f7_16_7427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nevoid melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 258px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAECAXcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6hoNL2zTasoWikpaAF7UYpKWkIKKKSmMXik6UCkJA5PAoAXNFJnPI6UtAC0UlLQAoWjFHNN6kEE8dhSELilHvVK+1OysB/pt3DCfRmAJ/Csa68XWiHFtBNN6O+Ik/76bFaRpylsilFvY6bNV7i+tbfme5hjx/ecCuFvvGWjAs2rasX28fY7BWZcnsXH3v0FUk8faJaNtsdBmKddxVFP65NbRwlR/Zf9epqqE30Z3ket6c0zr9tg/2ctjI9avxSxzLvhkSRfVGBFeZP8T9wYJ4fZgvQNOv3f8Avk4qvH4u0e6n82azvdFn7XNo4YH/AHlHBH4VbwVTrH8mP6vPsetUlec6Z4/hedoUvoLsDjFzG1o5+hPyn9K62y8S6bcN5ck6283/ADzlYDPuD0I+hrGeHqQ3RnKlKO6NmihWDKGUgqehHejrWBAUUnSimApNJ3psjrGpaRlVR1LHArC1DxhoGn8XOp2+/wDuRtvY/gKqMJS0irjUW9joKTrXKHx3o5A2i7YnkAQHJHrQPGWmREPIJYUbn5sH9AeKv2FTsWqU3okdZSmsW18T6NcY8vUIQT2Y7f51qRTxTDdDIkg/2GBrNxkt0Q4uOjRLS1Vu5WhQSKGIHVQucipoZUmTdG4ZfalYRJTcClooEIOtAXLZJ/Cl7UZ9KAF7elHQdckd6MGkK5IOT/SkAZpOTQy8+1OzimAnfFGaOtAUZyc5oAVCd49KKVPvCipYmREZxyeKWijHFUUGKKKUUAJQxxS5pDQAnWkJHAzS1j6/rkOlLHGI2uLyU4it0+8x/oKqMXJ2Q4xcnZFvVNRg062M07qvovJLewArII1rWo8iRdKtG6ApvlcfQ8Cl0fTLme/Ooa0Q92BlIR9yHPQD1PvW7PPDbKXuJY4l65dgo/Wr0hpHVl6Q0WrMBPDVwigDXtS2jnb8mPyxVzde6T5fnSi7siwDysArxZ7nHBH8qR/FOhqxB1azyPSQGprbVdJ1aN4ba+tLpXBVkSQEkH2qn7R6zWnoD5t5L8DUz8wHPPelJwCR2rDt5bvTIzbG0nu4IgQkyMGYjHAYE9e2a888V+K9Q1++k03Td1pp8ZCTOrgvI3dcjgAd8GnSw8qsrLbuVToyqSsjc1z4iLYzz2tpEl/ecAR27fJD67n7n6VyF54l8Vamzx/aks7Y4+W3GDz3LHk0+GytrKzf7ELUyRvjfKTtUsOCQOta9hNHJbIs6RCTG3ci4w2O3ce1ehGFOlrGN/U60qUPhV/U5eDRLh5/OD3M0p4LtIwJP1q7D4Vjjt2m1IeUo53Pl3Jrp0mhkiiUIwI+Q5OWVu+agjura9tLrcDNCr4MbMM8cc+nNU69R7aDeIfQydL0rRZY0ZMlWzt3MASR1GOa1PsFop/dWsZKnILkt+lPSd7aKZDDGIeixrGAUGOoPU1UuWiljidEbyUBGG+VT9c8nrWbcpPVmLqyfUtW1raxKftdlblmU7p0Jx+Azke4qvcaPpzArMI44zzvjfpxxgdcVVuJN07xtFIoUZVh0BHoT35PFWxezKAsaGaNVDOQMbfQqexxTSlumSpTXUyJ9BhnHl2wmVuimX+I9cenpWRJoNzbf8erfvF4ZEO5QD1yOnrXZzS2j3OZI5pVgCGLLH52/vEdPxqMebe3LfKFlwQoVfmyD1I7itY15x32OiOIklqclo+p+IdHE32TVHAH3YnGV/Edq3j8SfE9tHtfT7GZguS/K/1rTiMNymL+GIsM75U6ccdfWsjXbO0hjAtJA8aNhs5yO+SafNSqytUgrminSqP3olmz+K2sRwk3+iQu2cZikIH61PB8a9LTT77+17d7C+hiZ4Y871mbHyge9UrGFY1Vfs6yvgEMCCCx9fQds1lax4YsZJHlWIu6sHwyj5cnqDxSdHDSdnG3ozGcaDdkrFCxs9W8Sqmo67f3KrOodEd2C5PbH41tweEvLEYt7e2lUfMWz/jVqwgltpRHcXN1cWwX5AfmIOR82fatCIy5OJUlk8wKGLEkpnOWP+FVOtJO0NEDxEo6R2OfuNKiVznasj87V6f5+lUrZb6G4c6RcMVJ+bzTvA+ma6W/tkFy9zZrgDHnIFJwT3H1rmC76ZeFGLiKViVkA+Xk/dPpVxm5x01Z34Vwqr3zd07UL9YzEZ1DH7qSxIyt644pssutCWOWD7PBInzMIEMRYe5U/wBKrWjm8vlgK5jQh1k6Mhx0B7Zrbt7e6kIkYeWIztYtyXJ7/lWL5Vq0jKuoU3ZJWJ9L+Il5ZSRw6rameEnaJQQHH17H9K7PTNY0rXUEtjdCG69M7XH1HeuCvdHaeQq0f2g7QxXPb37muTn0z7LN5kCtAVIPlN/nI/Cs3hqNb4NGczoUqvwaM+g7WZ33RzLtlTr6N7irAFeLaN4rvILlIVungkPIF6+6IY6gP1GfQiu/0/VNcuU8yC3spkK5ytyrA/TArhq4WVN6nFUpSg7M6rFKK50+ILi0CnWNMuLaM8GaMiRB9ccitu2u4LmJJLeVZI2GQy8g1hKDWrM2mix0oozSZqBBRjiiigAozRQKAFTO8UUL94UUmJkdFZOo6/YaeGa7uIUVfSQFj+HWuVvviJDvZNOtiyjpLNkL+Q5reFCpU+FG8KFSfwo9A61Ve/tIjiW5hjPo7gGvIbnxLLfSzG7uNTghc/vDaKoDccYBOcfjVQXOjsheG11WbacvFcPGob6NnOfzrrjgH9pm6wjS95/gexw6vYXErR291FK6feCMCV98envViW5RGjCsrFz69B614ob/AMNyGNreLU9LvG+VGnI8st6Fge/rxW3Hr1xHdRSr5hEagOvBH1HqKUsE1t+Jf1Fvb8T0nV9Si03T5bqT5ggOFBxuPpXn6eIItFZtRvo5LzW75TJDbKeIIz0JP8IPHvxVPxfr0QKO12HgcAiHvvz0PoOK5+zj8xpbq7ufMmmbc4bOTnpj2HpW2HwqULz6/wBWNqOEtC8uv9WNOTxX4ouTcSG6htMnPlwRglR0HzHJrGls5Jrvz7oy3U54aeYl2J9s9KuMi4ViwMectnqR7e1aaDZpiybxG7KM+Z8pKg/d+uK67xpfAkrmkuWivdRRl0O2gtHlunVSVB2EfMB9Kp32l2JzHbRuArBQ5Yq2eDvGOmK173z/ALKd1ypzGZvKGTgZ7/X0qG5nmJcI7JGxMbEqFyR1I9vepjKd9zn9tNvc5Ob4h6lZQ6z4flvLmdplRYJZMEqpyHIf06D8a1NGnSawgW3RVZOIwPlbkAMcHg49aoa5o8eoOkjlJDD84KquFU9F+verehrAZlhjfzHVSrq52/XkV0uNNQvFa9Sm4qOhqvcIkoVk3BAMnJBI9R6jk1YXCO0qOV+ZuPvZP09sVn3fmWjSW5hYKHxFIvOQR0Ht/hSxT7o/JBchj/CQrZGf8Bz71g43WhizSvL6O3SO4mcIqMFjMXON3TIPfmuhuLQaP4bkt5II0u5x5q3CqFVjxwfU9ePauPnSMwibfvkxhd3BHfJrt9O1ltT8NyWmpxO07RFfOijDhARgHHqK560eVJra+pnO6SOfjO6ImNQ2/cfMDcDnJGKgu3MAkitgrk4IJOM+uDipmgkttOiEXyrCx/fJx5hI7AH+fWozOxgM0EiyHABQ5UK3uPfrxVpLdCIZZBFayBY2liQZ3ABfoAM8471LaqZ7lIcMzNldu7AZuOAPXr+VQKkXm2sbZcgszbRleO/txVzS1SG/ivbhRJHFMJLeGP7zSEcDP6kmm7JMOgXUv2awt4bdcMVaOUMuSXU/dOehqSw1CGBZVu7d1ldt6zI5DJ0wP/re1WL0NqR1Cfyo5Lp33LGpwAMc/jyRn2rHaOSB2QLtJ2yOjN04/iOeO+PWpilJWe43qac8nkxF4JQHmiDqMq0ZycE4HX3NZlwDNpF1sEnmxxMWU8jAPJ9cdxUsEbLalIXTeGyixp1TPb0Gc80sWVtroRHAniZHbHMaZzwO/T9aa90qOjRJZmKLE0CM8DxovzHGzIGce2efzqK3JWUOUCRr87tnPGOOe9R6dGTpVvEJgryRbJCf7uTz/OlgZYfNMEheJflBlwV3AdQRz0ptasJaNl+XbDLNEgiSOVPlOOn+cmi0nhjUb2LNtwMDliDjg/y9qispoLkND5ZaPIDDOSdpyR/nrUkcUE8sFwIkjQDbsYj7pByuexwR+VQ1bRkvsKJ/KmaKbCrIDhN+VxnofqRUFyixxswYOkgz5Z6oc8/WlmctNIFRdqqAmRktjo3FNtrowuzsssttJgny8L5XryecZFNK2qKjJwd0U7ZYkLyQMzAkc42jPUfhWwXLIzsBviVS0gziQjoo/wA81FNPaXNswmimifYCFJ3rgHh+O/fFQwXtq0geOVpmPyllHyggg9D9acry1sVKo5FkSE3BZVVpQzNvZSMEdh3xmrsVzBeRn7TGrIg272+859fpyMVTkkZGN2ypGEBIH3jye+enWmyS+Y8StD5Z67xwG9B6fjWLjfUy5mtiI6faXETubdo42YqomTJYHuR2/Gs6LQrq1v8AzdLuFjKtjzLeQKw9RtrWhSRxuEsW3PzYT7uO3FS3IkNzGvkwRxzJ5gkycnHUH8e9aRqSjpe5arTSs9SXT/GWsaNIsGu20l1bEZ84LhwvqexrodM1ayQNf6JMJ9Pk+ae2X78R7sF7e4rkg32me58op8qhnRs9Oy4PHSqE1qbTy7rTriSyuRxlAcEnsRUSown0s/wDlhLy/L/gHsljqFrfRCS0njlU/wB1s1Z3V4PPealZXjeYMgkb5449jn6difyre0bxfqEF4ba31C21EgZFvO2yQj2J6n86554GSV4sl4WVrp6f18j1oc0tctZ+MbX5E1S2uNPlbgeamVP0YVrx63pkgyt/bEf9dAK5HSmt0YShKO6NIEUlQxXUEwzDNFJ/uODUu6osQOX74ooQ/OKKliZ4RDo6SXQ+13ebg4LgfO+SeM56CtO0hhtbp/LAumWTaMJyjZxjb3+vtVyYMFRTGzNjLdjxyOfr2pJLgJaxySRnzdqxGRRwxOCCSO3vXtupKWh3yrTluyI20Ei+bcxRwz+YVLlgB16fLwf6VB9njivGaFW3ByPMIwR9D3qxAyx2bwRwFEiP+qPVj1IJ+vfoafdzbo5XkADAAhEG7B7gkeuPwpKTTsOE2nYzbzSXms/tLQo8DscqzHIH9DXnusf2lorsdPlk8nO8xtyAPQe1emzTSSRqtsztFMnnM3bIyNpOOxGc1zuu25mjMbFTI4G4g7icDkgdjXXh6jTtI7sNXalaRwN/q7Xl/ZmMrlsZ7BT6V6FZqZk3AA+YuQp4GBx2rzW8ghtdX6xIGbEYYc/U16z4Ps4rmCP52ZdoUEngnqOK6MS4wgmjrxjUIpoj2h1aIbxLwCwX7oroBDaK0ST4dzyoddyluoPPSoNYtDZrGOSrMQwU4Jzz/n60+VoUt0uUDudquRuyRgHHFebOfOk0eVUlzK5RuykVw05R3VmDDYchcDkH29qpO8LxBJSCxAIiCYC5OMe3qauPsMkqytsEj4AC53kDn/PrTIh5d9FM32j7Ig3NhVYtwMZyR/8AWq46IxKbWk8kM7MB+8k2xpgBTgY3AjpyD+VOnt/LNr5sew/IDtbLtz3PcnFWpLmOScyRJOiSFlCOQxOOWOQe+ahjGbWPzXbdFLtYEEERleD9e2fWqu+orsW6mimu2dXy0gYEYJCMDwMemB+tV4UilE0kYj3jLIN3CHHIPQ9KWd0iifzz5f2iMN5eDzyMEEVUjRHWbyIwodTGFfn5hyTx1FXGOmgIJWMwZYzIil9o+TJRh0PuPY1taYksGmai9sGS7iVWWQyFd6twylAevXFZ+547a1ijgCpKFJ2uDk4Gfpk5/Klt2VjeQKPNjTEcbsufm3ZABHPTNEveViXqrEBMrrLHIhiQEMegz8vJx1BpunbYII4xJFHCSCXCkg8+gHqc1LCbdPlJjkn3qcBipZieOnbHfPUVYns4BJcyQMCjIFMisQxYZIGPXim2tmK/Qda2kVnMwHm7VYxRvJk7yQCOe2cjOat6eIYNQgmulRLeLLMRnaXA4ycnvxUW1dqTpFK25V8xZeT82RnnoRgZ/CmQPKUjQsgTy2ZcsASAem36Ac1m7y6gXtLaSR7qZbY+a8rOFDEq/GBz+FXoI1e2e6uwjTFGSQYxsOflH454NGlWnlWzAsyTTXAdnLZVQvzDHrzmrcsqXNhcXMErornjcAQcdP05/GuapK70BbnOqRFM4yiuuEIRgdoAHyjPWoYIStxcpGrBWtn2LzgDBwee/NNZCZ/lJGeZWIyDkE/Qd+ntV20ZY2WWUPI0alVXgAA9gfoB+ddD0RSdmU9OgjOm2sskTvJLGrxgjuN3HseKtW8G2SNllwHBeUSAEYAx9309x6U3TQ6W8luZGTyJGYM2cYboM9hQ7RBS0qyeQCUZExyc8rjrilJttlT0k0Wpvs72Uku1kmbaWfb0IbAbIP8AnOazWS4DRQO58lrcr5qp1frkY5PTt1zVjAVBEXfyTiNTDj5VB7jHvULGRkkieYJGcqMDDLjgHj+VEdCC3boFYGQyeYwVYwjYCjHGT68elDsFaONXVX2gNgA7B3A68/Wq1mwjnje4dDK6YUomSzA8k+h+vekiMqNJNLmOIHG/Zt3+3vxS5dRPXUszrtjEShYmdlw2R2HQf0qpM80S+faQjEmd4A5QkjJz6EelI/mKMeWkkjbRFuOQnfPPQH07Vas4rgWcikeQAA0hXBjB6YXnnr+lVstQLTFkt13sA+M5P8Qx/Oo4JIlLGLzZF2/NnI25Hb0qIbpi5YbnY5I6OR9B06dvSql5iBkAJZ5PlUAsBx61CjfQFqXlSKQvjIVwCyg52g+49alWAWcSvAwaONgqoxzjnB4Pr6+1UY3WG3iMYYbGCM5GQrHsfzxV26sWQCZDJhmLMQeCSMHqeeuaHo7NjZBdW/mXjzOhkTHEm/Abngf57VZ2SKpcHC5wAcYH1PYVDaSR+S1vIu9UUDO4t3/M9queYVkYhh8qHEYO0Hjipk3sSV9iX0IjudyzjKhioxu9RXM3elwSTvDNEDImVJxkmur8kNcpLMyxjI2ovOMgn8+DVbTwJkkmdQWkYiNXb5sDPOa0p1HBNrY6aFZ00+xgwaPPGVC/aVRcj5JG+X681Pc6JOsavJI7ANlcMHOc9x/jW2LgQRSvIPKBHucnHX9aYLlohE4ZUYtyCNxIHcjtT9tNvYHiZXukZLz30I3zaZaMqHG9FaNj+KkVMPE2qWgdVhuUwMhlumOPwYEGtzzEeziZSGic7jhf4s9xSpdLNA6FBKzZMbvCF+o59Kjmi/iiJ1YS+KP4st+BfG99qWsWmm39sxM24CbbgrhC3OOOcUU/wfBB/wAJHbSrDiXDfvANoOUPbNFeZjFBVPcVtDkrcvN7iM7CmQkMiqhGNrA5HH5Y5GKjWYJOI5nkCYwHZMjPYt6c4+tMYNES0sjKyn5pEGflPqAMdvek3cNBNcBQqEfKQpIzkEHt2xzXfY1GzNK0H7xXdkbcu8gbW6fkc9T0FWlJthsbYVkJfYhz14P6mooUhnQwHCS43DjHPOOD2/xqrZsYJzC2I/LZmeZ/u4I7H/PSnvoNEA2W6+WsjEwvkN1G4HoO2cGq2pnzoiQFiibsOnv7g8/pV+6KqsjFQu1gUIHyrkdz3BrIkzmVSpaFsNhenuOeorpp6u51Q1kmeR+L4I49TIjQkAcgnoTzXpHwj1GC8tpbV5GJxgeZ1GOmD9awLXRIdf1q+SWRbYRJll/iHHAp2jWlx4X8QpaSyBo5h5kP8O/HUH3FehWUatN0762PVr8tSDh1PW/FBjltRscebGylgeSAfSo7NoTY20IABdNoLEE9Txjv/wDXrO1C7W+YPGnO3bx29/aremQhbWJonUBiRMXOWHQfh2rx+XlppM8aStAdIsex5UmVgOm3jB+n1/nSx3c9vGsQt0mjaUJllzhSOTnvVVyJGMGxlkUmJCiYJPUE/l1qJojGIhbsIRFlHLkqQSeCPTPNNRT0Zkx9zassxW1SQEc7umM8dD39qhN1A1z5xMcK8JIN25gAOOMY60/zXkWKOLcYcsQzdGOT15zg9qimjleW4AWB42iDK+3A3k5/EVpFdJCIzE7rvkcXAaXYcPtBY44zgnj0qrJO0N8igkSMrxmHcQVXO3JP8j71anCyTKqyOjbV8sK2UYAcMB2Oc8VVeXfqCSrHsKIBJIrAh144J6jH8yMVrHzASC3WPUQbnKiHc7gcqV5AwfUA54rSjtRLDCJPmJDSAqSoZgGIO7jtUEyLEkouFKnoshXkLkZB9vcVoaLZz36soIgijUrAyNk9euD27e9RUnpzXC5k2Z86XzWhcqik7yMhiucbsd8Yq5b3MiTmEDa0hBJ3ZLgAgYJ6n+mKYJf36wK6yzEAzBHbjAIyR0x+Nbulw217Yy2k0oUHcCCp+52Ce/8AhU1JJK7Wgtirte4slgbbvCPFlsHOMEMRxzwR7Vn38y2js0jjdCQoZTyOBkjHp+ftVu4itoxFp8MsiLJEY2dlCsmRgMTnvx0rGtZ7i2aWCxf7RbxKq8xqSXIw4LdjnkUqau/IaszRkuDPCbaSKQJHEzRkcOCx4OfU8n6Vrasq21iba3cjy4kd5GIO8Hk9fQD9KzbKyWTUZZPtCCGx2hkBChpVAAz+OfyrTvlhn+2m2SVnuFV2DcrkA9PbORmom1dJeojn0d445j5jiByAsmGOcZ/AZq1bzJ58czxlgAoCPjkg/ljGT9aghQzoyOpiQsHMe4q28ZGMjgjjgVFBGz3E0cxlEMhyDJx24/HNbNJ3E9SxKiw6/eQSM2x0MyqM7fUE0jgAxXDSAyNJsPljgZHX3oT/AJDFrvTJaML8/GRgjFRXuVUPHGRGjmKVJGOWHUFSPShK7S8japun5EjWsaPKgG1ZMlSDgjnr/wDWpsEAhIZ8tIRgBscg4zn68flS3dyJ2k87zHVSGJjYAMMHC57U2BRNEqQopQRko4Y5VcY5I9OlC5ramTLDXAwqR7Aqrly3JHXOAeo6Co/trC7LpL824lQV3AMe4HT8elCXUEU8L28agJGVHIYnsxbuATg+34UOkiQxTxASFQSdx2lT1wMD5h3pWS6CRq2l3G927hGcyYypPG4cnnp+FUNRMwhLQiQRkMvls4BXLZ3EfyqFLXzzGVRwke15Hi+bDZ+6Ae3qakutscPnFTKhfDK7ZOcnAI78fyqFFKWgPYSDzWOVcoVXcsh4wO2AeOxyatX7GSFJZ1M0zEgxZ6JnPAqjFF5m1QZWRxlR1wvQD2BxT5g0N6heQJNL/qzuGQB/CR+lU0uYErjtPCRq3DJPK29FYE/KR3BNWhILiCMSFThvkJ5CdenvkVVVInkG2JHeIMQcEnOO5706MO9kzSOIJWbbgr8wOcjPbOKmWruN6lgIZo9mMrnDqFKkDHJGfWkKoJF2K++MAMQ33frUYWWSGP8A0k4kOSwU8sPUj+VXtPkhjR0uA48o7m2jg+x9amWgWuV9QMaRTRxJtuLg7Vxxx3b8BTVaOGEGJUKhQSxXqOn1ploy3V/c3EgKny9qdDwT3FOGVjQ7CdvAAUDbnqfoRTtZWY5aLlK11JcpftAGjNoyg52AkkkADk9O9aImglnQKUZVUqxUcg+/fmqckCuZmjUxsvGDgZGeqntRZTt5sojCoNwjJI3Z9vce/vRyprQzbHNGYVkRZriMA4JVhjIzjn+tWHy6JJvklmj+dNx4HQc4696hm4Zrcxqu1sKxByAc96lhiIjhlg8uV/umPcQQP6mk+479Dd8KMW8RW4fDFd2CP4SUYn6UVW8GtjxRHErklGYOrg5AKMRg/hRXm4tWmvQyqbmHNMqMY1lZQ2QmUPT+WaWBFkJkIYRj5JEIxgDd2POMHNQy77WESyO88OdqSBRj2G73PP4UrtKu2VFjVFBaQqu4jI+Xj0OP6V6dtNDcthysTzSPFlQdrDgJgY9+oqtNbwSlSjEMcDDr3zkEjpilwQkYBKwsxDRqvB46sT9Ov0pbeRI7uVml2/OThUwDxzn1+tSrrVFIn1H5YBui2SDah28jZ2J+hrCl2iQ/Oko5yR39RW3pQlupkMMzhN4jlZlCgL/Dn/69Ur2IPJIiKAHO4uMDoTyMdsjP41rTai+Vm9J62ZzWi2xk8cXiCPZH9m3YA64P/wCqr3jO0ju/DtleB9t5ApliXvlfvD8RmrHhXf8A8JpqHGSdPd1GOSQwq7FPa/2Xcybo2uyDM0bjlhn7qj6Zrec2qia6WOqpO1RPtYztDkW4sYbncPJlQFjj5iPetjQ5JGE9rb7Rv+YbuOO/HWue8Nqsdxc2MDAIqieHPQRsM/ocj8K6LRjFbpLcFZJCFKMCcHP17VFe2pGISsyUzeRdvHJab5inJyR09MdM/rUcsTfaomtXl2tKM+WT0OOG9ea1J3Z44mVEkl2sqsq4OAPu/Xvx6VkW+I5YLpJpzLOmx8quB8/XGPw9a54u+pwskdpmjY2sJEqEb0wEyu7n5fUD86r3DwySwwxxF4iT5sb8FjkjoOnHQ1YaVFIcjJfdKSPXp83fA9KqRqiyvcySFs42pAMFupOfbANaRXURbGkq2bmzVmeNlYQh9pUjsfUD1HWqZt9jyETRxxMCrqF7YHA64PSrVrcvbEmBd/mKSsyMWIXsMf3sEcVLqsSrIQI4wjjdu6dAOT3B/wAKSlJSswKUiCAM85ZAsihWBDls8MpHtxT9GuZNM1GFzJDNBJ8uW/u8A7W9faiePyoInb5pfu8/KWH94dsY70l1KixM1tHG8EpB8sfxNgZCngA8Hr1qviVu4i34ntNkqmBXVHUqip8uM8ndjrVZYWhEciEOrSiJSpO8HB5J+uOfSrGm+WGayumM8LxbXhZizphuGXPpnnNMNjNaQzC1eOSBlG2eEMNy5649eTxUJ2XK3/wQE1KOV4omjHnhJDFcRKu0qByADjp7+1NsUkm14ra24lRgJdrtgONvfjqM5+oNTWt/PBLNBIPlcKoErbhzwB6574962NGuIdOWW7lMb6m6EIjZVS2BnFTKTirWFsjLuLeOx0qKZgk1ndlmY+WdyEEhVx6Z5yadbTXC6Tby3jDYjsqNCThlYfdI7/lxVjU9Ve52RGGCGMxGQuT8xGRnr0OT0qjoUkskMUCbjGpZ2DjKAZ42n/PWjVwvII+ZQkkht3EiRMYidiBycksN3SnWV0jQxzKs3HAaYYUZznGO9TalawQ39tNFlWcFmLcRkgZ49DVewzdgGK4R1lBlyueucYxW2jjcqxLeRlr7TltjsQgIxYngbscH3PenzoY5miliYjPlsofgk54z3pdX86K5gZvuiDIYnkYYEH9afqSuhmhjLTxxuHdgRuHfaM98ntUp3S/rqXU2Rn3FsLu+nt4wkbFGZSwOGKjv6dOo70WswLW1vDGSP9WRjBzznr25/SpYpQsyyoz7h2VRynvz7/mDUNvMqQIslwPNeJ23k5weAPatNbWMRbUQmWQpAwDsScjHI/iJ6jpyK1reBLrSngWc5aURhieVIOcgH1zjI9ax4rgRv5OGuFmVmVmHIO05GO2cf/WrT0RTHa3UC+VGsnlsH4ba54/mOv1qKt0r+glcWWF4JG2ghA8g3BtwwBgKB36/SqV5KWZBME8yXGN6kZX0Poc4wK6nVYc6bZLcBUVpdrnBXORlvwA4rnIR5CQu0ksiToxhifjZ1wxJ9Bj86zpy5tWOPvFee2uUgWCFpULY+cHYB09e3HSpWs4sSnzicpvErDBAJ5zUSyGaQxidmZcqpPO7Azkg1KJAA9sZtqNt2/ITz16981q7oryHQzBJihYucB+GwuD05+lSXQZSyCQPhzgsckH8v5elEKbrmFJ0SObqxzkt6cdKyry5uNQvRY6ckLTqdgbBYAZPP6/jSUbsqMeb0NU6hDpsO64uY/lGAjYO0+v+NZd7rM0sflWVrdPGx3EwQEkj3boB+Nadp4YEVxBDLFuuzn5pE3MpHUhfuqP1pniGCSBo7eS0juD0aR2k+T3OOPwog6fNpqwVSMXaKv6lO0vbmCMSyaTeW+wbfNeMFdv/AAHNX7HUILtVBMQLZBj35BOcjHoaytK02z1WcKkk1hJwGuF3eXIfRecr+NP1Tw5NZuQjNdMfmWaIjeB7HgN9DVyVNuzdmW5KT5ZqzNG+kkDFBKc8iRFH3sng+1Nt5y1vG6QETxy+SyMAN+f4h7Vi6VqcwvDp+pMI7hsmKfG0uvuD09x2rYvbORpy6zZUcN85AJ65474B61Ljye7IynHlL+owmK6jE+UWZBIUViu4gdvaoYk24ZWbzHzgZxknJ+o+tXry7W88NrIwD3NoypKMcrz94H0Pesyzk2uiGcmDf8+cEJ3x9Peso3cdehkjofBkzv4jtfPkInO7dHtOBhG/+tRSeE42XxZZuZEfd5nQc42Hv+VFebjLc6t2IqbnN22oLYXCyREzJGdsseBsaP8AiBX3yea1dZs7G3SxvNObyrC8BVMNny26lR/nHFYzyK4Ty4HmlAyUj+VSCMqD+tbFm8q+E2O3fJ9tzGABmIlcnGf8816U1azOl9yokMQRo1YMsOZIpDyG5H3fWnObO5aFZ5YI0j6eZyM89cc88frQ3myKrxiHyi2HD/Lljztx271VgVY7hJpyUmAJIAHHIxj1xwKEr6lGnFLHBbOks8Md0kgULCfkMPY/rnGe1U7y2EMsaoUlUZxJt2h8knIqFJI1KM8+YJpCG4JKNgg59RjsPrUV9cTR2wS4VS0IMZYHnA/i/HriqjF82hdJPmE8OMLbVvFGqbwfstkkSE9A7MeP0FVrLQ5NYtAZRL5g3NJcjARWzwoPcAYH41iW88kukXVjEG8y9umuJ8k58pMKo498muolvLeHQUtIbiYQyRSxouwjLAAZ9R7fnXRKMoO8d3+SX/Dm1ZtS03v+RzkubO1W8ijKtp8wtboMMExSH5G/BuPxrqtJAMF2jKoIwV5yqk9Qf8awNDmhOvyW2s+Z/Z2rQmylLk4B/hP1z0NSaXBdaNrj6JqaSC8tvkSVeVmjz8j/AIgciisr3i99/wDP7n+ZVRtpxfqdJD50kGy2T/SlDFRIcruAzlSfUGo4lGnSrczTSWsqDDKI/M357EfX0pkUzR3McroESR2OVY4UHqeOvHrUhaV5xIlxJK4QtE5KkuR1XH97g8Vy2e3Q4mRXqGC6XyniXlnfkjzDjPGeR9PrUaWzTToihonl5TcCGUDkFQeCM5H6U2BFuJJdQn8tpZH+RC20gADIPGR06VdltpZF82WULLZsrLMfusOoXHcHOB7iqvy6XF6lOFI0V41naO5BUsgiO0seMk59f5VfFu1wqlpmuHWN0kGRvc4O0r9Mn8KZIylYdQtCyo4zLHIpwWzgbsjt0qW7sxsZdvk5m3yGJuIsrz8392olK+4XKsjCFQpjjYrjDH5mRuwbtgnv71UuZlMkAAjiZyAsTj5RIDwv1BJrTGlD7I907ZAjVcJ86oFORn+90GKZYWMUjGe5d5FmGEc4GMAYYj+FueD6VSlFajvfQoSQz5H2Uq8rlljePOQuPmL+xOTWtoyxXUj2skLmAhthU5UD0J6c9RWRf2F1aXDO0cqjneI12kgY+b34zWpZRSWthNHkkIvzFGOXBGcgdc4xRUacdGIX7BPDf/aCzNFHL5rIckMMEjAH4dailZ57wTCIofXbnAznofXnmtTTJlmRHiZ8RIUZnfJxx29OO/NVNR+wNLvMx86OMF/LGcjd6fz9qyUm5WY+hFFZfY97X0hkzukSNmzt9/c4GdtJcI8sAtklwsjhd0R24OAeeoHatK6mgZ0t/LEibVfIO0DuWH+FVJRFLayKke+cAEKGY9Tw2aFJvVk3M5WltXS2LfaYoGO5GHMgOSWHqeDz2qPTJ1E8s3ltDNym1RuAAPK/Tkc1GZxHFFBhRHsLOd2Hcc9B378CltpZYJkaMDYEKZjXlsnOf/110cujKUrE/iKFw0MizEjiLGevvkdqfroiieG7kjDQzR4dcZIIHUkdqueIFkl0NnlhC4VH3bs8+3rVaSbzLKAwAP50cblXIypAweMdxis4N8sX2ui5O8Ux0NgszM0aIbkyEl3fIIA7e/8APNU7qy86zu5wERbZ2BHzcAjI+X3x/KqttqRsp7m5DExA+Wuf7vcj/a5q+TDe6BdXce3zFKEtkhsKRjd7jP0NVaUHd7aGJQsrEX5S3t8xNIoJljxlU6EYPGOST/Ot6eNbS00qzsdsStdGZ26koBkZH4HiszwokkMV3fSx+UxKIc9Nmct/Lp7102lW8t19rnWMMlnOqhpGB3gD5htHT72QamtO0n2RDetit4rDy6JJOhLTS+WZURz98jgH0G3rWDbpbGcwlyYlUQQADITAHzZHOOO9bOso8FstuoaWJbZrtnfhlIIC8fgTXNJI88UUiuAXQrkpj88d8UUV7n9f10HDREsk072kyS/Kxl2xkJwV7knrjIOKlhkSK0Aj2ujfLsYEtgHufcdBUcDQx6Y8sdwsjocYzwD2wfXoaTTxmcBlJRlxJJjbkjkHPfpya1aVn5F3G6jdC3iWO2VzdTAxgY5GTjPtXWQWEHhDRGnQob2WI+XI/TcersfyAA+grA8NWi3mvXUsh2woqW6yOeMk8n8h+teiXGjyTyKbhomjijTZvGRvDZz7ccVzYiootQe3UVV2tBHAWsSwXumza494XuXYqQ3llzxy+Oi9cD0r0bWIopdLCi4W3ibHKqDn25rnZNOMuoy6vqupQyWmTEsG3aiAjaMdeSfWsfxCYX06W18yNrm3YO0SsX2L/snjnHORWcl7aUbP/L+kZRSk7Izr7R4dOHnm6kSAsSqiPOM9uMcU8q32ZxHfusYbdGYssHGP4x/DzTxqVxHb29k8InWZOqsHYjtkHgevFERlsSAu+ExnYjIBt55KHHHPvXTeVveNZSa+LU5nVT9tcx36bIWYDcTkxt2ZT6VPoV9usbmBywvrYqAC3yygdxn1FXNUNvfHCgO6YVQR8w6/KawI1n02awll2K8Unkue+xuV/I5H410xSnG2xtTtUXKjrtLmhuFnNnGyzTRkvG4wGx1x6jmsqZGRYkE6gkbyCm0kY7CtnTAi6rZz3C4yx5UZ8zjlcdvUCsu7hUSGTaXBlcIQMqg7fjWEGuY53o7G34DvVfxVYWyrvIDlmBztOxutFP8AAjg+LLcFdpJf+AfN8jfNkdOKK8zH29ordjOpuYcSN5s75LfMUVY2yT0wSe1XJr8fZ7SKBDtiYzOfMGXc9Tj24ApzNcRM1qyKHbBDygqpxjoP89qqmeH51uUjKKwRZANhLL1A98sOa9H4uh1IkZZEjfcFiuUXy3YcBcjIJz1705dszBWNvNMpPyyfeEeCGC/pTbpZ/kc5KzZZ49pPIGBnPbHpzUMQKSLKyxlo/wB20u0ggHkgMfrnk1SV1cBpCLLKLSULK2ArOOFOc4APHtTtTPmac0yAuIzt8wAAsD6r25zT0Ql5d1u8cgYyOhPyuM/eB6ZxUBhkvHu0kdCJ8LyMYx3IHHTnIqlvfsXTdpJnLeAbj7dqrLNlShIkJGTgucKB6k8Cul8R2WLue5TEMombbg7sD0A4x0xxXBX1rrHhLULu4VPP024dPO2L8xCnO4Y5Heu3t9Wg1V1QywyQrFGYZ1ICunfI/vfzrqqr31Uhsa1tKnN0OX1JfMURTXDec2WjQkhhtGQcfWvT9W0ybxh4I0jXdOYLrNpBk5OPNAHzoT9RkV5p4pQwxJPYquYTlnbuAfWu6TdYfBi3mhdxc3pWJfmIA3ttJAzgnANRi78tOUd72+/cdVv3XHe5h+Hdaj1WIzOgiRMAxoOR7/8A162jFFi1ULhoSWR1P3TnB498nPfmqvhXRIbK0i8o7Qfm+fqwyeo+o96seTOJRI6NJGhP7kkbi3Q4wPQ1hUcXNqJjUtzNRJ7gMbpJY7Vw8G4schy5PYc9uDUZ85Lny5rgR4cvKSNyN3HB64wMelOKyC4g8qOYr5m4x9NpHHB79uKvxWEYilkvnaWMo5J358t8jG5QO9ZuSjuYtlOVJ/s0UxkVkly85RthYAnHHbPFWvNS107fkkxzCFiRvUgn7rHsBxg+v1pV2Wc1va3QM0rReYrmPCk4Hy4PTGfwqlYHIlluYNuGIi24CNk52le5Axz0FTutSbl+x1AXFssEsjxbxwhGTHg9c98YP51qXNrPJ5ht3gdZXDCVkyyqRwB2OKwIAkOpQF7dXaZjkjOUYjBP6fStiW4t47ZFnyLXbsII3FyDgc1nNWa5RsreK4ZAyvvfzISSp80g/Nx90dQeMVj2NxMNSsrcO8kM0h2BgBsznPU88HjvjnFdVIhF3avcWymWIFBtfIIx1B/xrNtdKNteyEwzMc7oC5UMhZSM49c96dOolDlYE0a3JLi3S2Ebu+8uxy6gfKWx06VU1SzuIbu2vIAiRyMBIGAJD55HuDg4qTQjLbWl4s6SeYGWLdIN2/B5H5E/lWjPcXN7ewRErHcu4F1AgyFQDKyAngdD+dTdxlpsJtplBZor6GZrYMSinBCYyxJwM9weao2gFzbXFu0qpLFH5isJCqkcHLAc4JzViOYreSRiPFtLGzySbs4wcjHtxx9ay42CCTZJFIHTblRzjPOfXpWkY9h3K13HLblLiRt7bGI8ttxA44GecUlvJKZlG4RLIwXcWDbTk5GR2x3q3e+XbOyOIvNlCzybScqvQhR69DgdKpTCN7cxXEkhEhAVIVKs+M/KD24INdMXdaoLnQ6vAY9GZCymBIjj3Ibt+GKrWhk/4R6wdfLkkR2Tg9cjhT9T+WKurJnQ4oHjby3hZU38n055/wA4rN0oSSeHmQKTPHK/lnoBkZ6/nXPH4Xfuabw9DMNvMiPHP5anbgsrFhHz0wOv6e9SwmKKK+lYkidAmxhu+X+JiO/r7VZvGuLqOSK0uhFARtbYoZtwHII4yOaODoUwt1UGNFUbgdzfLg8c8jk8VtzNrUzuSWn2i80wWVsgCRSKYJYcqXUcH69c4rRutY8rXL2zjZHtDKmACNuQo4GOuSPrWdBenT7+yaKRylmsLybk4YFcnj1OeP1qS+Mcbl4oVj3bZDMmFLsS2c9cYJxWTjeWq3/4Bg2a2r+ZLcM3ks0/2FQy7sdOSufXkVz6Iskbi8RreFMfLv3FjnqtadiZFsI5JlMrtC8bMzYJODk/icc+1VItOmEiCIodzBizKcbuSR7j3pQtG6uXB6FS4RIEgsTiOISNM4dcbiRhQW/A9PWrccS/ZjawNI/mkAPIOEUjJVQew4z60y7WG4hjZ2VWLllmUFd5xkKfQHNLGIxsaXf+7ORIpwRx0J6EE1d7o03ZqeArZporu2lXMfnMgl9CACOPwxW1a6rcavPqmhy28qyCaWGaUHHlxkAqQe+c1zvhu4FvoVyEYrcx3uSN3XjNdjeTXMWobrPy43mXJaQHZGB1Jx1J965a/wDEd1/XcmrpNmc8MlnYwWNs0yRuTHHk7pBt4PJHXjPNR3ukvHpJacqkALS8hSynPADHv+lX7B5r4QXzyxx6qodRGzHycZ9B14xg1StI7Wz1+a3uLYSnYzuVkPlopOThSe+ahSd/NGZyVw0721nLDGipJKUy4G9CB1HbJ9Rir+m2cstyou71UmcAiNiCHPvzz+laUl3NFq17JJHFLHEWZf3QDRJjO9ex+nWqUCW0MD3JR7uV2EZdVw7u3Tt0/HFdLm2rJDlO+lg1DTE2C+e2LCxkHmKGCFSemOzVx3jOWKXSp7lIZo/LeFysnUDevX/Guy0ua5vLm6tZifJjDrMrsCFxyF9CTj+dcb4pmed763j2tmATS7D8q4cEAfiK1wyfOk+n5F0ZcrT6/wDBNyxe5kt4bmLYHhIcAHdnHHI+laGjQ/bItZiCo8JdZYlI/wCWecN755rO0+Evpy7yyCNeVXgtkcDI79K6PwRYrHeQzhSrTRN8rHJ2jj/CorSUVJ/13LraO6MzwOwbxxb44RWlRVx0IRuR+FFS+EY1j8fxoWzKJJScLgEFGx/SiuDH6zj6I557lLi5izifdI4xE2VJGO2egqm9zGstxE6iKVN2TIuAmOhyeD1retbYppJllcCeH94nnjaXxyB+nH0rIvw01odTizJAXMPzNuJZjkjB7Aiu+DTduh1aFzVFYyFmJ81SvllVwSAnOMep70kpkt/DEsV4IvIDBkLZxyTgHHfOOaxfsvnW8EkhkjlAPVvlADcKB2OT19qtSyyosKsywEjzMH7zYPIb/wDVT9nZJX2FuQ3rlbUG3Uuqx7Gy24t6qPXpVp4pVVJd0hAIyofbtGOM/nzUFtIIYluVUAbmJ3Ak5zzz2PvUl1JK1tLNviDfuxxwUZs+vXpVu+w7k9xa+dAsUjQus+AdzZ5J5/xrxPXLG/8AC3iGSS0jMkBckw4IBBOeK9w0xree1YHOZV4G3lWAzx+dM1PTrLXrBobpPNfZhp0G1g47fgKvD4l0JNSWnU2pVEtJbHktjqY8QWbKtwkKgEPCxwyge/evTvEOr25svDPhuyYSm2iE85XoCqfKPzJNcHN8PCdWitLkoq53JNGdvmJ+FdDaaE1hqOYpM4OQ7N8zY9R344rrrulUcWntqjtcIaNPY6jTfM+wRlwyMHCpKcHBye30qWz817QNLG4Cb1l42OjZ4bNP0pd+noqgjErqPnwMnsfXNOEUlz5gtxJujYLgZG8fyPFeZJ6s82p8TK9jOumCOG9liljChnblmTk7Sc/z9cVrvdWY0u/lht5XkEYJaXIRy2DyB3+nasqd4YorqeVQXLBSzR4AwcAHv7ilu7hJ9PNjLK0wuSgVgMbFHO7PoNtJx5mmZtFuF4bt0F67Pbgl0QnkBlzhWB5QH19KxNQiMck0BkWO0HO2Mb1ds849MjP0qzIPs0uwMIom+cY5AHP3f6+1RRSn7eBeBWtsqwlJw2485A9T/KrgrO62C1h1rp99BZmWNdsW1GUNJkn2+mT+VbWn6kkkE1vfrHtZA0JiXCt6gH1qrZyo1tNbRugMo8xFCnbxyQD9MVZs7aKG5ilZ906p5iRKcbQyjK4Pbv1rOcua/MBY0pZ72K+8lljg2gxGQFsLjGCMcc06Zrh7d4tWl+ZYxsuFXBV84AX1z2pltO8V/Np8aMsd3CMujZCsQTtBP41YkhSex0+EF1leMOoPRnXrx1z1H41i9GS2ZG4PJAD5plJd1kcYBYdR6ZP8qshpYobiJlMckkZgimz8mGAIJA6/dwcdKuW+MTGUkSxIfMjZ85yOARjjOKpmeOF54Jt0sZtywRAFBDHA4OMcd6q93awtGUmspDIsYd3Ywud3lHy9vAIx6ZXIp2mWrXGpNamQm6MG4Mke0tg5JXPTrjFXbidS9ysUmApSMM7kLGAvCjH3j64qRbnUInjaBhEdoXAjUEqBn5T1BPTB9DVc8rWJ1MxZkF95snyQH5G83cfm/HoRwPzqC3sp57yaSJntvKYShduWftuyB0x+NbUy+ZKlxcQi2WSESz7kGPOfAyQehBH41VSSeTyRcEJcJJszu+9GeMr2J9vSqUuw0xVh8rEKlZI4JA0so5LtyAPbBb0HSqWgGQR6kVV3KuxRN+AxwRj6GryrFJDb3Es1sJeQ5A2lmPGHxx2HrWZprTW+q6lBhSGyQJDwpDf4Ghaxkv63NqesGVJ7VbZLeRNyCPCgOwbyxkAAdc46VLPbB7qO4WZreMXAgMuS2VYEZUdATjH61HfxmK0lt7VEnMjCTA+6q9enUk4roYbCWWys55fLmtopfM2w4TDj+EA+vFaynypNsylsU9YsUv57pPNjWQxMBv8AlMjRtgsDz144rAvZPIsbJTiSQiR5FRCUVWwVLHoG61r6iL1BJLIm508xY1C5+ckZYHqOMe/FRG2EMT+RJ5sYUB0yBIoxlgD9AGGTSpvlSuzIvWUrw6jptpH5ZWKFkkDdS7jdn6DIFQ+IrdrO7e1dGSCBCFVT1JOdxIPQ807TbiGHUob21hIRWQEv8zKCf17DPrWtr8irrcly0YdcbcseCByKycmprTp+P9MvZGLKWhtXijCsFHVhgvjOSv8AL8KoJI8c8FrcbUikQgEDv1GSexJwPpVq+IDwTzRFCymQMBlRk5IGenPH406+eJDBdxFJPNiVPKdSxU9yO9ax9NzQy4C0esSW0Lq73nzKoyMSJk4OemRkV2RuLzUrO0likBkhyLmPGNy+4HJKntXJanEssKzW00cd9DLujZDw+DyvrnFdD4a1QLe/2gwiW2mjIDA9JOhDe/HP51NZXipJf1/X5F1VzpNHQwNp5knsS0JndQ0iKm0sWHU+h71lajYpp2lMj3jN5suE83axUj0zyRUOqzpFNdXRW3gibB3XJIR+vIIzu+lTfatO1HTGZYftlsBkeX1zjoQexwcfSuaMWrS6GTjpoJoE5czWOpouQuYrhBhm/wBk1JNDeW0KNHLbRzcr5xIBOTkDaepAqkmowS20UAktoLlBlI3zuZOwPPpznOawvsqwa1Pda+XkkdgI9ikYXsc9ueM45rVU+aTb08u5Gj2NG1jc3moSrIUJlx5iqMYx39GIH4ZrkLm2jigu0RVTzpI4FAbJKp87c9+dorrpxG8Es0AJuGHlQwhdi724+Ud+OSTXM2liLrX1jUBrKyTyw2eCc/M34nj8K6qL3b8vwN6Mbu72RvJA0ISLzoYvLjBdd2eCOD9fatbwxfpFcPcRyMIYwIkjIyXPsfwJ+prJZoZ1u3jYGaAgqOzkn7tXfBKN/ays0gCBjI0YUbeAc4981hUV4NyIqs09Pt/s3xJg2tsEgdigPJzGxOfXB/nRUmi2803jt7sRoYFncK56geWw4/E0V5uKd3H0RlJ3MjTZo7tzFcXBG1iFJYFSAOh/x96pyWlzcyyxy4BhOELnG5eo49eODRBaQonlkqltIxy3G5SQT165/wAOtGoxNJdIWlkdXVWDEbVUYG0jHf3Br0klzaHSZTwOJbhFKLLghVkGCpz044PXrzUsj7gm9vLDnBVsMRnHJwPrWhbeRdpKs80RljyhwvyOMHk+/wDjVNZWcxyuREG5Yqy5I5HXjjpg1tzX36ANcKhaJXDPuMmRyDt7n1zkdOlF5I5LtGGlkwqEFMckcZPfnv7VF5stv5oXD4/eBlwOp6dc/wBOatQvAIpcsyhPkU8hQc5+99aHpqFx1iZ4LrddHfFFtO7gEnuAR1x0qzZSJLIUhmiVmUbGxtVmI5HsaqxNFHGgeK4AMh2kOQADjO1vQ4psG+W4EAhWJJArtvXILLnByPXI9Klq92FzSkR7iOK2fdv6RSlNrLz346Z7VTmV2fa+VnjXa3y5Bq3Y3FzE0SyCR3zhgowCevP0H51f1W2S6tWFlKouoidqo2N3fBrNS5ZWextTnbRmJpcjW87J+7LSPvTnALYwBjtn1q40wEqLFPDGyKzMuSCAfTH86525W8kk+40JB+bgbgw5rdtIvNsE8yYB5AdzHORxk8fXB/GtakEveHXgl7xdmuknsg7Okc0kQlMxw3PTOR3H8qoRLcJK1syNLHGP42zz1Jzjpzx+NFuBBIUtQHu4W4WTO3BHGQO4/wAKWMSuSrsS8bmTapAZSDhjz1GTWaVtjnYyUM26FoYwijG3oVPQ+3ORgUyaKeO3L3RCRtIA2BuKBcY469c1pIk00kjeZFG25FV5JOG6fNjt6Cman5cWpySWrrMbcDyhtB2Z4bHqM8EnJ+lEZa2FcdZfuxbs8G8ySBQoY5G4dTzzxj+dS3OnQT6tLJczvKWiJYKowwA6AHrgc/hWXNeNs+0QDdGwZsFyCdvX1z7dOlaLTrexWke5pXEbuyEZBBOMZzxwalqSdxMlvbBPs8cNlI8ozGVCnDKenU9M8cZzwav26iUQtPIqvbM3lyMu4qvBOMe44qt50Vhb3e0xq6gFgz5DEdF9ePap4Luzu4opoIpioXznfGegwVB6Zye596yfM15Esh1eWCbX5JrCKSR5DlzHkM7DAGM8Yxj8qq3DxfbVZ5C7SxGOJJoyNjc9CueBg9a1PsUlxZW6wyxK8zFoyQUJx8xUAdiO/aqZOxrBAjqyMXeVyT6nH6URa2EhiwNDbJHGDK5+YyAqVcZG1sZ69uKu31rcT20ksc/lHAO1x+7Dg+g5Ab8anjnhmKXMkZDtwi7tzBP7wXkLk/pWRLq7lxHDKVX5lmkCbghBJ78EHNC5pPQLXKmoXMiCUzosk2TIzNyHHTv1Ubu1Z6aibaeGWKEssADbWXgA9hk9zjnsKku5YHkiilubeVIlWQunAK+vqP8A9dRWsp+3bkEcwAKK6hTlDjt6jHvXVGKS1QHRpHEftEsZ8zzwrSRtyQuM4GK5xY5W17UQWchQPu9ewHsOuTWpZstvDIytKj7mZsYcKDzye2c1Wg3x6xfOgiIKKxVjjGSMge4BJzUQ92/p/kbQ+FkXkYVXmgeYqGEwLhQeeGz3zxWvpWXdVtDuhgZJJB5hCMM8kev6VQLFr1ng2RqJFHnOThE6cgjBP070+JvJeWFiYFBbeqxkebhgQVP1HSid5IyfmWL7TDHqaLGyzWrsJg0rYV155G3uOSR7VY09AY9Re3aCQMiqkrgZUZwM46cZx7EVBbW017bmC3jlSUqCHxtKhyTnrwO1XmjgU3ccmRHcbMiMcNs4xnHPTOfwrFy05WZ2Oft7VxdLdKwa0MjKrsc/L2HsOh/Kte7ZHeOWSMJKYMqh+Ylhxnjg8A96qppzWsV15QN3C8BLRO2TuTBOff29qtNbgDTGkCuvljD5ONxbhe2SB/KrnJN3L6mNdvIJcmPNtJbBFZcbgTzwM+vNUw7fZ7G2Q7CXJUbsMvqAcd8Voaylta3tvLBbsss8eARkrnJGMetQhY5bF49rSNIWyp6vtxz6j1H0raL91OxQ6OWK1u/Kbe+1lfDoCD78dDVcSQ6XNPFKjSaXdklyn3opM43L7/zqxw6kMyeeyhmAJJBPcnuvFT3ckEjGKJC7bQ8ZfChueV468Ur66mkJWE/tdLSz8i4aG9gBwGJyCvY4HtV/TLrRokQrFDGvG1Uk2sPpk4xWBqNr5Ad7dd0bnkOgdAT9DkfpTLRbSI5vba/jOOHhdZE/ANyKfs4yjdX+Q5U5SV6ep1jXlojl44o41Vh8iOryemazNSnguXEMKPKN2DI3zHOc9e/4VlWo0lHLJY6pPIegkZUH881YnF3d2pW0jhsLY5H7t90jfUnnH0qVTUX/AJ/1ciNFp3loRXsj+TNDYEtqDqU8zdxbqfvHPTef0FOtkto7aK1tZWjUAFnzhsAck/0pDbLa2gijLJGUzzwCc87varFvHD5ZQxPJNPCI0cjOwHrirbVtC21FWRSnvo7bSdkTfv3XgsuGZjnp2+70rQ8LQTWlxZzFVjeLazCQk+Wh4/FmJrNtrAanewWtq0rxQ4jdyuPJXdjJB6kkcGupvYYNLurSyszFcz3VwGup3Ylhg5AHt+lTUkkuRbs5ZXk7HQho4PF9la2ibA++WbaOuUbk/jiiqmmTC48dvMxZBsMcaHo4C53UV49dWa9BPc4q+sJbeKIsWhUsz8OM8DG0445z+tP8z7Vp/lCCJioMYjJIKqeQevIHQ+9PfUIp9PjVVVn3OF3E7YwDx1zk/Wq7xLFcKY/lEke0ZGCWODxjv3r2Fd/FudSK6iJJVeVFJKsNkh6MBkggfpV2/nluAvkPELZEKl1ADbSOvSqauk1wECMAZQQvGRx0U56dc1sQ2EV7ZAQzJbmPJLhh+7GckZ9c96c2otNh0MV908yh2VZOD5gQbSQO+SeOgrWmeK38PmLyZDdCQFflB+YnPA7jHOT2pbK2FvAW2242xbxIgGz5uNwqpfyyrjZMHeRjlwOAmOCew5DfNUt87SWyE0LdqkhDB1E6MAnmryBwS3Htx+NIZWdSLKMqruVKk444O7t6c1VkwbiJ/NWIHLbd3LED7pHsMVPB8smwygKcsWdcuQOmB+f1FVy2SC5e0pWe/cOsiQM7BM5G1gvH1HbPvUtuWRZY4mYCOMcyEhm55J9wKzJFSMlbbdIwZht37d+48NnsPb2rT02dftJSVVnB4ebGAMDkN69aia6oCC8liu4xeRs26P8AdyFhtVgejmq9jLKkoia53K+DtVc49h+VbVp9ljnuBNNDJBIDtVTuyo/DGPb2rn9Qt3imdURwAfMWQdCM5BGKdNqV4nTTtNcrNm9SCfzCtwS08RYso2ceu7sQAfzqo1taQxAI0ewnad7bty4zyc5J75qxbt/aMLMj+Tc4B2ZwJMHJ/Aj1qL7O8ix4mWDYzBpU5xt6AjGORxn8qhXjpc55Jp2ZCTE7OqzquE3lkOQAOR17fyzUTxE20ImluElYME2jA3PgrjHbjqadLJayRbnhYyb+cKPkTOMDOOO+amlgkt7gWsUsmTGBGyxn936At0I6fStNiCORfLs12wxrjIJdedzZLDHXueKZCyWEtqA0rqJNjEJjHGDz6cVNbjzHubZlK3U2C4fnYwHGQO3P1qODMBExxKvnAuu7Z8o/iOfQnH6Uu6EaNw/mX0sbKQyIkbBF3O24jaw5HOPyqSaR7coZWkdIWLLsHDLkgj5evynj6GohqDtO0jNHPgKxRRgZBPK++MHHcVBaSzXiX0rSTS7HG0SAqdp+6ApA6AZIrNJ212JbNe3vHsv7QPmfMy43CI7UUKBkH1NZsklxK4MwEMaDEZPGcD7wPvnr0NReYz6Lst5GQyOFUO3OBjjbzj/69T3TGCAwFnuJFTZuHKkKo6+gzk/jQo2fmAvn3AuncB5IBKR5Zwu8YGAMdQD0rLCQtcyyBEg52tnDKuGA7eufT0q/f3FrBCmxWljVWkUqx53DJ5/AjFRSIEjtoWRPO3bnTcSdp7ZAPGD0NXDTWwuhVu4Fhl2ShUTG1UI2ggZ4z2OP05qLTWi3PMwiwcD5MbVUjnBHIJz3q9qVj5s3lebJI3OSF2uMqMcdjg+vaqsKJawywu3lklQ235gCc87u3WrTTj5gibS5maVLdYRJFM4+V5DwCcA5x9KNMib+2b1blFJCiM5AbbyAR9fapI7eYXMKPsaVV29/mZTnH+905NFpN5Ov6i4KJIyZUHneeOg7mpbve3b9TaHwyIp5yWmt7idhGpc9lwR0A9P14qSxmExgW2UyQRMrPhM+YemVJPJ6/hT70rciYIYzGygEBcMQM9SR8vzcH2qGH7Hbq1veSyQxGQtCGyVjcDOD7UaNeZk9TTtmWO6Js5mYxuqBUBbYB1Vge+G4Psa0oZbezgNxKZXhdvKZmIzEAeW9AP8ACuevp7h7eYvIPs0mHO0ESLg9Rj73JUfjVi2vZmsjZ3OQ0aiQxqfmXnKsc8Y9R7ispU21cR0baaLzUGjeZBKhWa3wcgcdR3x6g1lapZXs9zAJI1hWIMqoSAFYE4I9cg0W1xL9pvZndpfs6oYXCjoSCMYPI5xz6VLc3lzqAxejfJE5YBBtK7SQV9+MGskpRYXsylqBhuZZ1V0jufPD7CckEABl/MVUktzDLbtbglnfaSGDYz/eH14+tSXVtDd3MYuPLTYcyyj7hD5IbPrWXe3/AJET2sYkWeNmBYKQzIcYIxwScfXrW8It2SC/RGwkyHzoyJZ4s43+UuEYdf8AgPOAKrxR2pmk2wTidjgOi/KeOjj+oqrA0kSqICwEoUEY+T6r9RmpEuxOGXZIIiNq5J4yeBnrk0+VrYpLQs24lhW5Ro0OcjcAGI/4FWY8YW4kiSOVoyysMjsevFXDcoFf5JjM6L90qOFPHHv3pdWjhGr2iuxWNVUMN2MbucZqotpm1NtMJYhAoNssaqGAQyAozd/l7n8aqGL5WWfylbgBkbnjkbhnjPNbuoaTJHCnk3AeIAsjO2Apxj8azERZw0Cqj7GHmkpksccA/Q1MJ3VyLlM3NuWCs8UjEDasQAG3+LPBx64q1b2+LVo0uJBczsFgJX/VxZ5P48gVTu75LW68yaGLKE7VA4OOM/X2q34Wsby+vNO1PUp2hsI5GMYkODKMZ/759PatJK0ebZGcpWOgs4ItG8MldHEc07sXnuSBtbHLYJ61z3haWXUNSlv7s744yXeWQkbT/CqjpW74jtrnW4MzFbHTA4S2VDhpM9WI7DHas28j2Q+RpQhhs0kGHc/NJ2J/wrCEk4u/xP8AAUU2a3hB5p/ESSXLlsMTGWXHBRvSioPCgmPiiyY/KvzBhv4IEbAYFFcOLVpr0FU0ZiPDAjMh8sbI8NCFy2CBknb0NSRAx3MZBB2KAU64UHAOfxP4VPtS3WL9wUjkXLylSzMCTkDBzngYzWUQrtI0j7pX4iCrjB6rnpknPWvTXvG4+aQ+bDKF8mRjkyRsOdp+6M8c+gp8CsfLZkiWCQNI3ynkHAwx7c5x71TaRoo5JGuo2lhbOCcjOSMDt9SKsR3Unk2TyRBeJFLDDKy9kI/u+/NW46aAaXmwQwxiKK3t0jHlud+WOcce475rJnhkWN4lkDRsmxWjbGQGyAR27DFXVntJ0ZUj8s7MqJE4LE8cn8x+VIbCT7bBLu+0qflZwoABySQQOOvX8KiPu7gZ63Eb+fIpWNo2CkBeDjg7vQkYFX55rIXzrG0hjUByNg9MhR646celL9nVbm4lwohmK5w+4nJycY5x0qW8tUt7M28AjaYSFl3PngdQB2+naqcotglqUGtjJLG2QHLiIuAN7DGOfQjjr61f8mI23lJIxCEqS2QrHqT+IqC2kslikM0joWXKfLu+YnjefYmpm3BUklWPbKp3FWGF4OSfY8DilJsLiDdPHLJb5RQchc7iM/3Rg5PWr1/AbnTPuiOe2+ZMYJKjjFZs2Y1CQHyZkPmuOo2lgPzx36c1p2bMLpt5UblKhm5cjjH04qJaWaHF2dznsxsVlhYwy79oOTxn0q/DqAkIea2BWQhDtbaCOuSO54qpHEBcXFsyAmFtoHTB9fauqsdHtPIRZxC0jj59xwB7Z/CrqzjHc6Krj1Mi2vNPS685oHhkdQGZlDc55GD/ADHrV+5nstStZba3n8mWX920x+QjrjA4z1ovdN06SPBVcYY7kOCB2C4zntWedKZCLq2M25GDbJiACAeAD+XX1rK8Ja3aZh7jLcljNa/u3VVmBEsc7OTuIJyTx16d+aoSlItQZZ43eJI/MEjfdPPzE9MHOOvUdKfFqbJctbXLPsLYdZGBKjjkE5GPart1p8FwpNs8LRgAOrknODjBA6DHFO7i/f6kSi0ZwjZRcLCwM0O0shkyu3nOB2I7ewpY2cO1v5ZlUIHLJ8o3EgcE9SAT15FTad5US3gaRdkn7uIqufm7sGPUgYAHTrVW9tZYoYEt3driH5JnX7sSkk5Yd+OOvHFWrN2MmWJIntSLh98kBkMEKoNo2n5SQc9RyBxnmoYJYIbeJFtJWgO6KRc4YISRlt3AHIHNXJLySyiMs7w3M4CGcEnKEjA2qec85rn9Z1KPTlkWaNPOuSBF5bEmRiONvtznpSWu4LY1tbmMt7vlkjtRAoXZkEFSMALjr06njvUurolvBZXM0jRSu0kMpi5MbL0OTz0xkVj6XevfWtxqji2uIrCFY5VmDLGdhAPI6nge+e2Ktw6hpmr6JNcXp+2SmVpYgjNskkOflA46DAz/ACoTV0l07E36GlA6w3E0sc/nAsHaB8oWHfnp6cUkhjnlUqXhCHaIxH0B5+VumOT0NZ9tex3NtKl5InkGIfuI/vDBxtJGdoOMfT3qI6zEgYSTLBE8hhjtAd7FgvYE8Acduc5pNW9f6/r9Ro0XW7knhljv4BKGZyi/xEL8oJ7DvWfdAi5mlx+/kYAYA2h+FDD05q1p1la3824rKCgIZip29MEqT16nn1NZWolZsRQTqsZdUjcthiA+c5/zmmnvbojaOibKluNQstSvtP1KUPdwyn90nPm7gOS38PGSK6iwys3+mhZYRiXa4zv+pPGRxyMZxWN8RIBZeJJ45HEdzd2yzidztR2+6yr+H86n0WdLvSYktSIjnezFiVbtsVTyeB1HHWmmp0lJfMzVrF+4BuGcxygRrP5Djd1GM85+7k9Ki0q6Ed8Wv4iysrRCUoMkEEkH1zwM02bzIyblRIEVQGKFdxYAEHr1A4xU/lCXUIHmZEVT84I2sWznJx8vr049aNOWzJTJfKFnawWMbtBKYWnMZTkKGBUEg/1qzaxlptLu5Ll4ZwwVYd/BbOArcfh9OtUb2IzW8lz9oWIy3AA3t8xXIbg/geKn1tobO7t4IGm+0XEakPKw5ZmJ3FfUHv8ASo+LTqyW9Lm3DZRXP9r2LtbLdSbGjtiw3IQMgEjtmuMnt4jdysyvbSwsUZVP3HOSSoPUY7V0/iO7uVs5ruxgSeW2kVVaJhuyByXI65OfpVa7RdZtFutplLW7lmyM5BztB46fyqaUnH3nsyouzObBkKLBLGIiBkMZPnKj7pLdu/H4VdjiUKUTDMgDl5pMEcccdMjPWoLOCV2WbyjEXA3M6Zx3zirIQXL2vlKohlfyxuPzMmfvZ/pXRJ9C9hhkllEiyIFLE79ig84wCPaprBFbVbOATxPKYtzBxw3XB98UrFFtZPKyoUlFQqPmA/Wo9InebX4ZgkecbYzg9qneLsaQ6s0tU8m6ZbBtu4EEF5MAHPJyPbFUyiJM7Ru3nsG+V8gDnglsfjV+/s4tHieJVkaIqyu7SDcATknPse9YsX2maa6XM7RoAQAQC3Xo386zp6q6ehlca9rZxWa2l3PJdyHM0zSqyojHORnGSK67RLZLuGHVdRWNYLaAJDBGfkHeuTsjFfXg859hkYhw/PmDPAGf8O9bmr60Z2mtpYRFaxH93GgIDHp83c+1FVSfurczS1INW1K91mOO6iQRQDIXc20gew7+lUL3y3tmi8uFFBCnbIO/Q4+tLBqNuigZZy7bPNdPuAH7uOwquf3F6zStHK6gMHWMYwc7ffJqox5dLWsbR0R0Xg238nxDZ7njLHech9247GBxRVfwSJW8UWLEhSI385cj721u1FedjU+dX7GdTcju4hc6TbTKojV8M0ZfIXjgZ7DvWVKxeaCeQ79rEIq8lvbOOR05rY1EIJfLtxGJERFKsOo7A9uKybiZTcLgRvHE4CjaVwDy3XrzjivQpttHQzK3iWQu7geXtPkkFXyDkcgZI571LiVsSQrct5hyQqjCHvkHqvUVJDHuFxHbSW0gO5gHBBYjnB7imRsPNf7OoG1Fz8pwfm55B9RjJxXTfsSTsJiSLrbM5Pybgfn/AIsk/Tt6VZlM1oVjuYGSB02yPFJgNngZ/P8ASs37V5chg81haNIxwkeeegbOPlPv6VpJKGsVgRxHA+I4yWJRj1A4zwcE571nJNWuMgtLuGKYz3O8iNQgGAp3E4+V/wBeO1WrqW2l1GW5063QzNIC4LfLG56nPfP0xVOVZ7R2gmtpCxVZFTGVK9FwOQDx096rDUN92rBYopIQAzDglR97Hrx6U+TmfMguat9bR+ZFeqkEaSZVkOeXHJx7d+arRTlVkRowzRfeVyAGBPXcOO4446VPFqVmJQ6ImZwrW4foW9hn271WmlgjkdnAVj8rLjci/Uduf6VMU9mhly5hulVIIwxCrtQ4wSPc9wCBV6JmuIba5EkjTSNtnjyMoRwBx0B9T9Kj8PiOXV5TqzSR2MkG6OUtsiB6Z9yVOPwq3qOpaZZaZNZeHw8jMfMnmct8oXjdnHJOB9ayk23ypak31sjH11FS5SeNisswGQQG2sADj6nitOad7jSpWuNgkwSqgZye2B6j0+tUrdP7WsdTNtcRloY8hCACpHJIB/Gm6HPO1ncIkh+VN6jdluWHbp61TV4rujaXvQv2NSOWBI4Rbxs00jFUgVjHkDjGB1AOaw/E3iTUbLVVsPscEtlOhims3IDFiTu2EdsDn8KbPeaZJPCNSmeYxMAUQFt7Z+UA47k5zXn3jjWpL/UQtsP9Ns2aKTMeGRT1YHnJOCO/SiNHmZznc6Vr+l63cXNtYCIzWqrFtDByi4AUbjxnjFXXml0q7KsFxJ94q33k56e/pXFfDPwlL4nsddvtNubiyuIYvskI+XEr4zmQ45Oe/Wta3TUPBcVv4e8WPHPAVEkd2AW/dng5b1Vj+VJSjzcl/kVGp0Z195DAbeK4huGeNypO7g7gDgkKPzHTiqmp6k8doPKRzbAGSV8fKvQhs84XAJ6e3WmaRevFcmBnjELLlXU8OCOHVh/nmqXi3w5qWqaVcW1rO9vC67ZBBIQ8jdhx1X86l+67MU4Wd0cG/wASY9Z1OCzt7BGEZZUuVBYzKAdpK5Ge2Mms9Ly81TXtMvr+G4kTeUZLkqqMVwsgjVASB9fzrpfD/wAL0s7e2ivr147hCXeaNVDqFHCjqAOT711vhOx0TRItkFirkBsTSHeWyefmP0FXKSt7uouRsh1GZtTsr+1sDHbWsc0cqw+SQWVcY3Y4Y8c5/EVzms+Htak1a3n0hXJULIYbltqxKTyiIOCuD09q9BXWre3mkligfBAwhdcenAHTPrVqHxDaiZQfMVSpP3Mkn6+lRHmgvdiCp26Hmuq6T4hvrSTUY7aO2nhOIDDD5fmqCcKw9jnB9+hrZ8BeGroG6u9bt0ju35VY8ZiPcjHPpk966uTxJEJsw28kkjDcGk4GPTOfas2+1Wad2csbdXz8sY2nj3HJ61S9o1ZKyLjTZoXtwbSKOCGJvMlJZufugd/bPp71y83m3CjbuWN3XdGjYcZYfdPY9xV6V8h9kTmRhhJGH8Pvnmq2oTSW1tZxWyb7qS8hSFRjcTuHrx0BqlFQiXJcsGdp8SvC8viDwlHFPLD9rsn89ZWYqCoHIJ9SOCa8nswJbM6jaSGawtpY7Z7FpNz2ygny5Fc4yjY5B+lfRd7bQ39lPaXSCSGaMpInqCMGvKvDXwfTRNQ8QwC8S50bU7fyoo5QTLC4JKtnp8ueDXn0KygndnGyvYWtu8Fs5uGmEkqlEZ9rICwzjB+vX0rSgcx3Dho0jhXMnmyn747njoenTNcXpq3GjahceHL/AMpbqwQRlsYWaH/ntu6jA4I9DXXaewla4hje3ERQRM6yHYI8D5gx4HAzx7967XJPrdCvpYv+SXu7uOO2ju2BQ+WcAs3c9OgG4evFS6+sE14t55qR7dlrbsu1mGTkHB7jA61n71ayC280xv8AerTOSQQgzgjPAGAaxXWe4trB7icRxqyrI0kZ81SM5A7nqMGiEG5XuK+h0d0bi2juorSBD5wJuIpGOJIunmIR36E0mlROXY7jOluHjWRPkZVxySvfFVtbmuJJI7ss6yzqVWB2wUjXIzgclcnrUehuHU3oVzPtIAUnYxPA3H3IPH8qOV8lwvqQXMAs3CiWYWwGEOCqxH8f5deafprW4nhV2aQlyybEyGxj8RgZq5e3MlwsaT7p4slw4+Qx9Bzxzjt1qzpCWUspa4gS3m+bDF+HUjIb603J8mpsnoZd6kka3GIyimQxr83Zsjp9OaqQP5MyESFWjUEsgycDrgY6mrmuv5VzDbRsr+UzNkHgggY+vWmWNq1z50m5kZQFG0AN1525/nWkXaF2dKtGm33Ld5qM+0XSRMJD9xJgDuBbkEd6zb4XM4KWUjRTI+9FYcHPYeoq8bZ5YYYTL9mLu20SDd06tx71rFoNB0+3uINuoXUg2qxO1VC/xY+tZcyhblWpzSdiNPs3hbTY7nUOdUnTarGMfulJ/hUdOTXNks8xaB33ly5kYYJx1/E+lWroXN3dXE9+0kzsyhJcDn2Uen0qGNxu8m6iuFWM71ZjjjPB69a0gravVjirGkttF9jnuJ3NqpIJRDnzW7kD+Gs9YDPqEaXDSSbFwoQ4CnGQT/8AXplwu+1md3IDMQ0yAjIA4X8/SrckEkIR7a28po4+TnPmErzu+lJadSrmn4Zt5IPF2l7ZI3hYyE7TznymH5daKXwXOjeI9Pt44pSYlcs7rtAJRunrRXm42/Or9v1ZlN3Zj3WoMLmeeMvEkuAGb7uOg6kY/Ks/LRxuy3cV24YsATuIXjgAYzyPrSzlY3mUSQyMFMitIRgDrk+2e3bHvUCzRyqksggYbGyinBkYEHgc4A/rXrxjZaHQxXuZJZ41KFicDdtCFsZ54546fgKi3oyiUSE8GNcA5T2bjrn61TkdbibDgNc4YkJx0z1HqPWob7Vls4o4hCZrqZsC3SZdzNgL0z1I7nBrXlsiTrdJsIb4I5DrEq73YjghewPGQeOtYWt3MdtDPOtwkAZCUdCMAd/bg81nz3+uXmo6lYWOl30lxpwQSx2sgcYYDCEjofUV0Ph/4X6nqN3HqHi69SG2xuOmphxnORuOAB9BXM6kKfvSl8hNpHJ6N4xsruG3fUtWtgIWZAFUnzCOrEgdOQORzz0rVa4EOmQzvBNbLMoeP7SrKHXPVQenH4kV69pngbwxpeqtqFhotlBesmzcqdF9l6D64q3IsGq313puoWNpcWkARk3Mrgk9inUEYrn+vK94x0J5zw641i286KGWUwymIyblORgDoFGSePp0rQsbu71u1ur/AEuyvblYnB2JbkF+dpK568CvZofD2mwXUM9pZwWzxvvPlRgbztKgH25rS8hfLZAAFII+UYxUSx/8sQ9oeEeIdS1kpp8+raHcafpsSeVbvOMbTn/loB0Ixx2rFs9dtrmOS3intJC2Vx52CzDnHXlvevpGO3jjgWFVzGoxtbnI989a4vxb8PtI1KKW603S9Pg1lgRHO0Xy5I53BSO3ftVUseorlcQVSxxGk6jvnKm6SOVcsIChUydiATnsM++amtbmSxOqygoz28TMQRjZjkdugrKs/B3jOTxPcWNxFFGBA3l6kVBjY8BT65A455ra0L4a61HcvDq15E1hNJ5125cyGVQ2fKHTA4radalZ67o1VRWdzy7VPEGt6HdRRa7Gbq8u1BVjHswW9+mAcDjjg16jpfhe08LW+kHxBaNe/aVee/ljcyLGyruXgD7gH6mu+ttC8OnT7Cw+xR3UEjtcW4uEMmG6k5PTrwKtav4di1KC/tdz2cF2EEsls+JJABgrzwoxxxXJUxTklHYwcmzL+GOraHq/h9j4bspLOyhlaPy5E2ktnJPv1611FzaQXIcXEKSgqUIdQflI5A9jVPwxoVp4c0aDTdP3mGEcNIdzN9TWsSABmuSbTk2iDyfxH4Lk0Sz+0aPJJLpcADfZXy0kXPOw91x2PSqvguyvH0S4k00S3xgdjJFcSHzJSckFGPGMYH4V7CVGCOOevvUK20ccKxQxiONSCqp8oHftW31mThys0VRpWPPLHw/4n1WKD+0WtdLty25o4/nlAB4BPTmtxvAeiNFtdLknOS3nEZPrxXWqOBnk98UuKj28+jt6E877nF3fw+0uUE2ktzaN22vuHr0auf1LwdrVp5jW4t79AMIo+VsfQ9/xr1SkxVwxdWPW/qXGtOPU8TmFxYTbL6xuIQVGd0RIB/lSG7tS0ZLJuGQT3AHt78V7aQGBDDg9jUD2ls5Je3gYnrmMHNb/AF6+8S3iG+h46WgxIQYl3Esh35z2wf8ACqs1pd6hZzLpk5iv4yJbVtgb5wMcA/WvUtR8IaPerJi0SCVznzIflOfXHQ1iw+C5NKiu7q2uDd3aoGt0KeWAwOex5z0q3i6coeY5Vk4W6nmHxM8bazbWkelWTXtpqFm8c0t6jDbPtT5gqj+HgkdjXqXwi8X/APCX+GFnuJVe/gby5+Apb0baOmf6V5Jq9+pvrjU9S0p7O5wY7jcrELjOFwOBwTx06V3HwM0WLQ9DTU/IDT63MWaRThYowCUGPzH1qK1KMaSfU5nbRo2/ilol3LHaaxoVj9r1aEmAxgcSRP1DewOK4bTPMubiS6163ks4hCIbmHrCDuAB2n5lwa96rE17RotTljEtnazx4O4yZBB7dOorGhiPZqzQmrnmr2+NSjssx3mxDMyLuw7MclQeccYwDim67i0s4Lm98lHSYBx5owqnt1POBx9K53xvq2veG9cgsNSvLFRebnVoEMaBx9wM+OeKq6Vb7ra/tPEMCtPc2U1xb2ETbhHtOfMdh7gmuz2toqf9eYtFuegQXlrLb2gaPz12nAiz8yFmCnPXB7+hqrrtyUtUjaRbRLfD5iAxLwdwI9RxXjXhzxY7BJb1PLtYEeMM8mA6ZBHyjnNXNE8UjX7zUPtEUcdpE4FsqKQzStwBn04y3tWip8vvFpcurPRTq6zskzyMFjXChxjeOgI+me+auWc8UUFxI6bd4CMznIHbdx7ViaZaXOk20FzcOJikZLnqZT2AB6fWmxyX+oXq29qVjVlMjmT/AFcS9WZiO1auMeVvZHRGnpzS0RoxbdT1B3M6iCMiPfIcEAemPate2RX86KFRvgAbzHXClSdygYPP9aoWD20FnbRW6F4mbEkw+7Jg5yW7Dvj3FSNPGS+RjySTHgEqQTnr9BUT97bYKk1LRbFbUZ7h7mG5ZPJMWYgA4UD6Y4FbEDLKBZoirFCuG81t5ZTyRx371h6U32jVPNt2nNjJl3mKEIuMnGTxW/HaxXCFo7eCCeQEbZG3SMMfeJH3en1qakoq0exjdbEH9l3N2yqz28gYmTdvJKg9+PbtTL+0RQGXMiR/diIy2M9cf1qC+uDpULQ28qTNjMmAEVjjGB6gVnWSrLqCvFKTEFBkDSEFMjoO9VGMmua+hRej0e5uZZn4C4ydrYUD0x/hUN59ttbwQxumwLu9RGMdc9ScVZBe1ezluJpvMD8eYvMgOeGA7DirV5drBIipHCWbA3uBuz3zxRzyvrqGpo+DlEHiGwEly8k8u/Mbdl8tiDjt+NFVvBD+Z4stZHgIZvMAYk5+43OOw4orzMarVFfsZSvfU5QTWjRzPZSvLHDOVlG0qImHGGJHfI5xinwrDcaq0ZuokhgXdJHHICe2NpHPJNa9x4M8SaoY1K21hvV9kp+ZoTgZ3BTg55x196qQ/BFXELrq1zZTr+7uHT5xKBjDKCeCSM816LxVJaN/qdDaT3OK1nUX05DJLFNNidnklhfepBGclecY6D9ao38ugazdtDdzyLJIv2kkxEc9Rnpjp1r6C8GeAtH8K28i2qSXdxLnzLm7O92B6j0A9hXR/wBmWX/PnbdAv+qXp6dOlZzzFaxitCHUPnbwpd+L9PhjTw/K1xZWm1pDb2eFmXdj53ILSEeoOQK6vUPiVryWwEfh26ubaceW1xbtuaKQr0XjnBxjI9a9liiSGNY4kVI14VVGAPwFKkaKxZVVSepA61xzrwk7uJLkn0PDdS0HxVcW6avqAubSdIvMlnM5c28aDhFUcsWGc/XNZvwt8Fa3qd5dalJfX2nxs+37UsewzLnPAbk+zV9AXVrHdpEshcBJFkG1iuSDkA+o9qsU/rcuTlsHO7EcMfkxIm5n2qFyxyTjufen7wTtyN3pSmolRhcu7BdhUBT375/pXKSSnNBGKbLIkQDSOFBIUZPUnoKdSEAFMlUSI8bbgGXBI44PoafRigZFbwpDbxwpkrGoUbuTxUvWigUCClopKAFoxR3ooAOlJ1paKAExRQaAKAA0AUtFACUGloxigDz34lWPi64MI8MNE8DvumXaoYKB93Lfeyc4rm7ey8ca5p62jS3UEEj7ZGuIkiCrnnGMEY5xivZqAK2hW5Y8vKgK2n2iWNlBaxF2SJAgZ2LMcdyfWrBpSKTtWW4GZrmg6ZrtqbfVrOK5ixgBxyvup7H6Vi+FvAml+GtX1G+05pit4APIkO5Ix7Z55rraKak0rXCx4v4yt/CcXiAWWiaFay63l98mPLhjPq/GGweg9aqxw2yLaiXTtPsVt90iRWw3DzGOGctxycfrXaeLfBsst9/aGixxFpG3XFu3AkP94H19q4+XT/ENvHK58PXErrkcOpyPpmvRw8acop82vqb0aUJatj7yUzQ73KeaQcLncMe3oPaqejzWmn6zZ3V686WMeYZVD4jLOAPnHRhziq0mpSafEq6tp15bR7efMiJANOjuIZcSwMjdJNo7fUfSu2VHng49DsnS5ocprXWsvp2kDbaCWFXZkjjKsHwThQw6cY+tY/h6PX/EkEt79jmg0qXeZYWUBlx/Avfn1+tdDEbS7RLbUFjwUzvTHXqpHXnmr+l3dzo9nNp9teTXdnsxETgSwsf9o8HHvXFPmgrRWpwVIyWxz9reWlgJprmcW8UCGKKzDH5QOg2n160ovAEZZZ44hMNzsrZ3E9AW6g4qrd6eNbu2fX9QhFysw2MIsfKM8MwGPeobK2k0lby3lsgkznImJ3K654YCtaDTfK9xQfRGtYyRW1pJFOIZFCkMJTuGAc4BAzn60RhL+WF/NhiVCWRQv3h1+b0qlvsfNGZnkgRMOig8+3TnnoafbSwpcSmzgNw2NqLnGxfoepNb8u8luXYmuWd3a1nQbpF3RBDhj/wLpj6U+GU3V8pePy51jAdXXzDJ7D396jtcsPJlDRptJHmRkshP06elS3E62t8iPH50iqpVmBGeOWGO/tS8kHKb/giZj4hgijhYRhpMsQOPlPHtRS+CR5uuWcokCgPISijhzsaivKxv8T5GdTc9GWPDs+5uRjGeKdRmlrmEFIxA49admkoEGKO9Hag0DFpKMetGaADABJx160Uc0tAivcWqXEkDSE4hfzAvYsOhP0zU4FHf60DA6CncYtB69KBS0hCUcClpMUAFAoFBoAKKMetFABRig0UAApKDS4oASloFFACiikxQKAFooooAMcUlFFABikoo4oAKTByMdKdRQBHNDHMpWVFkU9mGRXL674E0XVXMpgNvPj78B2fyrrDRirhUlB3i7FRk47M8i1Hwdq+kbWtiL6FTx2cDtn1rGTUmW5Nuzm1nUEPG4+8fXBr3U1m6poem6mo+3WcMpHRivzD6Gu2GOe1RXN1iL/GrnlQnjEkRdovOwMyodmAO5HTNRS6hFAZ5BJbeWwJPmMXBJ/lXoDeAdCfBeCTf0yshXP4U628B+H4HDNZeeRyBMxYfl0q/rNDezDnpb2Z5G+uaY18kzAq0Ywoichf/ANVblvHbGSOe0aSElQu7O4AH3PNeoP4a0ZoJoRplqqSrtfbGBkVzNx8OY1jZbDU7iNcYVJAGA9s9atYulLTWP4gp02+xzkkFsziWecK6jGDk5I7k0CWGFBIZmlcDho8gcnqRmtBfA2uhsNd2cijhSdw4+lXLX4dXDSMb3VSsUgHmRwR4Lfiap1qSWsyv3a6mR4K1yzn8d2NnG0xkfzSoHKj92x5xwOhor0bw54b03QEZNOg2l23s7HcxOMdfpRXm4mpGpO8NjnqSUpXRu0UUVzmYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power light photomicrograph. Note the resemblance to a dermal nevus on low power.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_16_7427=[""].join("\n");
var outline_f7_16_7427=null;
var title_f7_16_7428="Branchial arch derivatives";
var content_f7_16_7428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 627px\">",
"   <div class=\"ttl\">",
"    Branchial arch derivatives",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 607px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Lateral view of the head and neck region of a 4-week embryo demonstrating the branchial arches participating in formation of the bones of the face and neck.",
"    <br>",
"     (B) Definitive structures formed from branchial arch mesenchyme.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Sadler T. Langman's Medical Embryology, Ninth Edition. Baltimore: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_16_7428=[""].join("\n");
var outline_f7_16_7428=null;
var title_f7_16_7429="Tetracycline: Patient drug information";
var content_f7_16_7429=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tetracycline: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     see \"Tetracycline: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/38/28262?source=see_link\">",
"     see \"Tetracycline: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F226309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Tetra&reg;;",
"     </li>",
"     <li>",
"      Nu-Tetra",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat bacterial infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691503",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat GI (gastrointestinal) ulcers caused by infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692013",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat swelling of tissue around the teeth (periodontitis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tetracycline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696874",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take dairy products, bismuth (Pepto-Bismol&reg;), calcium, iron, magnesium, zinc, multivitamins with minerals, colestipol, cholestyramine, didanosine, or antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not lie down for at least 30 minutes after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop tube feeding for 2 hours before giving this drug. Restart tube feeding 1 hour after giving.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any unused part of this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11881 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-B2407C6BAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_16_7429=[""].join("\n");
var outline_f7_16_7429=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226309\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021596\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021598\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021597\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021602\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021603\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021605\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021600\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021601\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021606\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021607\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=related_link\">",
"      Tetracycline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/38/28262?source=related_link\">",
"      Tetracycline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_16_7430="Cerebellar arteries";
var content_f7_16_7430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F73656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F73656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Major cerebellar arterial branches",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 383px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The intracranial vertebral and basilar arteries are depicted with their major cerebellar arterial branches, including PICA (posterior inferior and cerebellar artery), AICA (anterior inferior cerebellar artery), and SCA (superior cerebellar artery).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Caplan, LR. Posterior circulation disease. Clinical findings, diagnosis, and management. Blackwell Science, Boston 1996. Copyright &copy;1996 Blackwell Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_16_7430=[""].join("\n");
var outline_f7_16_7430=null;
var title_f7_16_7431="Intraduct pap mucin neo";
var content_f7_16_7431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histologic appearance of intraductal papillary mucinous neoplasm, intestinal type",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intraductal papillary mucinous neoplasm (IPMN) of the intestinal type with intermediate-grade dysplasia. The duct lumen is to the right. Hematoxylin and eosin-stained section.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel S Longnecker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_16_7431=[""].join("\n");
var outline_f7_16_7431=null;
var title_f7_16_7432="Treatment of anti-GBM antibody (Goodpasture's) disease";
var content_f7_16_7432=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of anti-GBM antibody (Goodpasture's) disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/16/7432/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/16/7432/contributors\">",
"     Andre A Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/16/7432/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/16/7432/contributors\">",
"     Charles D Pusey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/16/7432/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/16/7432/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/16/7432/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/16/7432/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/16/7432/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-GBM antibody disease is one of the three major forms of rapidly progressive (or crescentic) glomerulonephritis. Although some patients present with relatively mild renal insufficiency, this disorder is typically associated with severe renal injury that, if untreated, progresses quickly to end-stage renal failure.",
"   </p>",
"   <p>",
"    An important determinant of the response to therapy and long-term prognosis is",
"    <strong>",
"     early diagnosis",
"    </strong>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. There is a direct correlation between the initial plasma creatinine concentration and the percent of glomeruli with crescents; in particular, crescents are present in more than 75 percent of glomeruli when the plasma creatinine concentration is above 5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (442",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Avoidance of maintenance dialysis is rare in patients who require dialysis within 72 hours of presentation, particularly in those who have crescents involving all glomeruli [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/3\">",
"     3",
"    </a>",
"    ]. In comparison, prevention of end-stage renal disease can usually be achieved in less severe cases, although some do progress. The proportion of preserved glomeruli may be the best determinant of prognosis (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Selection of patients to be treated'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The treatment of anti-GBM antibody disease is discussed in this review. The pathogenesis, prognosis and clinical manifestations of this disorder are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=see_link\">",
"     \"Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of choice in anti-GBM antibody disease is plasmapheresis combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/1,3-8\">",
"     1,3-8",
"    </a>",
"    ]. Plasmapheresis removes circulating anti-GBM antibodies and other mediators of inflammation (such as complement), while the immunosuppressive agents minimize new antibody formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the reported studies have been uncontrolled. Reviews of available reports suggest that approximately 40 to 45 percent of patients will benefit by not progressing to end-stage renal disease or death, when treated with plasmapheresis in combination with immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/4,5,8\">",
"     4,5,8",
"    </a>",
"    ]. However, recovery is much more likely in patients who begin treatment before oliguria ensues, and is rare in patients who require dialysis or who have 100 percent crescents on biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Plasmapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only available randomized trial evaluated outcomes among 17 patients who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    alone, or with plasmapheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/9\">",
"     9",
"    </a>",
"    ]. After the end of treatment, two of eight patients who received plasmapheresis, compared with six of nine in the immunosuppression alone group, became dialysis dependent. The authors concluded that, although there may have been some benefit from plasmapheresis, the percent of crescents on initial renal biopsy and entry plasma creatinine correlated better with outcome.",
"   </p>",
"   <p>",
"    Regardless of therapy, patients with less than 30 percent crescents and a plasma creatinine below 3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (265",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    did well, while those with severe crescentic involvement and a plasma creatinine above 4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (354",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    did poorly. Potential explanations for the inconclusive results are lack of adequate power and more severe baseline disease in the patients treated with plasmapheresis.",
"   </p>",
"   <p>",
"    Despite the absence of definitive evidence of benefit, plasmapheresis is generally recommended for the treatment of patients with anti-GBM disease. Two factors are considered by many experts to justify this recommendation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improved morbidity and mortality in the era of plasmapheresis compared to historic rates. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=see_link&amp;anchor=H4#H4\">",
"       \"Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease\", section on 'Prognosis of untreated patients'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Biological plausibility of greater amelioration of the consequences of disease with rapid removal of anti-GBM antibody, compared with a slower reduction in levels seen with immunosuppressive agents alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommended initial plasmapheresis prescription is either daily or alternate day 4-liter exchanges for two to three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/1,3,6\">",
"     1,3,6",
"    </a>",
"    ]. In general, albumin is given as the replacement fluid. If, however, the patient has had a recent renal biopsy or has pulmonary hemorrhage, then one to two liters of fresh frozen plasma should be substituted for albumin at the end of the procedure to reverse pheresis-induced depletion of coagulation factors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential complication with fresh frozen plasma (14 percent citrate by volume) is the development of metabolic alkalosis. Metabolism of the administered citrate generates bicarbonate, the excretion of which may be limited by concurrent renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6646?source=see_link\">",
"     \"Complications of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient should be reassessed at the end of this two- to three-week regimen. Further plasmapheresis may be unnecessary if the patient has improved and there is a marked decline in serum anti-GBM antibody titers. In comparison, continued pheresis may be required if the patient still has hemoptysis or antibody titers are still elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmapheresis must be accompanied by corticosteroids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/4\">",
"     4",
"    </a>",
"    ]. Most patients are given pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (15 to 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    to a maximum of dose of 1000 mg intravenously over 20 minutes) daily for three doses followed by daily oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day to a maximum of 60 to 80",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    which can be tapered once remission is induced. However, some patients have been treated with oral corticosteroids without an intravenous pulse [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/3\">",
"     3",
"    </a>",
"    ]. The initial cyclophosphamide dose is 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally. It has been suggested that the dose should not exceed 100 mg per day in patients over the age of 60 years to limit toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although we recommend oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , the relative efficacy of oral and intravenous cyclophosphamide in anti-GBM disease is not known. Intravenous therapy may be used in patients who cannot take oral medications, who are unreliable, or who have severe renal failure and oliguria, a setting in which the bladder toxicity of oral cyclophosphamide may be increased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This aggressive regimen is warranted because anti-GBM antibody disease may be fatal and has a high risk of permanent renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of therapy is unknown. Spontaneous cessation of autoantibody formation can take six to nine months or longer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/4,13\">",
"     4,13",
"    </a>",
"    ]. This observation led to the suggestion that, after remission is induced, maintenance therapy with less toxic drugs, such as low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    should be given for six to nine months.",
"   </p>",
"   <p>",
"    However, most patients in a large series were treated successfully with two to three weeks of plasmapheresis (daily when possible), approximately three months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and prednisone alone for the subsequent six to nine months (which was slowly tapered) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. These results and the low risk of recurrent disease, led some experts to suggest that the duration of therapy may be as short as two to three months, if anti-GBM antibody titers (which should be monitored regularly) are persistently negative [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anti-GBM antibody levels should be monitored every one to two weeks until they are negative on two occasions. We periodically monitor anti-GBM levels for up to six months to confirm that remission is maintained or at any time if there are clinical signs suggestive of recurrence. Recurrent clinical signs, in the presence of positive anti-GBM antibody, should prompt a further course of plasmapheresis.",
"   </p>",
"   <p>",
"    If antibody levels remain elevated, the immunosuppressive regimen above should be continued. If the anti-GBM antibody titers remain positive after three to four months of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, which is substituted for cyclophosphamide) should be continued for six to nine months.",
"   </p>",
"   <p>",
"    In this case, it should be ascertained that the persisting antibodies are directed towards the pathogenic epitope (the NC1 domain of the alpha-3 chain of type IV collagen). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Selection of patients to be treated",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, the above regimen was primarily utilized in patients with a plasma creatinine concentration below 5 to 7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (442 to 616",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary hemorrhage, which can be fatal. It is now recognized that aggressive immunosuppressive therapy may also be beneficial in patients who present with higher plasma creatinine concentrations.",
"   </p>",
"   <p>",
"    This was shown in the largest report of long-term outcomes of patients with anti-GBM antibody disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/3\">",
"     3",
"    </a>",
"    ]. In this retrospective review of 71 patients treated with plasma exchange,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , patient and renal survival varied with the severity at presentation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who presented with a plasma creatinine concentration of less than 5.7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (500",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      patient and renal survival were 100 and 95 percent at one year and 84 and 74 percent at last follow-up (median period of 90 months), respectively.",
"     </li>",
"     <li>",
"      For patients who presented with a plasma creatinine concentration greater than 5.7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (500",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      but who did not require immediate dialysis (within 72 hours of presentation), patient and renal survival were 83 and 82 percent at one year and 72 and 69 percent at last follow-up, respectively.",
"     </li>",
"     <li>",
"      For patients who required immediate dialysis, patient and renal survival were 65 and 8 percent at one year and 36 and 5 percent at last follow-up, respectively. All such patients who had crescents in all glomeruli on renal biopsy required long-term maintenance dialysis. By comparison, two patients with significant acute tubular necrosis plus crescents on biopsy eventually recovered long-term independent renal function.",
"     </li>",
"     <li>",
"      Among the 42 patients with pulmonary hemorrhage, bleeding resolved in approximately 90 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, plasmapheresis combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    should be administered in the following settings [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with pulmonary hemorrhage, independent of the presence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severity of renal involvement. Pulmonary bleeding appears to occur only in patients who have some concurrent pulmonary injury, since an increase in alveolar capillary permeability is required for the circulating antibodies to have access to the alveolar basement membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/15\">",
"       15",
"      </a>",
"      ]. Smoking is the most common cause of underlying pulmonary disease, although pneumonia and smoke or hydrocarbon inhalation have also been implicated in selected cases [",
"      <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with renal involvement (including those with plasma creatinine concentrations above 5 to 7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [442 to 616",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      who do not require immediate renal replacement therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The optimal therapy in patients who present with less severe disease (variably described as less than 30 to 50 percent crescents on renal biopsy) is uncertain. As described above, these patients may do well with pulse",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      followed by oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/4,9\">",
"       4,9",
"      </a>",
"      ]. However, we, and most physicians, treat such patients with the combined regimen, consisting of plasmapheresis plus prednisone and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/14\">",
"       14",
"      </a>",
"      ], used for patients with more severe disease [",
"      <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, there is a very low likelihood of a renal response in the patient who presents with dialysis-dependent renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/3\">",
"     3",
"    </a>",
"    ]. In this setting, the risk of therapy may exceed the likelihood of benefit if the patient does not have pulmonary hemorrhage. The recovery of renal function is particularly unlikely in those who are dialysis-dependent (8 percent renal survival at one year) and virtually unknown in dialysis-dependent patients with 100 percent crescents on renal biopsy.",
"   </p>",
"   <p>",
"    However, the inability to consistently and accurately identify the dialysis-dependent patient who may recover renal function has led some investigators to suggest that a short trial of combined plasmapheresis and immunosuppressive therapy should be considered, particularly among:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with very acute disease, in whom irreversible injury is less predictable [",
"      <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Younger patients who are better able to tolerate aggressive immunosuppression.",
"     </li>",
"     <li>",
"      Patients with anti-GBM antibody disease who have both antineutrophil cytoplasmic antibodies (ANCA) and clinical signs of a systemic vasculitis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/4,19-22\">",
"       4,19-22",
"      </a>",
"      ]. As an example, findings such as a purpuric rash and arthralgias are suggestive of a concurrent vasculitis, since they are uncommon in anti-GBM antibody disease alone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"       \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link&amp;anchor=H19#H19\">",
"       \"Classification of and approach to the vasculitides in adults\", section on 'Clinical manifestations and approach to diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment in this setting may be associated with a higher likelihood of a renal response [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. An older report suggested that as many as 40 percent of such patients recover some function if they are also ANCA positive [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/19\">",
"     19",
"    </a>",
"    ]. This frequency of improvement was thought to reflect the better renal prognosis seen in granulomatosis with polyangiitis (Wegener's).",
"   </p>",
"   <p>",
"    However, a later report found much worse outcomes in double-positive patients who were dialysis-dependent at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/22\">",
"     22",
"    </a>",
"    ]. In this retrospective study of 27 double-positive patients with both anti-GBM antibody and ANCA, renal biopsy showed extensive glomerular cellular crescents in most patients; among the 17 who were dialysis dependent at presentation, none recovered renal function despite immunosuppression. However, treatment was not optimal since not all patients were treated with plasma exchange. The overall renal survival rate was only 26 percent at one year. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H21#H21\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Role of plasma exchange'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Complications of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are potentially serious complications of therapy, such as intercurrent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/23\">",
"     23",
"    </a>",
"    ], which should be promptly treated since it may exacerbate disease. If there is a severe infection in the setting of plasmapheresis, a single infusion of intravenous immune globulin (100 to 400",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    can be given to partially replenish antibody levels [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    (oral or intravenous) can cause Pneumocystis jiroveci (carinii) pneumonia, amenorrhea, and bladder toxicity (cystitis and bladder cancer). Complications with high doses of corticosteroids include oropharyngeal fungal infections, gastritis (which can result in gastrointestinal bleeding in patients at increased risk), and bone loss. These complications and recommended prophylactic measures are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H12#H12\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Prevention of gonadal toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H16#H16\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Prevention of bladder toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Novel and experimental approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary evidence suggests that immunoadsorption may be effective in anti-GBM antibody disease, even in dialysis-dependent patients. In one such individual, as an example, the combined use of immunosuppression and immunoadsorption using a sepharose-coupled sheep-antihuman IgG column for 25 cycles resulted in the recovery of renal function, with a stable creatinine concentration of 2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/25\">",
"     25",
"    </a>",
"    ]. This result must be verified in additional patients before this technique can be recommended.",
"   </p>",
"   <p>",
"    Although anti-GBM antibody disease is initiated by antibodies, the cellular arm of the immune system is quickly enlisted and activated, thereby resulting in the pathogenic findings of a crescentic glomerulonephritis. This observation provides the rationale for attempting to suppress T cell involvement. The effect of blockade of CD28-B7, a costimulatory pathway for T cell activation, by the fusion protein CTLA4Ig was evaluated in a rat model of anti-GBM antibody disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/26\">",
"     26",
"    </a>",
"    ]. The development of crescentic glomerulonephritis was completely prevented. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=see_link\">",
"     \"Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the self-limited nature of anti-GBM antibody disease, patients who survive the first year with intact renal function generally do well. As previously delineated, renal and patient survival correlates closely with the degree of renal impairment at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with moderate to severe disease who do not require dialysis upon presentation generally respond to therapy, with recovery being maintained during long-term follow-up. By comparison, few who require immediate dialysis escape the need for maintenance dialysis. A report of a large series of Asian patients from China confirms the earlier findings seen in Caucasian patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relapses are uncommon (around two percent in one center's experience), but data are not sufficient to determine reliably how often this occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/3,28-31\">",
"     3,28-31",
"    </a>",
"    ]. Clinical relapses are more common in patients who are also ANCA-positive, in whom it is the vasculitis and not the anti-GBM antibody disease that is reactivated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a higher rate of recurrence in the patient who is a smoker or has exposure to hydrocarbon in his occupation. It is therefore recommended that they stop smoking",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    change their environment.",
"   </p>",
"   <p>",
"    The outcome in patients with recurrent disease, whether ANCA positive or negative, is typically superior to that in the initial presentation of anti-GBM antibody disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/32\">",
"     32",
"    </a>",
"    ]. In this setting, the diagnosis is usually clear, leading to the quick initiation of appropriate therapy.",
"   </p>",
"   <p>",
"    The role of renal transplantation in anti-GBM antibody disease, including the likelihood of recurrence, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22531?source=see_link\">",
"     \"Anti-GBM antibody disease: Recurrence after transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;If left untreated, anti-GBM antibody disease usually progresses rapidly to end-stage renal failure. Early diagnosis is critical for achieving the best response to therapy, since the percent of crescents on initial kidney biopsy and the pretherapy plasma creatinine concentration correlate best with outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/3\">",
"     3",
"    </a>",
"    ]. Recovery of kidney function is rare if dialysis is required at initiation of treatment.",
"   </p>",
"   <p>",
"    The treatment of choice is plasmapheresis in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . Plasmapheresis removes circulating anti-GBM antibodies and other mediators of inflammation, such as complement, and the immunosuppressive agents minimize new antibody formation. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend treatment in the following settings (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Selection of patients to be treated'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients with pulmonary hemorrhage (hemoptysis), independent of the presence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severity of kidney involvement.",
"     </li>",
"     <li>",
"      All patients with kidney involvement who do not require immediate renal replacement therapy.",
"     </li>",
"     <li>",
"      Selected patients on dialysis, without hemoptysis, such as those with very acute disease or antineutrophil cytoplasmic antibodies (ANCA) and clinical signs of a systemic vasculitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of hemoptysis, the risks of plasmapheresis and immunosuppression may outweigh benefits in patients on dialysis with a high percentage of crescents on biopsy. However, given the inability to consistently and accurately identify patients who may recover renal function, a short trial of therapy (two to three weeks) should be considered. The patient should be informed that the likelihood of regaining significant kidney function in this setting is small (8 percent at one year in the study cited above) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7432/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend concurrent treatment with plasmapheresis and immunosuppression (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Duration of therapy is largely determined by attainment of clinical remission and disappearance of anti-GBM antibody, which occurs in two to three weeks in most patients (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Treatment'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Plasmapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest daily (if possible) or alternate day four-liter exchanges with albumin given as the replacement fluid. In patients who have had a recent kidney biopsy or have pulmonary hemorrhage, we recommend substituting fresh frozen plasma (one to two liters) for albumin at the end of the procedure to reverse pheresis-induced depletion of coagulation factors (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We suggest initial plasmapheresis therapy for two to three weeks, with serial assessment of anti-GBM titers and clinical status. If the patient still has hemoptysis or positive anti-GBM titers at the end of the two- to three-week regimen, we suggest continuation of plasmapheresis until hemoptysis resolves and anti-GBM titers are markedly suppressed or negative (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For patients who develop a severe infection during plasmapheresis treatment, we suggest an infusion of intravenous immune globulin (100 to 400",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    in addition to antibiotic therapy (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;To minimize antibody formation, and recurrence of disease manifestations, we recommend an initial two- to three-month course of immunosuppressive therapy (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We suggest the following two medications concurrently (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day to a maximum of 60 to 80",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      whether or not it is preceded by a three day pulse of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (15 to 30",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum dose of 1000 mg) on each of the three days. The dose of prednisone is tapered after remission is induced (usually by three weeks) to 20",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      This dose is maintained until six weeks, then slowly tapered until discontinuation at approximately six months.",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) for two to three months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest monitoring anti-GBM antibody levels every week during plasmapheresis, then approximately every two weeks, until they are negative on two occasions.",
"   </p>",
"   <p>",
"    We suggest continuing to periodically monitor anti-GBM levels for up to six months to confirm that remission is maintained, or at any time there are signs suggestive of recurrence.",
"   </p>",
"   <p>",
"    If anti-GBM titers remain elevated, we suggest continuing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    as above, for up to four months (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If the titers remain positive after four months of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , we suggest ascertaining the specificity of the antibody to the pathogenetic epitope, and if specific, we suggest continuing prednisone alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, which is substituted for cyclophosphamide) for up to six to nine months (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the toxicities of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , we recommend prophylactic therapy for Pneumocystis pneumonia with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In the patient who is a smoker or has exposure to hydrocarbon in his occupation, it is strongly recommended that they stop smoking",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    change their environment given the higher rate of recurrence in this subgroup.",
"   </p>",
"   <p>",
"    In patients expected to receive larger doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , or who are at higher risk for gonadal or bladder toxicity, we suggest appropriate prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H12#H12\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Prevention of gonadal toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H16#H16\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Prevention of bladder toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the potential toxicities of prolonged steroid use, we suggest prophylactic treatments for oropharyngeal fungal infections (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    ), gastritis (H2 blocker or proton pump inhibitor for patients at increased risk for gastrointestinal bleeding) and bone loss (calcium and vitamin D or bisphosphonate). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/1\">",
"      Savage CO, Pusey CD, Bowman C, et al. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. Br Med J (Clin Res Ed) 1986; 292:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/2\">",
"      Pusey CD. Anti-glomerular basement membrane disease. Kidney Int 2003; 64:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/3\">",
"      Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001; 134:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/4\">",
"      Bolton WK. Goodpasture's syndrome. Kidney Int 1996; 50:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/5\">",
"      Madore F, Lazarus JM, Brady HR. Therapeutic plasma exchange in renal diseases. J Am Soc Nephrol 1996; 7:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/6\">",
"      Jindal KK. Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: evidence-based recommendations. Kidney Int Suppl 1999; 70:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/7\">",
"      Kaplan AA. The use of apheresis in immune renal disorders. Ther Apher Dial 2003; 7:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/8\">",
"      Couser WG. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis 1988; 11:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/9\">",
"      Johnson JP, Moore J Jr, Austin HA 3rd, et al. Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore) 1985; 64:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/10\">",
"      Lockwood CM, Rees AJ, Pearson TA, et al. Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome. Lancet 1976; 1:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/11\">",
"      Smith PK, d'Apice JF. Plasmapheresis in rapidly progressive glomerulonephritis. Am J Med 1978; 65:564.",
"     </a>",
"    </li>",
"    <li>",
"     Rees A. Goodpastures Syndrome. In: Current Therapy in Nephrology and Hypertension, 4th ed, Glassock R (Ed), Mosby, St. Louis 1998. p.166.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/13\">",
"      Flores JC, Taube D, Savage CO, et al. Clinical and immunological evolution of oligoanuric anti-GBM nephritis treated by haemodialysis. Lancet 1986; 1:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/14\">",
"      Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int 2003; 63:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/15\">",
"      Queluz TH, Pawlowski I, Brunda MJ, et al. Pathogenesis of an experimental model of Goodpasture's hemorrhagic pneumonitis. J Clin Invest 1990; 85:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/16\">",
"      Donaghy M, Rees AJ. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet 1983; 2:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/17\">",
"      Bombassei GJ, Kaplan AA. The association between hydrocarbon exposure and anti-glomerular basement membrane antibody-mediated disease (Goodpasture's syndrome). Am J Ind Med 1992; 21:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/18\">",
"      Maxwell AP, Nelson WE, Hill CM. Reversal of renal failure in nephritis associated with antibody to glomerular basement membrane. BMJ 1988; 297:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/19\">",
"      Jayne DR, Marshall PD, Jones SJ, Lockwood CM. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int 1990; 37:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/20\">",
"      Weber MF, Andrassy K, Pullig O, et al. Antineutrophil-cytoplasmic antibodies and antiglomerular basement membrane antibodies in Goodpasture's syndrome and in Wegener's granulomatosis. J Am Soc Nephrol 1992; 2:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/21\">",
"      O'Donoghue DJ, Short CD, Brenchley PE, et al. Sequential development of systemic vasculitis with anti-neutrophil cytoplasmic antibodies complicating anti-glomerular basement membrane disease. Clin Nephrol 1989; 32:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/22\">",
"      Levy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004; 66:1535.",
"     </a>",
"    </li>",
"    <li>",
"     Rees AJ, Lockwood CM, Peters DK. Nephritis due to antibodies to GBM. In: Progress in glomerulonephritis, Kincaid-Smith P, D'Apice AJ, Atkins RC (Eds), Wiley, New York City 1979. p.347.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/24\">",
"      Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis 1994; 23:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/25\">",
"      Laczika K, Knapp S, Derfler K, et al. Immunoadsorption in Goodpasture's syndrome. Am J Kidney Dis 2000; 36:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/26\">",
"      Reynolds J, Tam FW, Chandraker A, et al. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J Clin Invest 2000; 105:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/27\">",
"      Cui Z, Zhao MH, Xin G, Wang HY. Characteristics and prognosis of Chinese patients with anti-glomerular basement membrane disease. Nephron Clin Pract 2005; 99:c49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/28\">",
"      Mehler PS, Brunvand MW, Hutt MP, Anderson RJ. Chronic recurrent Goodpasture's syndrome. Am J Med 1987; 82:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/29\">",
"      Levy JB, Lachmann RH, Pusey CD. Recurrent Goodpasture's disease. Am J Kidney Dis 1996; 27:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/30\">",
"      Fonck C, Loute G, Cosyns JP, Pirson Y. Recurrent fulminant anti-glomerular basement membrane nephritis at a 7-year interval. Am J Kidney Dis 1998; 32:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/31\">",
"      Borza DB, Chedid MF, Colon S, et al. Recurrent Goodpasture's disease secondary to a monoclonal IgA1-kappa antibody autoreactive with the alpha1/alpha2 chains of type IV collagen. Am J Kidney Dis 2005; 45:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7432/abstract/32\">",
"      Kluth DC, Rees AJ. Anti-glomerular basement membrane disease. J Am Soc Nephrol 1999; 10:2446.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3085 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-23F828356C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_16_7432=[""].join("\n");
var outline_f7_16_7432=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Plasmapheresis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Selection of patients to be treated",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Complications of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Novel and experimental approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Plasmapheresis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22531?source=related_link\">",
"      Anti-GBM antibody disease: Recurrence after transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6646?source=related_link\">",
"      Complications of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=related_link\">",
"      Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_16_7433="Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults";
var content_f7_16_7433=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/16/7433/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/16/7433/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/16/7433/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/16/7433/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/16/7433/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/16/7433/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/16/7433/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defective conversion of 17-hydroxyprogesterone to 11-deoxycortisol accounts for more than 90 percent of cases of congenital adrenal hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/1\">",
"     1",
"    </a>",
"    ]. This conversion is mediated by 21-hydroxylase, or in current terminology, CYP21A2.",
"   </p>",
"   <p>",
"    The treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults will be reviewed here. The genetics, clinical manifestations, and diagnosis of 21-hydroxylase deficiency, and the management of infants and children with 21-hydroxylase deficiency are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link\">",
"     \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link\">",
"     \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31754?source=see_link\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOALS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to plan for the transition from pediatric to adult care and to consider additional issues that arise after puberty, such as sexual function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy of 21-hydroxylase deficiency in adults is directed toward providing glucocorticoid in sufficient doses to ensure normal cortisol replacement and to reduce the excessive secretion of both corticotropin-releasing hormone (CRH) and corticotropin (ACTH) and the degree of hyperandrogenemia.",
"   </p>",
"   <p>",
"    In patients with the salt-losing form of the disorder, mineralocorticoid is given to restore blood pressure, serum electrolyte concentrations, and extracellular fluid volume to normal.",
"   </p>",
"   <p>",
"    These goals can be difficult to achieve without overtreatment, with its attendant risk of osteopenia, obesity, and other clinical manifestations of Cushing's syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOIDS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treating 21-hydroxylase deficiency in women is lower serum concentrations of adrenal precursors and androgens (17-hydroxyprogesterone, androstenedione, DHEA sulfate, testosterone) to slightly above the upper limits for normal women. As in children, this may not be possible without causing Cushing's syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of men with 21-hydroxylase deficiency varies with the type of disease. The salt-wasting forms require glucocorticoid and mineralocorticoid replacement. In comparison, some men with the simple virilizing form require no treatment except glucocorticoid supplementation during acute illness or major surgery. There is, however, a continuum in the degree of excess ACTH secretion across the various forms of 21-hydroxylase deficiency.",
"   </p>",
"   <p>",
"    Testicular abnormalities are more common in the salt-wasting form of 21-hydroxylase deficiency, but also occur in simple virilizing forms in which their presence may affect treatment decisions. These abnormalities include intratesticular masses comprised of adrenal rest tissue,",
"    <span class=\"nowrap\">",
"     oligo/azoospermia,",
"    </span>",
"    and low testosterone production. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link\">",
"     \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H19\">",
"     'Male reproduction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    , given as a bedtime dose of 0.25 to 0.75 mg, effectively suppresses ACTH secretion for much of the next day, and is the preferred regimen for older adolescents and adults after epiphyseal closure is complete. The few studies reporting treatment of testicular rest tumors or infertility in men initially used doses of 0.75",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    which often were reduced over time because of the development of cushingoid features [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We consider bedtime",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    administration to be optimal because most ACTH secretion occurs between about 2:00 AM and 10:00 AM. The duration of the biologic action of dexamethasone taken at bedtime encompasses this period. Additional doses of dexamethasone increase the risk of osteoporosis and Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United Kingdom, other regimens are popular, including daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (median dose 7",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    range 4 to 10",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    and single or split dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (median 30",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    range 15 to 40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef64138 \" href=\"UTD.htm?41/61/42972\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Endocrine Society&rsquo;s 2010 Clinical Practice Guideline suggests that either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    or long acting glucocorticoids may be used for adults with classic 21-hydroxylase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of infants and children with 21-hydroxylase deficiency is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31754?source=see_link\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Monitoring treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standards have not been established for monitoring glucocorticoid therapy in adults. In general, the same principles apply as in treating children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum concentrations of 17-hydroxyprogesterone, DHEA sulfate, androstenedione, and testosterone should be measured.",
"     </li>",
"     <li>",
"      Some women who fail to have menarche despite treatment may have nonsuppressible serum 17-hydroxyprogesterone concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One should be alert to symptoms and signs of Cushing's syndrome and bone mineral density should be measured periodically to look for bone loss.",
"     </li>",
"     <li>",
"      Men should undergo periodic testicular evaluation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link\">",
"       \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Stress dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with classic 21-hydroxylase deficiency are at risk for acute adrenal insufficiency during acute illness or major surgery, regardless of age or sex. These patients should have a bracelet or wallet card that identifies their disease and therapy, and should take extra glucocorticoid when ill [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of adrenal insufficiency in adults\", section on 'Illness or surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MINERALOCORTICOID REPLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mineralocorticoid is usually given as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    , in a dose sufficient to restore normal serum sodium and potassium concentrations and plasma renin activity; excessive dosing can induce hypertension and hypokalemia as seen in any form of primary mineralocorticoid excess. Optimal mineralocorticoid replacement has the added advantage of permitting the glucocorticoid dose to be reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The need for mineralocorticoids typically decreases after infancy, but remains relatively stable during adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Underdosing can lead to chronic volume depletion that is clinically inapparent but results in persistent overproduction of renin and angiotensin II. Angiotensin II can stimulate early steps in the steroidogenic pathway leading to higher adrenal androgen synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with the simple virilizing form of 21-hydroxylase deficiency have increased plasma renin activity and plasma aldosterone concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Such patients may benefit from mineralocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. While there are no large-scale trials of this approach, small studies show that the addition of Florinef can normalize renin levels and improve control of 17-hydroxyprogesterone levels [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. This is similar to the approach used in patients with primary adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usual adult dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    is 0.1 to 0.2",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    but some patients require more [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Monitoring therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aim of mineralocorticoid replacement is to lower the plasma renin activity to the upper limit of normal, which should be associated with normalization of the serum sodium and potassium concentrations. Standing and supine blood pressure and dependent edema should be monitored for evidence of undertreatment or overtreatment. Suppression of renin to the lower limit of normal or below normal indicates overtreatment. In adults receiving a stable dose of glucocorticoid and Florinef, monitoring renin values every two to three years is sufficient in the absence of any acute symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RECONSTRUCTIVE SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to medical therapy, many girls with classic 21-hydroxylase deficiency eventually require reconstructive gynecologic surgery as adolescents or adults, usually clitoroplasty and vaginoplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/1,23\">",
"     1,23",
"    </a>",
"    ]. This may represent an initial procedure or revision of a procedure performed in infancy. In one report of 16 adult women with 21-hydroxylase deficiency, 15 had undergone reconstructive genital surgery with 8 of 16 requiring second procedures; 12 of 15 who had undergone surgery were considered to have an adequate vaginal introitus for sexual activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31754?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\", section on 'Ambiguous genitalia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=see_link\">",
"     \"Management of the infant with ambiguous genitalia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SURGICAL ADRENALECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been some reports of total bilateral adrenalectomy for severe 21-hydroxylase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. The major benefit of this procedure lies in eliminating the need to administer glucocorticoids to suppress adrenal androgen secretion. However, substituting primary adrenal insufficiency (with its need for strict compliance with lifelong glucocorticoid and mineralocorticoid replacement therapy) for congenital adrenal hyperplasia should be given great consideration before this irrevocable decision is made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PSYCHOLOGICAL AND GENETIC COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents should be offered counseling as soon as the diagnosis is established. Children should eventually be informed of their condition by both their clinicians and parents, repeating the information in a manner appropriate for their age. Anticipatory counseling of parents about a possible tendency toward male gender role behavior of affected girls and sensitive counseling and reassurance of adolescent girls should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link&amp;anchor=H10#H10\">",
"     \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\", section on 'Sexual behavior'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data on long-term psychological outcome are limited, with at least one study reporting an increase in psychiatric disorders in these patients as adults [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/27\">",
"     27",
"    </a>",
"    ]. In contrast, in a study of 18 women with 21-hydroxylase deficiency, social adjustment and self-esteem scores were normal, with no obvious increase in mood disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may be a delay in establishing sexual relationships, and sexual function may not be optimal, regardless of previous reconstructive surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/29\">",
"     29",
"    </a>",
"    ]. These issues may require counseling and possibly treatment.",
"   </p>",
"   <p>",
"    The Endocrine Society&rsquo;s Clinical Practice Guideline recommends that genetic counseling be provided to adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT OF PREGNANT WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with 21-hydroxylase deficiency, particularly those with the salt-losing variant, have decreased fertility, which is thought to be related to noncompliance with medical therapy (resulting in anovulation) and, in some cases, inadequate reconstructive surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In women who do conceive, serum androstenedione, testosterone, and 17-hydroxyprogesterone should be measured in the mother every two to three weeks. The glucocorticoid dose should be increased, if necessary, to maintain the concentrations within the normal ranges for the stage of pregnancy. A glucocorticoid that is metabolized by the placenta, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    , should be used to avoid glucocorticoid exposure and suppression of the hypothalamic-pituitary-adrenal axis of the fetus.",
"   </p>",
"   <p>",
"    Full-term pregnancies and delivery of healthy female infants with normal external genitalia can be achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/31\">",
"     31",
"    </a>",
"    ], with subsequent normal growth and development in girls as well as boys [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/32\">",
"     32",
"    </a>",
"    ]. Even if androgen production cannot be suppressed to normal, placental aromatase activity protects the fetal genitalia and, presumably, the brain from masculinization [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis of 21-hydroxylase deficiency and prenatal treatment of affected offspring are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\", section on 'Prenatal diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31754?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\", section on 'Prenatal therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OUTCOME OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome of medical therapy for classic 21-hydroxylase deficiency in adults can be measured by evaluating bone density and Cushingoid features. Menstrual function in women and testicular function in men are also important indices of treatment.",
"   </p>",
"   <p>",
"    Pediatric outcomes (growth) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31754?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\", section on 'Growth'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Bone density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone mineral density in adults with congenital adrenal hyperplasia is low when compared to healthy controls and is thought to be due to a number of factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient age &mdash; The likelihood of decreased bone density varies with the duration of and possible chronic overtreatment with glucocorticoid therapy. In two different studies, bone density was similar to matched normal subjects in 30 younger patients (mean age 17.5 years) who had been treated with glucocorticoid therapy for a mean of 15 years [",
"      <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/33\">",
"       33",
"      </a>",
"      ], but was significantly reduced in adult women who had been treated since childhood [",
"      <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type of congenital adrenal hyperplasia &mdash; The type of congenital adrenal hyperplasia appears to modulate the effect of glucocorticoids on bone mineral density. In a series of 11 adult women with the salt-wasting form (SW) and 15 with the simple virilizing form, osteopenia was seen in 5 of 11 (45 percent) of the SW patients compared to only 2 of 15 (13 percent) simple virilizing patients, and one of nine (11 percent) of healthy controls [",
"      <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/35\">",
"       35",
"      </a>",
"      ]. Women in the SW group were, on average, taking higher glucocorticoid replacement doses. Patients with the most suppressed serum DHEA and DHEAS concentrations had the lowest bone density.",
"     </li>",
"     <li>",
"      Short stature &mdash; The adult height achieved in treated patients is usually less than that in reference groups and short stature can result in an underestimate of an individual's BMD. However, BMD in patients with 21-hydroxylase deficiency is lower than in healthy controls, even after adjustment for height [",
"      <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/36\">",
"       36",
"      </a>",
"      ]. Other mechanisms that may explain the low BMD values include overtreatment during childhood and diminished peak bone mass acquisition [",
"      <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Menstrual cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most girls undergo menarche (at a mean age of 13 years in one study). However, most then have anovulatory cycles secondary to hyperandrogenemia, which results from inadequate glucocorticoid therapy. Fertility rates are decreased, which is thought to be related to anovulation and, in some cases, inadequate reconstructive surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link&amp;anchor=H12#H12\">",
"     \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\", section on 'Female reproduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adolescent girls with virilization should have gynecological consultation before or during adolescence, ideally with the pediatric surgeon if reconstructive surgery has been done. Guidelines suggest that this examination be conducted under anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/9\">",
"     9",
"    </a>",
"    ]. Women with CAH have normal fertility but fewer children, probably because other factors (eg, surgical outcome, fewer partners) reduce the number of women trying to conceive [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During pregnancy, women should not receive glucocorticoids that cross the placenta, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , for routine replacement therapy. Instead,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    should be used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ovarian adrenal rest tumors are rare in patients with congenital adrenal hyperplasia, with none found in a systematic evaluation of 13 women [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/38\">",
"     38",
"    </a>",
"    ], and only 10 cases reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. They occur primarily in the ovarian tissue, and less often in the",
"    <span class=\"nowrap\">",
"     paraovarian/adnexal",
"    </span>",
"    area. The true prevalence may be higher, as the tumors are difficult to identify by imaging, with most identified during surgery or at autopsy. Imaging with",
"    <span class=\"nowrap\">",
"     18FDG-PET/CT",
"    </span>",
"    localized rest tissue in three women [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/39-41\">",
"     39-41",
"    </a>",
"    ] (including one with Nelson&rsquo;s syndrome); in one case tumors were only visible after administration of cosyntropin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/40\">",
"     40",
"    </a>",
"    ]. While the etiology appears related to sustained elevations in ACTH as a result of poor compliance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adrenalectomy for Cushing&rsquo;s disease, it is not known if glucocorticoid or mineralocorticoid therapy reduces the tumor size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Male reproduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reproductive function may be impaired in men with 21-hydroxylase deficiency due to testicular masses composed of adrenal tissue, referred to as testicular adrenal rest tumors (or testicular rests),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impaired spermatogenesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link&amp;anchor=H13#H13\">",
"     \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\", section on 'Male reproduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Testicular adrenal rests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular adrenal rest tumors are typically bilateral and painful. Glucocorticoid treatment is sometimes but not always effective for decreasing the size of the testicular mass and relieving pain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/3,4,42,43\">",
"     3,4,42,43",
"    </a>",
"    ]. Case reports have noted either a decrease in size or even disappearance of testicular masses with supraphysiologic doses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, in a series of 14 men with testicular adrenal rests, no patient had an adequate response to glucocorticoid therapy, and all eventually required testicular surgery for pain relief [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest replacement glucocorticoid therapy for men with the simple virilizing form who have testicular rests. In men who do not respond to glucocorticoid therapy, testis-sparing surgery (tumor enucleation) is suggested to relieve pain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. However, surgery may not result in return of fertility, as illustrated by a report of eight men with oligospermia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    testicular pain due to the testicular mass. Although testis-sparing surgery provided pain relief, no improvements in sperm concentration were seen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no available data on the use of glucocorticoid therapy to prevent testicular rests in men with the simple virilizing form. If glucocorticoid therapy is chosen, it should be discontinued when fertility is no longer desired. However, ultrasound monitoring for testicular adrenal rest tumors should continue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Semen analysis is recommended in all adult men with classic 21-hydroxylase deficiency, as spermatogenesis may be impaired. For oligospermic men with the simple virilizing form, we suggest glucocorticoid therapy until fertility is no longer desired. Although glucocorticoid therapy is sometimes effective [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/46\">",
"     46",
"    </a>",
"    ], it does not always result in improved spermatogenesis and fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It appears that both undertreatment and overtreatment with glucocorticoids may impair fertility as illustrated by a report of 22 men with classic 21-hydroxylase deficiency (15 salt-wasting, seven simple-virilizing) receiving glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/48\">",
"     48",
"    </a>",
"    ]. All patients had an abnormal semen analysis and 10 had testicular adrenal rests (five of whom had biochemical evidence of undertreatment). In several other patients, decreased serum gonadotropin concentrations suggested over-treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although mortality is increased threefold in patients aged one to four years, often due to adrenal crisis after an infection, mortality does not appear to be increased in adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid therapy in adults with 21-hydroxylase deficiency may be associated with undesirable side effects, including the development of cushingoid features, and unfavorable changes in body composition (an increase in fat mass and body mass index (BMI), particularly in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7433/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]). Therefore, the smallest possible dose of glucocorticoid should be used to avoid these adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/56/19330?source=see_link\">",
"       \"Patient information: Congenital adrenal hyperplasia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goals of therapy of classic 21-hydroxylase deficiency include providing",
"      <strong>",
"       glucocorticoids",
"      </strong>",
"      in sufficient doses to reduce hyperandrogenemia, and",
"      <strong>",
"       mineralocorticoids",
"      </strong>",
"      (in patients with the salt-losing form of the disorder) to restore blood pressure, serum electrolyte concentrations, and extracellular fluid volume to normal. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Goals of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      These goals may be difficult to achieve without overtreatment, with its attendant risk of osteopenia and clinical manifestations of Cushing's syndrome. Therapy for nonclassic 21-hydroxylase deficiency is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19560?source=see_link\">",
"       \"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Both men and women with the salt-wasting form of 21-hydroxylase deficiency must be treated with both glucocorticoid and mineralocorticoid therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Goals of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with the simple virilizing form of 21-hydroxylase deficiency require glucocorticoid, but not mineralocorticoid therapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Men with salt-wasting and simple virilizing forms of 21-hydroxylase deficiency who desire future fertility should be evaluated with serum testosterone level, testicular ultrasound, and semen analysis. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Fertility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest replacement glucocorticoid therapy for men with the simple virilizing form who have testicular rests",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      oligospermia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Male reproduction'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      While glucocorticoids may also be considered in men with the simple virilizing form for prevention of testicular rests and oligospermia, there are currently no data to support this approach. If glucocorticoids are chosen in this setting,",
"      <strong>",
"      </strong>",
"      they may be discontinued when fertility is no longer desired. However, ultrasound monitoring for testicular adrenal rest tumors should continue. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Male reproduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For glucocorticoid therapy, we typically use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , given as a bedtime dose of 0.25 to 0.75 mg, for older adolescents and adults. While other regimens are widely used, the ease of once-daily dosing probably improves compliance. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For mineralocorticoid therapy, the usual adult dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"       fludrocortisone",
"      </a>",
"      is 0.1 to 0.2",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      but some patients require more. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Mineralocorticoid replacement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of infants and children with classic 21-hydroxylase deficiency and patients with nonclassic 21-hydroxylase deficiency is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31754?source=see_link\">",
"       \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19560?source=see_link\">",
"       \"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients on mineralocorticoid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      glucocorticoid therapy, we suggest monitoring annually or more often if treatment goals are not met. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Monitoring treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Monitoring therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women receiving glucocorticoid therapy, we suggest monitoring serum concentrations of adrenal precursors and androgens (17-hydroxyprogesterone, androstenedione, DHEA sulfate, testosterone). The goal is to lower serum concentrations to slightly above the upper normal limits. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Monitoring treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men receiving glucocorticoid therapy, we suggest monitoring serum concentrations of adrenal precursors and androgens (17-hydroxyprogesterone, androstenedione, DHEA sulfate). The goal is to lower serum concentrations to slightly above the upper normal limits. Testosterone should be measured to assess testicular function; subnormal values should prompt additional evaluation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Monitoring treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients on mineralocorticoid therapy, we suggest monitoring plasma renin activity and serum electrolytes. The goal is to lower the plasma renin activity to the upper normal limit and serum sodium and potassium concentrations to normal. Standing and supine blood pressure and dependent edema should be monitored for evidence of under- or over-treatment. Suppression of renin to the lower normal or below normal range indicates over-treatment. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Monitoring therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In pregnant women, we recommend using a glucocorticoid that is metabolized by the placenta, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      , to avoid glucocorticoid exposure and adrenal suppression of the fetus (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment of pregnant women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest measuring serum androstenedione, testosterone, and 17-hydroxyprogesterone concentrations in the mother every two to three weeks. The glucocorticoid dose should be increased, if necessary, to maintain the concentrations within the normal ranges for the stage of pregnancy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment of pregnant women'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/1\">",
"      White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/2\">",
"      Kruse B, Riepe FG, Krone N, et al. Congenital adrenal hyperplasia - how to improve the transition from adolescence to adult life. Exp Clin Endocrinol Diabetes 2004; 112:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/3\">",
"      Bonaccorsi AC, Adler I, Figueiredo JG. Male infertility due to congenital adrenal hyperplasia: testicular biopsy findings, hormonal evaluation, and therapeutic results in three patients. Fertil Steril 1987; 47:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/4\">",
"      Cutfield RG, Bateman JM, Odell WD. Infertility caused by bilateral testicular masses secondary to congenital adrenal hyperplasia (21-hydroxylase deficiency). Fertil Steril 1983; 40:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/5\">",
"      Cunnah D, Perry L, Dacie JA, et al. Bilateral testicular tumours in congenital adrenal hyperplasia: a continuing diagnostic and therapeutic dilemma. Clin Endocrinol (Oxf) 1989; 30:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/6\">",
"      Horrocks PM, London DR. Effects of long term dexamethasone treatment in adult patients with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 1987; 27:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/7\">",
"      Ogilvie CM, Crouch NS, Rumsby G, et al. Congenital adrenal hyperplasia in adults: a review of medical, surgical and psychological issues. Clin Endocrinol (Oxf) 2006; 64:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/8\">",
"      Ross RJ, Rostami-Hodjegan A. Timing and type of glucocorticoid replacement in adult congenital adrenal hyperplasia. Horm Res 2005; 64 Suppl 2:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/9\">",
"      Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95:4133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/10\">",
"      Cabrera MS, Vogiatzi MG, New MI. Long term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86:3070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/11\">",
"      Holmes-Walker DJ, Conway GS, Honour JW, et al. Menstrual disturbance and hypersecretion of progesterone in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 1995; 43:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/12\">",
"      Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet 2005; 365:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/13\">",
"      Lopes LA, Dubuis JM, Vallotton MB, Sizonenko PC. Should we monitor more closely the dosage of 9 alpha-fluorohydrocortisone in salt-losing congenital adrenal hyperplasia? J Pediatr Endocrinol Metab 1998; 11:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/14\">",
"      Jansen M, Wit JM, van den Brande JL. Reinstitution of mineralocorticoid therapy in congenital adrenal hyperplasia. Effects on control and growth. Acta Paediatr Scand 1981; 70:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/15\">",
"      Schaison G, Couzinet B, Gourmelen M, et al. Angiotensin and adrenal steroidogenesis: study of 21-hydroxylase-deficient congenital adrenal hyperplasia. J Clin Endocrinol Metab 1980; 51:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/16\">",
"      Nimkarn S, Lin-Su K, Berglind N, et al. Aldosterone-to-renin ratio as a marker for disease severity in 21-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab 2007; 92:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/17\">",
"      Frisch H, Battelino T, Schober E, et al. Salt wasting in simple virilizing congenital adrenal hyperplasia. J Pediatr Endocrinol Metab 2001; 14:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/18\">",
"      Kuhnle U, R&ouml;sler A, Pareira JA, et al. The effects of long-term normalization of sodium balance on linear growth in disorders with aldosterone deficiency. Acta Endocrinol (Copenh) 1983; 102:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/19\">",
"      R&ouml;sler A, Levine LS, Schneider B, et al. The interrelationship of sodium balance, plasma renin activity and ACTH in congenital adrenal hyperplasia. J Clin Endocrinol Metab 1977; 45:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/20\">",
"      Simpoulos AP, Marshall JR, Delea CS, Bartter FC. Studies on the deficiency of 21-hydroxylation in patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1971; 32:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/21\">",
"      Oelkers W, Diederich S, B&auml;hr V. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J Clin Endocrinol Metab 1992; 75:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/22\">",
"      Hughes IA. Management of congenital adrenal hyperplasia. Arch Dis Child 1988; 63:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/23\">",
"      Premawardhana LD, Hughes IA, Read GF, Scanlon MF. Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience. Clin Endocrinol (Oxf) 1997; 46:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/24\">",
"      Gunther DF, Bukowski TP, Ritz&eacute;n EM, et al. Prophylactic adrenalectomy of a three-year-old girl with congenital adrenal hyperplasia: pre- and postoperative studies. J Clin Endocrinol Metab 1997; 82:3324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/25\">",
"      Bruining H, Bootsma AH, Koper JW, et al. Fertility and body composition after laparoscopic bilateral adrenalectomy in a 30-year-old female with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/26\">",
"      Van Wyk JJ, Ritzen EM. The role of bilateral adrenalectomy in the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab 2003; 88:2993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/27\">",
"      Slijper FM, Drop SL, Molenaar JC, de Muinck Keizer-Schrama SM. Long-term psychological evaluation of intersex children. Arch Sex Behav 1998; 27:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/28\">",
"      Morgan JF, Murphy H, Lacey JH, Conway G. Long term psychological outcome for women with congenital adrenal hyperplasia: cross sectional survey. BMJ 2005; 330:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/29\">",
"      Kuhnle U, Bullinger M, Schwarz HP, Knorr D. Partnership and sexuality in adult female patients with congenital adrenal hyperplasia. First results of a cross-sectional quality-of-life evaluation. J Steroid Biochem Mol Biol 1993; 45:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/30\">",
"      Mulaikal RM, Migeon CJ, Rock JA. Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 1987; 316:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/31\">",
"      Lo JC, Schwitzgebel VM, Tyrrell JB, et al. Normal female infants born of mothers with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1999; 84:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/32\">",
"      Krone N, Wachter I, Stefanidou M, et al. Mothers with congenital adrenal hyperplasia and their children: outcome of pregnancy, birth and childhood. Clin Endocrinol (Oxf) 2001; 55:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/33\">",
"      Mora S, Saggion F, Russo G, et al. Bone density in young patients with congenital adrenal hyperplasia. Bone 1996; 18:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/34\">",
"      Falhammar H, Filipsson H, Holmdahl G, et al. Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007; 92:4643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/35\">",
"      King JA, Wisniewski AB, Bankowski BJ, et al. Long-term corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 2006; 91:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/36\">",
"      Sciannamblo M, Russo G, Cuccato D, et al. Reduced bone mineral density and increased bone metabolism rate in young adult patients with 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006; 91:4453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/37\">",
"      Caster&agrave;s A, De Silva P, Rumsby G, Conway GS. Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate. Clin Endocrinol (Oxf) 2009; 70:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/38\">",
"      Stikkelbroeck NM, Hermus AR, Schouten D, et al. Prevalence of ovarian adrenal rest tumours and polycystic ovaries in females with congenital adrenal hyperplasia: results of ultrasonography and MR imaging. Eur Radiol 2004; 14:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/39\">",
"      Tiosano D, Vlodavsky E, Filmar S, et al. Ovarian adrenal rest tumor in a congenital adrenal hyperplasia patient with adrenocorticotropin hypersecretion following adrenalectomy. Horm Res Paediatr 2010; 74:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/40\">",
"      Crocker MK, Barak S, Millo CM, et al. Use of PET/CT with cosyntropin stimulation to identify and localize adrenal rest tissue following adrenalectomy in a woman with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2012; 97:E2084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/41\">",
"      Lila AR, Malhotra G, Sarathi V, et al. Localization of remnant and ectopic adrenal tissues with cosyntropin-stimulated 18F-FDG-PET/CT in a patient with Nelson syndrome with persistent hypercortisolism. J Clin Endocrinol Metab 2010; 95:5172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/42\">",
"      Rutgers JL, Young RH, Scully RE. The testicular \"tumor\" of the adrenogenital syndrome. A report of six cases and review of the literature on testicular masses in patients with adrenocortical disorders. Am J Surg Pathol 1988; 12:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/43\">",
"      Ashley RA, McGee SM, Isotaolo PA, et al. Clinical and pathological features associated with the testicular tumor of the adrenogenital syndrome. J Urol 2007; 177:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/44\">",
"      Walker BR, Skoog SJ, Winslow BH, et al. Testis sparing surgery for steroid unresponsive testicular tumors of the adrenogenital syndrome. J Urol 1997; 157:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/45\">",
"      Claahsen-van der Grinten HL, Otten BJ, Takahashi S, et al. Testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia: evaluation of pituitary-gonadal function before and after successful testis-sparing surgery in eight patients. J Clin Endocrinol Metab 2007; 92:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/46\">",
"      Tiitinen A, V&auml;lim&auml;ki M. Primary infertility in 45-year-old man with untreated 21-hydroxylase deficiency: successful outcome with glucocorticoid therapy. J Clin Endocrinol Metab 2002; 87:2442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/47\">",
"      Merke DP, Bornstein SR, Avila NA, Chrousos GP. NIH conference. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Intern Med 2002; 136:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/48\">",
"      Reisch N, Flade L, Scherr M, et al. High prevalence of reduced fecundity in men with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2009; 94:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/49\">",
"      Swerdlow AJ, Higgins CD, Brook CG, et al. Mortality in patients with congenital adrenal hyperplasia: a cohort study. J Pediatr 1998; 133:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/50\">",
"      Stikkelbroeck NM, Oyen WJ, van der Wilt GJ, et al. Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2003; 88:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7433/abstract/51\">",
"      Falhammar H, Filipsson H, Holmdahl G, et al. Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007; 92:110.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 136 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-0970125B04-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_16_7433=[""].join("\n");
var outline_f7_16_7433=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOALS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Monitoring treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Stress dosing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MINERALOCORTICOID REPLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Monitoring therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RECONSTRUCTIVE SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SURGICAL ADRENALECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PSYCHOLOGICAL AND GENETIC COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT OF PREGNANT WOMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prenatal diagnosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OUTCOME OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Bone density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Male reproduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Testicular adrenal rests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Fertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/136\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/136|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/61/42972\" title=\"table 1\">",
"      Relative potency glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=related_link\">",
"      Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=related_link\">",
"      Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19560?source=related_link\">",
"      Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=related_link\">",
"      Management of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/56/19330?source=related_link\">",
"      Patient information: Congenital adrenal hyperplasia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31754?source=related_link\">",
"      Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_16_7434="Patient selection for and immunologic issues relating to kidney-pancreas transplantation in diabetes mellitus";
var content_f7_16_7434=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Patient selection for and immunologic issues relating to kidney-pancreas transplantation in diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/16/7434/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/16/7434/contributors\">",
"     Christina Klein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/16/7434/contributors\">",
"     R Paul Robertson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/16/7434/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/16/7434/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/16/7434/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/16/7434/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/16/7434/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/16/7434/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many institutions offer pancreas transplantation as an established definitive treatment for selected type 1 diabetic patients. Those with end-stage renal disease (ESRD) can receive a simultaneous pancreas-kidney (SPK) or sequential pancreas after kidney (PAK) transplant, while non-uremic diabetics may be candidates for pancreas transplantation alone (PTA).",
"   </p>",
"   <p>",
"    This topic will review patient selection for and immunologic aspects relating to combined or sequential kidney-pancreas transplantation in patients with diabetes mellitus and ESRD. The benefits and complications (other than those induced by immunosuppression) associated with these procedures and the roles of pancreas transplantation alone and islet transplantation in diabetic patients without renal failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/19/41272?source=see_link\">",
"     \"Benefits and complications associated with kidney-pancreas transplantation in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7162?source=see_link\">",
"     \"Pancreas and islet transplantation in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110232793\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among 1331 pancreas transplants performed in the United States in 2007, 65, 20, and 15 percent were SPK, PAK, and PTA, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Nearly 70 percent of those undergoing PAK had a previous living donor kidney.",
"   </p>",
"   <p>",
"    While SPK most often employs grafts procured from a single deceased donor after brain death, some are simultaneous living donor kidney and deceased donor pancreas, and a few are living donor for both organs. Rarely, SPK is also procured from a deceased donor after cardiac death [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PAK typically involves transplantation of a deceased donor pancreas graft into a recipient with a functioning living or deceased donor kidney allograft. Some patients without substantial renal disease may be candidates for PTA. In a report from the University of Minnesota, which has the largest experience, 1194 pancreas transplants had been performed as of 2002: 498 simultaneous with a kidney, 404 after a kidney, and 292 alone for nonuremic diabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GRAFT SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The one and five year unadjusted pancreas graft survival rates (usually defined as freedom from insulin therapy, normal fasting blood glucose concentrations, and normal or only slightly high A1C values) in SPK recipients are approximately 86 and 73 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Insulin secretion less than that required to restore normal glycemia may still be beneficial by transforming patients with type 1 diabetes to a more stable metabolic state.",
"   </p>",
"   <p>",
"    After decreasing during the 1990&rsquo;s, the technical failure rate has remained stable at approximately seven percent among pancreas transplants performed in the United States since 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/5\">",
"     5",
"    </a>",
"    ]. Graft thrombosis causes the majority of technical failures.",
"   </p>",
"   <p>",
"    Overall, kidney allograft survival rates among type 1 diabetic recipients of SPK are generally comparable to those seen with living donor kidney allografts alone and superior to those observed after deceased donor kidney allografts alone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/6\">",
"     6",
"    </a>",
"    ]. The reason for the improved kidney allograft survival among SPK recipients compared with recipients of deceased donor kidney allografts alone likely reflects differences in the type 1 diabetic patients who are selected for SPK versus kidney allograft alone, characteristics of the transplant procedure and organ quality. Overall SPK candidates are younger and more often preemptively transplanted using younger donors with minimization of cold-ischemia times and use of induction agents. After adjustment for these factors, kidney allograft survival rates are reportedly superior in type 1 diabetic recipients of living donor kidney allografts, compared with SPK [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/7\">",
"     7",
"    </a>",
"    ]. Allograft survival comparable to that of SPK recipients may be achieved among recipients of deceased donor kidney allografts if the deceased donor kidney is from a young, previously healthy donor or is a zero mismatched kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retrospective data suggest that SPK performed prior to the need for dialysis (eg, preemptive transplantation) may be associated with improved renal allograft survival compared with SPK after the initiation of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/9\">",
"     9",
"    </a>",
"    ]. Preemptive SPK transplantation may also be associated with improved long-term patient survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/10\">",
"     10",
"    </a>",
"    ]. Similar observations have been made for preemptive transplantation of renal allografts alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11224?source=see_link&amp;anchor=H2#H2\">",
"     \"Dialysis issues prior to and after renal transplantation\", section on 'Preemptive transplantation and outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110233780\">",
"    <span class=\"h1\">",
"     PATIENT SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall patient survival is similar between recipients of SPK transplantation and recipients of living donor kidney transplantation alone. However, survival is higher among SPK recipients compared with recipients of deceased donor kidneys alone. As described above for allograft survival, the apparent benefit in patient survival among deceased donor SPK recipients may be due to selection: there may be no survival benefit associated with SPK compared with deceased donor kidney transplantation among young diabetic recipients of kidneys from young donors. Issues surrounding patient survival are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/19/41272?source=see_link\">",
"     \"Benefits and complications associated with kidney-pancreas transplantation in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When all risk factors and outcome data are taken into account, the best candidates for pancreas transplantation are younger (age &lt;45 years) type 1 diabetic patients without cardiac risk factors who are to receive SPK transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However in organ procurement organizations where no priority is given to pancreas-kidney candidates, wait times for a SPK can be three to five years. The one- and four-year mortality for waitlisted SPK candidates has been reported as 6.6 and 41.3 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/12\">",
"     12",
"    </a>",
"    ], and many waitlist candidates die without ever being transplanted. If facing a long wait for SPK organs, and a suitable living donor is available, living donor kidney followed by deceased donor pancreas may result in superior patient survival and allow preemptive transplantation of the renal allograft. After a kidney is transplanted, the wait for a pancreas alone is weeks to months and nearly always less than a year. Thus, patients with a similar clinical profile who have the option to receive a living donor kidney allograft would do well to choose PAK transplant, provided they are willing to wait for a well-matched pancreas.",
"   </p>",
"   <p>",
"    Pancreas transplantation is generally performed in patients with type 1 diabetes, although the procedure has been done in selected patients with type 2 diabetes, and in those with exocrine pancreas failure (eg, pancreatectomy for benign disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/13\">",
"     13",
"    </a>",
"    ]. The rationale for performing pancreas transplantation in patients with diabetes mellitus is that achievement of near normoglycemia and insulin-independence will improve the quality of life and may prevent progression of and even improve diabetic microvascular and macrovascular complications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. However, the extent to which the latter occurs is variable. Risks of pancreas transplant include operative risks and those associated with chronic immunosuppression use.",
"   </p>",
"   <p>",
"    The evaluation of potential recipients should include consideration of patient age, duration of diabetes and insulin use, C-peptide levels (as a marker of endogenous insulin secretion), daily insulin requirements, body mass index (BMI), tobacco and other substance use, functional capacity, presence and severity of diabetic-related complications, and additional comorbidities, particularly coronary disease, congestive heart failure, peripheral vascular disease and active infections. All candidates for pancreas allografts should undergo extensive pretransplant evaluation for cardiac risk factors.",
"   </p>",
"   <p>",
"    The evaluation for pancreas transplant is generally similar to that for kidney transplant (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Issues that are specific to pancreas transplant candidates are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19164686\">",
"    <span class=\"h2\">",
"     Insulin requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The insulin requirement and serum C-peptide levels are assessed in order to determine whether the patient will benefit from pancreas transplantation. Since pancreas transplantation restores insulin production, patients who are insulinopenic and who have undetectable or very low C-peptide levels are most likely to benefit from the procedure. In our practice, a very high insulin requirement suggests that the patient may have insulin resistance, or",
"    <span class=\"nowrap\">",
"     anti-insulin/islet",
"    </span>",
"    cell antibodies; such patients are less likely to benefit from pancreas transplant, although no studies have examined this issue.",
"   </p>",
"   <p>",
"    <br/>",
"    In general, patients with insulin requirements exceeding 1.0",
"    <span class=\"nowrap\">",
"     units/kg/day",
"    </span>",
"    may not achieve euglycemia after pancreas transplant.",
"   </p>",
"   <p>",
"    Patients who are on peritoneal dialysis may have large insulin requirements due to the use of dextrose-containing dialysate; this must be taken into consideration when such patients are assessed for transplantation since the insulin requirement will likely decrease when peritoneal dialysis is discontinued following transplantation.",
"   </p>",
"   <p>",
"    Complications of insulin therapy, including the presence of hypoglycemic unawareness and",
"    <span class=\"nowrap\">",
"     frequency/severity",
"    </span>",
"    of hypoglycemia episodes may increase the urgency for pancreas transplant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7105545\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Younger candidates tend to have better outcomes. Recipients over age 45 carry a twofold greater risk of graft loss, most often due to technical failure, and a threefold greater risk of dying than younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some highly selected older individuals may do as well as younger individuals. In the International Pancreas Transplant Registry (IPTR) reports, for example, there was little difference in pancreas allograft survival rate between SPK recipients 30 to 40 years of age and those older than 40 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19164703\">",
"    <span class=\"h2\">",
"     Body mass index (BMI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maximum allowable body mass index (BMI) for pancreas or combined kidney-pancreas transplant varies between centers but is often lower than that for kidney transplant alone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. This is because, unlike kidney transplantation, pancreas transplantation requires intra-abdominal surgery, and post-transplantation wound healing is affected to a greater extent by an elevated BMI.",
"   </p>",
"   <p>",
"    Furthermore, an elevated BMI is associated with insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/21\">",
"     21",
"    </a>",
"    ], and in a single center, retrospective series, was associated with posttransplant diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cardiovascular evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease remains the most common cause of death following pancreas transplantation among diabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/11\">",
"     11",
"    </a>",
"    ]. Coronary heart disease, defined by prior myocardial infarction, coronary bypass, or percutaneous coronary angioplasty, is associated (independent of age) with a 20 percent one-year mortality in SPK and PAK recipients, four times greater than in diabetic recipients without history of myocardial infarction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/11\">",
"     11",
"    </a>",
"    ]. Among such patients, traditional cardiovascular risk factors include a long duration of diabetes, hypertension, dyslipidemia, tobacco use, age and sex. Nontraditional risk factors include long dialysis vintage, proteinuria and hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29703?source=see_link\">",
"     \"Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All pancreas transplant candidates should be screened for coronary heart disease in order to identify modifiable cardiac conditions and potentially reduce morbidity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mortality on the waitlist and following transplantation. Additionally, the evaluation may identify patients who have limited expected survival due to severe cardiac disease; such patients should not undergo transplantation.",
"   </p>",
"   <p>",
"    The optimal approach to screening the potential pancreas transplant recipient is not clear and there are no reliable comparative studies in this cohort to guide the evaluation. All pancreas transplant candidates should undergo pretransplant cardiac risk evaluation that includes at least",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    induced stress echocardiography. However, a significant number of false negative non-invasive stress results are observed among patients with ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/22\">",
"     22",
"    </a>",
"    ]. Thus many centers specifically require cardiac catheterization in pancreas candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], particularly in those with a long history of diabetes (defined as &gt;25 years), smoking history, or other cardiovascular risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/25\">",
"     25",
"    </a>",
"    ]. In patients not yet on dialysis, one must weigh the need for catheterization against the risk of contrast-induced nephropathy.",
"   </p>",
"   <p>",
"    According to surgical preference, pancreas transplants are not performed in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    or similar anti-platelet agents at many centers; thus the placement of a drug-eluting stent may delay transplantation. In such situations, the option of coronary artery bypass surgery should be considered as an alternative therapy to clopidogrel. Given the significant mortality of waitlisted diabetic patients who are on dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/12\">",
"     12",
"    </a>",
"    ], decisions regarding pre-transplant catheterization and revascularization must be carefully considered, with the input of a cardiologist if necessary. Significant coronary heart disease that is not amenable to revascularization may exclude candidates from pancreas transplant consideration.",
"   </p>",
"   <p>",
"    Type 1 diabetic patients with ESRD who are determined not to be appropriate candidates for pancreas transplantation may still be appropriate candidates for kidney transplant alone versus dialysis therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110233183\">",
"    <span class=\"h2\">",
"     Evaluation of peripheral vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral vascular disease is common among diabetic patients with ESRD and may prevent a successful anastomosis to the kidney allograft. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20905?source=see_link&amp;anchor=H2#H2\">",
"     \"Peripheral artery disease in chronic kidney disease\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Careful examination of iliac and peripheral pulses should be done among all patients. To identify patients with iliac calcifications, we screen all diabetic patients older than 45 years of age, or those with poor femoral pulses or evidence of vascular disease elsewhere (eg, coronary heart disease or cerebrovascular disease), with a noncontrast abdominopelvic CT scan. Many centers screen all diabetic pancreas transplant candidates with a non-contrast CT scan.",
"   </p>",
"   <p>",
"    The diagnosis of peripheral vascular disease is difficult to establish in such patients because of the presence of medial artery calcifications that render vessels non compressible for a standard ankle brachial index and or toe brachial index. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20905?source=see_link&amp;anchor=H7#H7\">",
"     \"Peripheral artery disease in chronic kidney disease\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with symptoms of peripheral vascular disease (eg, claudication), diminished pulses on exam or abnormal imaging are referred to a vascular specialist for further assessment and testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7105596\">",
"    <span class=\"h2\">",
"     Pancreas transplantation without renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preemptive pancreas transplant alone (PTA) in nonuremic type 1 diabetic patients is advocated and offered by some centers. Given the risks of surgery and immunosuppression, this procedure is particularly appropriate for patients with life-threatening hypoglycemic unawareness for whom the potential benefits outweigh the risks. An extensive discussion of this issue is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7162?source=see_link&amp;anchor=H867495#H867495\">",
"     \"Pancreas and islet transplantation in diabetes mellitus\", section on 'Indications for transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SURGICAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the most common configuration for SPK consists of placing both organs intraperitoneally via a midline incision. Centers differ in regards to the surgical management of the exocrine secretions and the venous outflow.",
"   </p>",
"   <p>",
"    After procurement, the arterial supply of the pancreas is reconstructed with a Y-graft derived from the donor iliac artery bifurcation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]: the internal iliac or hypogastric artery is anastomosed to the splenic artery, and the common or external iliac artery is anastomosed to the superior mesenteric artery.",
"   </p>",
"   <p>",
"    The donor Y graft then is anastomosed to the recipient common or external iliac artery. Venous drainage from the graft portal vein to the recipient iliac vein rather than to the recipient's portal venous circulation is convenient but results in hyperinsulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/28\">",
"     28",
"    </a>",
"    ]. Interest has been shown in the use of portal venous drainage to avoid this potential metabolic problem [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initially, management of the exocrine pancreas secretions was most commonly accomplished by bladder drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/5\">",
"     5",
"    </a>",
"    ], whereby the duodenum is anastomosed side-to-side to the bladder. However, over the past decade the preferred duct management technique has become enteric drainage, or the anastomosis of the donor duodenum to the recipient small bowel, with or without a Roux-en-Y. According to the International Pancreas Transplant Registry (IPTR) report of 2002 to 2003 United States transplants, 82, 72, and 57 percent of SPK, PAK, and PTA were enteric-drained, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enteric exocrine drainage is comparable to bladder drainage in terms of patient and pancreas graft survival and superior in terms of metabolic and bladder-related complications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The advantage of bladder drainage is the ability to use urine amylase to monitor for rejection in solitary pancreas transplants or pancreas transplants done after kidney transplant from a different donor (PAK). With SPK from a single donor, the serum creatinine can be used to monitor for kidney rejection and used as a surrogate for pancreas rejection. Isolated rejection of the pancreas without kidney involvement is rare in SPK, and enteric drainage is utilized commonly in this group to avoid complications associated with bladder drainage.",
"   </p>",
"   <p>",
"    As an example, a 2005 survey of 102 articles of both SPK and pancreas alone transplants found that urological complications were significantly more frequent with bladder versus enteric drainage (62 to 63 versus 12 to 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, a retrospective study of 71 SPK patients found that enteric drainage resulted in a significantly lower incidence (versus bladder drainage) of volume depletion (3 versus 34 percent), acidosis (0 versus 41 percent), pancreatitis (3 versus 40 percent), and urinary tract infection (27 versus 71 percent), although patient and pancreas allograft survival was similar [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/31\">",
"     31",
"    </a>",
"    ]. According to the IPTN, in bladder drained pancreas recipients between 2000 and 2004, enteric conversion was required in 9 and 17 percent at one and three years post-transplant, respectively.",
"   </p>",
"   <p>",
"    Preservation time of up to 30 hours in University of Wisconsin (UW) solution has no untoward effects on short- or long-term pancreas graft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/33\">",
"     33",
"    </a>",
"    ], although allograft survival rates for SPK decrease with increased preservation time. Many centers target cold-ischemia times (CIT) of less than 12 hours, given the association of CIT with graft pancreatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Segmental pancreas donation",
"    </span>",
"    &nbsp;&mdash;&nbsp;With segmental pancreas donation, a segment of pancreas is donated by a living donor who is willing to undergo a hemipancreatectomy, and in some countries segments from cadaveric donors have been used. In one instance a patient who had been diabetic for 17 years received a segment of pancreas from an identical twin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/34\">",
"     34",
"    </a>",
"    ]. No immunosuppressive therapy was needed to prevent rejection. However, within two weeks, there was insulitis with lymphocytic infiltration of the beta cells in the grafted segment, indicative of recurrence of autoimmune diabetes in the transplanted tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     IMMUNOSUPPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppression regimens continue to change over time, with variations from center to center, such as decreased use of corticosteroids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Induction therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many centers have favored quadruple sequential induction therapy consisting of an anti-T cell antibody, either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/5,27,35\">",
"     5,27,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2007, the following frequency of use of different induction agents in the United States was noted for kidney-pancreas transplant recipients for whom information was available [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"       Basiliximab",
"      </a>",
"      &mdash; 6 percent",
"     </li>",
"     <li>",
"      Daclizumab &mdash; 6.5 percent",
"     </li>",
"     <li>",
"      Thymoglobulin &mdash; 52 percent",
"     </li>",
"     <li>",
"      ATGAM &mdash; 2 percent",
"     </li>",
"     <li>",
"      OKT3 &mdash; 1.2 percent",
"     </li>",
"     <li>",
"      None &mdash; 22 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      is started at 8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day orally and adjusted to achieve a whole blood level of &ge;200",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (HPLC) or 300 to 500",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (TDx). Alternatively,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      is given at a dose to maintain blood levels of 8 to 12",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      for the first six months, 5 to 8",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      for the next six months, and 3 to 5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      after one year.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      mofetil is begun at 1000 to 1500 mg twice per day with dose reductions as necessary for leucopenia or gastrointestinal side effects. Among those also taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , mycophenolate mofetil should be administered at a lower dose, such as 750 mg twice per day. Patients who do not tolerate mycophenolate mofetil secondary to gastrointestinal toxicity are given",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      at 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, with reductions if neutropenia occurs.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      , if given, is begun at a dose of 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day and tapered to approximately 5 mg per day over weeks or months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative efficacy of quadruple sequential induction therapy compared to triple therapy has been evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/35,37-39\">",
"     35,37-39",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 175 SPK recipients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      , and corticosteroids for baseline immunosuppression were randomly assigned to induction or non-induction groups [",
"      <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/35\">",
"       35",
"      </a>",
"      ]. Any commercially available induction therapy could be used, including the interleukin-2 receptor antibodies (daclizumab and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"       basiliximab",
"      </a>",
"      ) and T-cell depleting antibodies (muromonab-CD3, antithymocyte globulin [equine], and antithymocyte globulin [rabbit]). At three years, allograft survival was significantly better in the induction group (92 versus 82 percent), with patient survival being similar in both groups. However, higher rates of cytomegalovirus (CMV) viremia and CMV syndrome were reported with T cell depleting antibody induction (36 percent) versus anti-interleukin-2 receptor antibodies (2 percent) and non-induction therapy (8 percent). The incidence of acute rejection was similar in both groups.",
"     </li>",
"     <li>",
"      A randomized trial directly compared antithymocyte globulin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , corticosteroids, and delayed",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      to triple therapy consisting of azathioprine, corticosteroids, and cyclosporine among 50 patients with type 1 diabetes undergoing SPK [",
"      <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/37\">",
"       37",
"      </a>",
"      ]. A significantly lower incidence of acute renal rejection episodes was observed among those randomized to the quadruple regimen (36 versus 76 percent for the triple therapy group).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Maintenance regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maintenance immunosuppressive regimen that is most commonly used is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    <span class=\"nowrap\">",
"     mofetil/mycophenolate",
"    </span>",
"    sodium, with or without steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/36,40,41\">",
"     36,40,41",
"    </a>",
"    ]. Although many centers favor a corticosteroid-free regimen, most continue to use steroids, which is usually tapered down to 5 mg per day by three months post-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/36,40\">",
"     36,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil is associated with a decreased incidence of cellular rejection compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . The substitution of mycophenolate mofetil for azathioprine, in both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    -based regimens, has been associated with more than a 50 percent reduction in the incidence and severity of acute cellular rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. It is currently the most commonly used antimetabolic agent for maintenance therapy in the United States.",
"   </p>",
"   <p>",
"    There is also evidence that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil results in enhanced graft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. A retrospective study evaluated the outcomes of 358 consecutive SPK patients who received either mycophenolate mofetil or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    in combination with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -based regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/45\">",
"     45",
"    </a>",
"    ]. At two years after transplantation, superior survival rates were observed among the mycophenolate mofetil group for both the kidney (95 versus 86 percent) and pancreas allografts (95 versus 83 percent).",
"   </p>",
"   <p>",
"    However, many patients discontinue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil due to gastrointestinal intolerance. In one series of 120 patients, the frequency of conversion (principally because of gastrointestinal toxicity) from mycophenolate mofetil to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    at one year after transplantation was 14, 26, and 39 percent in those who had undergone SPK, PAK, and PTA, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    (FK506) may be used for induction, maintenance, and rescue therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/35,47-52\">",
"     35,47-52",
"    </a>",
"    ]. It is currently the most commonly used calcineurin inhibitor for maintenance therapy in the United States. In 2006, for example, tacrolimus was administered prior to hospital discharge in approximately 90 percent of recipients of kidney-pancreas transplants.",
"   </p>",
"   <p>",
"    Similar outcomes have been observed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -based maintenance regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. However, some data suggest that pancreatic graft survival is higher with tacrolimus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the European-SPK 001 trial, 205 SPK patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      plus corticosteroids and either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/52\">",
"       52",
"      </a>",
"      ]. At one year, both groups had similar patient and kidney allograft survival, with pancreas survival being significantly higher with tacrolimus (91 versus 75 percent). At three years, although patient and kidney survival rates were similar, pancreas survival remained significantly higher with tacrolimus (90 versus 72 percent), with pancreas allograft loss due to thrombosis being markedly increased with cyclosporine (10 versus two patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/53\">",
"       53",
"      </a>",
"      ]. In addition, an increased number of initial rejection episodes that were moderate or severe were observed with cyclosporine (28 versus 3 percent). Adverse events were largely similar between the two groups.",
"     </li>",
"     <li>",
"      In one study, 33 SPK patients were randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (Neoral), each given in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"       basiliximab",
"      </a>",
"      (for induction therapy), corticosteroids, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil [",
"      <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/51\">",
"       51",
"      </a>",
"      ]. At median follow-up of approximately 16 months, patient, pancreas, and kidney survival rates were approximately 94 and 100 percent with cyclosporine and tacrolimus, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One concern is a possible relative increased incidence of diabetes with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , which has been noted in recipients of kidney allografts alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26250?source=see_link\">",
"     \"New onset diabetes after transplant (NODAT) in renal transplant recipients\"",
"    </a>",
"    .) However, this has not been confirmed in pancreas recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/48,49,53,54\">",
"     48,49,53,54",
"    </a>",
"    ]. As an example, among 136 type 1 diabetics who underwent successful SPK and received either a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    - or tacrolimus-based regimen, glycemic status was the same in both groups as determined early (3 months) and late (3 years) after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/54\">",
"     54",
"    </a>",
"    ]. In a separate study of 674 pancreas transplant recipients, the incidence of posttransplant diabetes at 10 years was not increased in those receiving tacrolimus compared to cyclosporine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As previously mentioned, the addition of induction therapy to a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    -based regimen may improve allograft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/35\">",
"     35",
"    </a>",
"    ]. However, it may increase the risk of cytomegalovirus viremia and syndrome. There has also been a reported four percent incidence of posttransplant lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/5,48\">",
"     5,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Sirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2007, the mammalian target of rapamycin inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , was used for maintenance immunosuppression in approximately 10 to 11 percent of kidney-pancreas recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/36\">",
"     36",
"    </a>",
"    ]. A single center study reported one-year kidney and pancreas survival rates of 100 percent among 20 SPK patients administered a",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"      tacrolimus",
"     </a>",
"     /rapamycin",
"    </span>",
"    maintenance regimen after induction therapy that also included antithymocyte globulin and a rapid corticosteroid taper [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=see_link\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\"",
"    </a>",
"    .) Adverse effects including poor wound healing, lymphocele formation, and dyslipidemia may limit the utility of mTOR inhibitors in certain diabetic recipients, such as those with recurrent lower-extremity ulcerations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     REJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute rejection is 1.5 to 2 times more common, more likely to be steroid-resistant, and more likely to be recurrent and to occur late in SPK than in kidney transplantation alone recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/24,27,56\">",
"     24,27,56",
"    </a>",
"    ]. There also appears to be a difference in outcome between SPK and PAK recipients. The frequency of pancreas graft loss due to rejection in SPK transplant recipients is 2 and 8 percent at three years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/5\">",
"     5",
"    </a>",
"    ]; the comparable values for PAK recipients are 6 and 11 percent, respectively, and for PTA 10 and 20 percent, respectively.",
"   </p>",
"   <p>",
"    Unlike autoimmune diabetes mellitus in which the beta cells of pancreas islets are destroyed, acute rejection of the pancreas is initially directed principally against septal structures and acinar tissue. Thus, marked loss of glycemic control occurs late in rejection, often portending irreversible graft destruction. Therefore, alternative markers are used to monitor for graft rejection, including serum amylase and lipase, urinary amylase (bladder drained allografts) and serum creatinine in recipients of SPK.",
"   </p>",
"   <p>",
"    An important clinical observation in SPK recipients is that rejection of the pancreas graft is uncommon in the absence of concurrent kidney allograft rejection (&le;15 percent), and it tends to lag in severity behind the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. As a result, the plasma creatinine concentration is used to monitor for possible acute rejection of both grafts in patients with a functioning renal allograft. Although a rise in the plasma creatinine concentration can reflect nonimmunologic causes of functional impairment (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"    </a>",
"    ), a relatively small increment in the serum creatinine is typically the first clinical sign of rejection.",
"   </p>",
"   <p>",
"    A rejection-induced decline in renal function will precede any physiologic changes related to the pancreas graft. It should therefore be followed by biopsy of the kidney",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pancreas grafts",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    institution of antirejection treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Urinary amylase excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary amylase excretion is a commonly used and readily accessible means of monitoring the pancreas graft for rejection in patients with bladder drainage of the exocrine secretions. The lower one-year graft survival rates for pancreas grafts managed with ductal occlusion and enteric drainage rather than bladder drainage would appear to support the clinical utility of this marker [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urinary amylase is best measured in terms of unit activity per unit time, comparing samples obtained during similar time periods on different days. This requires careful documentation of sample collection time and volume. Concentration alone is generally an unreliable marker due to the variability in urine volume.",
"   </p>",
"   <p>",
"    There are no absolute norms for adequate values, but the urinary amylase in individual patients with good initial function will typically have a baseline value between 1500 to 7000",
"    <span class=\"nowrap\">",
"     IU/hour",
"    </span>",
"    within a few days following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. When the urinary amylase falls during acute pancreas graft rejection, it typically does so 24 to 48 hours before hyperglycemia develops. A 25 percent decrement from baseline in the urinary amylase on two successive determinations obtained at least 12 hours apart or a 50 percent reduction on any single determination is often taken as presumptive evidence of acute rejection.",
"   </p>",
"   <p>",
"    The value of urinary amylase excretion as a marker for rejection was evaluated in a study of 66 cystoscopic transduodenal pancreaticoduodenal biopsy specimens that were obtained for hypoamylasuria; an additional 13 specimens were obtained from patients with stable urinary amylase levels [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/61\">",
"     61",
"    </a>",
"    ]. The above criteria to define hypoamylasuria were found to have 100 percent sensitivity and 30 percent specificity for rejection.",
"   </p>",
"   <p>",
"    Thus, while a stable urinary amylase reliably rules out pancreas graft rejection, a decrement in urinary amylase as defined above is not necessarily associated with histologic evidence of pancreas",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    duodenal rejection. Other common causes of low urinary amylase can be distinguished from rejection in part by their clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Volume depletion (any time)",
"     </li>",
"     <li>",
"      Leakage (early, from the pancreaticoduodenocystostomy or from the graft itself)",
"     </li>",
"     <li>",
"      Graft thrombosis (early, sudden and complete)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      toxicity (any time)",
"     </li>",
"     <li>",
"      Obstruction",
"     </li>",
"     <li>",
"      Graft pancreatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Noninvasive monitoring for pancreas graft rejection is considerably more difficult in recipients of enteric drained PAK or PTA, settings in which the plasma creatinine concentration or urinary amylase excretion cannot be used as a sentinel marker.",
"   </p>",
"   <p>",
"    Although serum amylase and lipase are followed in enteric drained pancreas transplants, increased levels can not only be observed in rejection but many other clinical scenarios, including graft or native pancreatitis, infection, dehydration, post-transplant lymphoproliferative disorder (PTLD), or due to technical causes (graft thrombosis). The serum amylase concentration will increase in graft pancreatitis and (transiently) in 20 percent of patients following biopsy of the pancreatic allograft [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Biopsy of the pancreatic allograft",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the lack of reliable signs or symptoms and the low specificity of the urinary amylase as a marker of pancreas allograft rejection, ultrasound-guided percutaneous and cystoscopic transduodenal pancreatic allograft biopsy are being used with increasing frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/61,63\">",
"     61,63",
"    </a>",
"    ]. These techniques replace the traditional, more invasive, approach requiring open laparotomy and are generally free of serious complications. They are, however, more frequently nondiagnostic than renal biopsy due to sampling error or inadequate tissue recovery (3 to 15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/57,63\">",
"     57,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of rejection in the duodenum correlates well with pancreas rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/57,63\">",
"     57,63",
"    </a>",
"    ]; however, absence of histologic evidence of rejection in the duodenum does not rule out rejection of the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/64\">",
"     64",
"    </a>",
"    ]. Biopsy of the pancreas",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    duodenal segment is most useful in the setting of hypoamylasuria in a recipient of a bladder drained SPK or PAK transplant with a stable functioning kidney graft. Transcystoscopic biopsy is the procedure of choice when it can be performed by an experienced operator.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment of acute rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute rejection episodes in SPK recipients are more likely to be steroid-resistant than in renal transplant recipients. In the absence of pancreatic histologic diagnosis, antirejection treatment strategies have often employed anti-T cell antibody treatment as first line therapy, although there are no controlled trials comparing this approach versus using high dose steroids first.",
"   </p>",
"   <p>",
"    Early evaluation and treatment initiated on the finding of an increased plasma creatinine with preserved endocrine function, with or without a decline in the urine amylase, typically result in preservation of graft endocrine function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/5,60\">",
"     5,60",
"    </a>",
"    ]. Urinary amylase tends to recover, albeit not usually to the previous baseline level, following successful treatment of rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/16/7434/abstract/59,61\">",
"     59,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combined kidney-pancreas transplantation is offered as definitive treatment for selected type 1 diabetic patients with end-stage renal disease due to diabetic nephropathy. Kidney-pancreas transplantation can be offered as simultaneous pancreas-kidney (SPK) transplants and sequential pancreas after kidney (PAK) procedures. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors considered during the evaluation of potential SPK or PAK candidates include patient age, insulin requirements, presence of and severity of diabetic related complications, body mass index (BMI), and other comorbidities, particularly cardiovascular. All patients should undergo a cardiac work-up including stress test and possible coronary angiogram, with revascularization if indicated prior to transplant. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunosuppression regimens for recipients of kidney-pancreas transplantation continue to change over time, with variations from center to center. Many centers have favored quadruple sequential induction therapy consisting of an anti-T cell antibody, either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      corticosteroids. For maintenance therapy, the regimen that is most commonly used is tacrolimus plus mycophenolate",
"      <span class=\"nowrap\">",
"       mofetil/mycophenolate",
"      </span>",
"      sodium, with or without steroids. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Immunosuppression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute rejection is 1.5 to 2 times more common, more likely to be steroid-resistant, and more likely to be recurrent and to occur late in SPK than in kidney-transplant alone (KTA) recipients. Although early diagnosis of graft rejection is potentially more difficult for the pancreas than the kidney, the plasma creatinine concentration is used to monitor for possible acute rejection of the pancreas and kidney grafts in SPK recipients. In patients with bladder drainage of the exocrine secretions, decreased urinary amylase excretion is a commonly used, readily accessible, and sensitive (albeit not specific) means of monitoring the pancreas graft for rejection. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Rejection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/1\">",
"      Port FK, Dykstra DM, Merion RM, Wolfe RA. Trends and results for organ donation and transplantation in the United States, 2004. Am J Transplant 2005; 5:843.",
"     </a>",
"    </li>",
"    <li>",
"     2008 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1998-2007. U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/3\">",
"      Fernandez LA, Di Carlo A, Odorico JS, et al. Simultaneous pancreas-kidney transplantation from donation after cardiac death: successful long-term outcomes. Ann Surg 2005; 242:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/4\">",
"      Sutherland DE, Gruessner RW, Dunn DL, et al. Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg 2001; 233:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/5\">",
"      Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. Clin Transplant 2005; 19:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/6\">",
"      Gaston RS, Basadonna G, Cosio FG, et al. Transplantation in the diabetic patient with advanced chronic kidney disease: a task force report. Am J Kidney Dis 2004; 44:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/7\">",
"      Young BY, Gill J, Huang E, et al. Living donor kidney versus simultaneous pancreas-kidney transplant in type I diabetics: an analysis of the OPTN/UNOS database. Clin J Am Soc Nephrol 2009; 4:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/8\">",
"      Kamgar M, Huang E, Kamgar M, et al. Zero-mismatch deceased-donor kidney versus simultaneous pancreas-kidney transplantation. Transplantation 2012; 94:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/9\">",
"      Israni AK, Feldman HI, Propert KJ, et al. Impact of simultaneous kidney-pancreas transplant and timing of transplant on kidney allograft survival. Am J Transplant 2005; 5:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/10\">",
"      Pruijm MT, de Fijter HJ, Doxiadis II, Vandenbroucke JP. Preemptive versus Non-preemptive simultaneous pancreas-kidney transplantation: a single-center, long-term, follow-up study. Transplantation 2006; 81:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/11\">",
"      Gruessner RW, Dunn DL, Gruessner AC, et al. Recipient risk factors have an impact on technical failure and patient and graft survival rates in bladder-drained pancreas transplants. Transplantation 1994; 57:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/12\">",
"      Gruessner RW, Sutherland DE, Gruessner AC. Mortality assessment for pancreas transplants. Am J Transplant 2004; 4:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/13\">",
"      Orlando G, Stratta RJ, Light J. Pancreas transplantation for type 2 diabetes mellitus. Curr Opin Organ Transplant 2011; 16:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/14\">",
"      Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/15\">",
"      Navarro X, Sutherland DE, Kennedy WR. Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol 1997; 42:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/16\">",
"      Fiorina P, La Rocca E, Venturini M, et al. Effects of kidney-pancreas transplantation on atherosclerotic risk factors and endothelial function in patients with uremia and type 1 diabetes. Diabetes 2001; 50:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/17\">",
"      Larsen JL, Ratanasuwan T, Burkman T, et al. Carotid intima media thickness decreases after pancreas transplantation. Transplantation 2002; 73:936.",
"     </a>",
"    </li>",
"    <li>",
"     www.med.umn.edu/IPTR/annual_reports/2003_annual (Accessed on August 8, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/19\">",
"      Neidlinger N, Singh N, Klein C, et al. Incidence of and risk factors for posttransplant diabetes mellitus after pancreas transplantation. Am J Transplant 2010; 10:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/20\">",
"      Sampaio MS, Reddy PN, Kuo HT, et al. Obesity was associated with inferior outcomes in simultaneous pancreas kidney transplant. Transplantation 2010; 89:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/21\">",
"      Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/22\">",
"      Ohtake T, Kobayashi S, Moriya H, et al. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol 2005; 16:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/23\">",
"      Becker BN, Odorico JS, Becker YT, et al. Simultaneous pancreas-kidney and pancreas transplantation. J Am Soc Nephrol 2001; 12:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/24\">",
"      Douzdjian V, Abecassis MM, Corry RJ, Hunsicker LG. Simultaneous pancreas-kidney versus kidney-alone transplants in diabetics: increased risk of early cardiac death and acute rejection following pancreas transplants. Clin Transplant 1994; 8:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/25\">",
"      Manske CL, Thomas W, Wang Y, Wilson RF. Screening diabetic transplant candidates for coronary artery disease: identification of a low risk subgroup. Kidney Int 1993; 44:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/26\">",
"      Marsh CL, Perkins JD, Sutherland DE, et al. Combined hepatic and pancreaticoduodenal procurement for transplantation. Surg Gynecol Obstet 1989; 168:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/27\">",
"      Sollinger HW, Knechtle SJ, Reed A, et al. Experience with 100 consecutive simultaneous kidney-pancreas transplants with bladder drainage. Ann Surg 1991; 214:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/28\">",
"      Diem P, Abid M, Redmon JB, et al. Systemic venous drainage of pancreas allografts as independent cause of hyperinsulinemia in type I diabetic recipients. Diabetes 1990; 39:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/29\">",
"      Gaber AO, Shokouh-Amiri MH, Hathaway DK, et al. Results of pancreas transplantation with portal venous and enteric drainage. Ann Surg 1995; 221:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/30\">",
"      Kuo PC, Johnson LB, Schweitzer EJ, Bartlett ST. Simultaneous pancreas/kidney transplantation--a comparison of enteric and bladder drainage of exocrine pancreatic secretions. Transplantation 1997; 63:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/31\">",
"      Bloom RD, Olivares M, Rehman L, et al. Long-term pancreas allograft outcome in simultaneous pancreas-kidney transplantation: a comparison of enteric and bladder drainage. Transplantation 1997; 64:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/32\">",
"      Demartines N, Schiesser M, Clavien PA. An evidence-based analysis of simultaneous pancreas-kidney and pancreas transplantation alone. Am J Transplant 2005; 5:2688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/33\">",
"      Morel P, Moudry-Munns K, Najarian JS, et al. Influence of preservation time on outcome and metabolic function of bladder-drained pancreas transplants. Transplantation 1990; 49:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/34\">",
"      Sibley RK, Sutherland DE, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest 1985; 53:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/35\">",
"      Burke GW 3rd, Kaufman DB, Millis JM, et al. Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results. Transplantation 2004; 77:1269.",
"     </a>",
"    </li>",
"    <li>",
"     www.ustransplant.org, accessed May, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/37\">",
"      Cantarovich D, Karam G, Giral-Classe M, et al. Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation. Kidney Int 1998; 54:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/38\">",
"      Reddy KS, Stratta RJ, Shokouh-Amiri H, et al. Simultaneous kidney-pancreas transplantation without antilymphocyte induction. Transplantation 2000; 69:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/39\">",
"      Kaufman DB, Iii GW, Bruce DS, et al. Prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation. Am J Transplant 2003; 3:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/40\">",
"      Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/41\">",
"      Toso C, Baertschiger R, Morel P, et al. Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. Am J Transplant 2006; 6:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/42\">",
"      Stratta RJ. Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multi-center report. The FK/MMF Multi-Center Study Group. Transplant Proc 1997; 29:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/43\">",
"      Stegall MD, Simon M, Wachs ME, et al. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. Transplantation 1997; 64:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/44\">",
"      Merion RM, Henry ML, Melzer JS, et al. Randomized, prospective trial of mycophenolate mofetil versus azathioprine for prevention of acute renal allograft rejection after simultaneous kidney-pancreas transplantation. Transplantation 2000; 70:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/45\">",
"      Odorico JS, Pirsch JD, Knechtle SJ, et al. A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation. Transplantation 1998; 66:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/46\">",
"      Gruessner RW, Sutherland DE, Drangstveit MB, et al. Mycophenolate mofetil in pancreas transplantation. Transplantation 1998; 66:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/47\">",
"      Bartlett ST, Schweitzer EJ, Johnson LB, et al. Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy. Ann Surg 1996; 224:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/48\">",
"      Gruessner RW, Burke GW, Stratta R, et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation 1996; 61:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/49\">",
"      Jordan ML, Shapiro R, Gritsch HA, et al. Long-term results of pancreas transplantation under tacrolius immunosuppression. Transplantation 1999; 67:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/50\">",
"      Kaufman DB, Leventhal JR, Stuart J, et al. Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases. Transplantation 1999; 67:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/51\">",
"      Boggi U, Vistoli F, Del Chiaro M, et al. Single-center, open, prospective, randomized pilot study comparing cyclosporine versus tacrolimus in simultaneous pancreas-kidney transplantation. Transplant Proc 2004; 36:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/52\">",
"      Bechstein WO, Malaise J, Saudek F, et al. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicenter trial. Transplantation 2004; 77:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/53\">",
"      Saudek F, Malaise J, Boucek P, et al. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial. Nephrol Dial Transplant 2005; 20 Suppl 2:ii3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/54\">",
"      Dieterle CD, Schmauss S, Veitenhansl M, et al. Glucose metabolism after pancreas transplantation: cyclosporine versus tacrolimus. Transplantation 2004; 77:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/55\">",
"      Kaufman DB, Leventhal JR, Koffron AJ, et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation 2002; 73:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/56\">",
"      Shaffer D, Madras PN, Sahyoun AI, et al. Combined kidney and pancreas transplantation. A 3-year experience. Arch Surg 1992; 127:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/57\">",
"      Gruessner RW, Nakhleh R, Tzardis P, et al. Rejection patterns after simultaneous pancreaticoduodenal-kidney transplants in pigs. Transplantation 1994; 57:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/58\">",
"      Reddy KS, Davies D, Ormond D, et al. Impact of acute rejection episodes on long-term graft survival following simultaneous kidney-pancreas transplantation. Am J Transplant 2003; 3:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/59\">",
"      Prieto M, Sutherland DE, Goetz FC, et al. Pancreas transplant results according to the technique of duct management: bladder versus enteric drainage. Surgery 1987; 102:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/60\">",
"      Morel P, Brayman KL, Goetz FC, et al. Long-term metabolic function of pancreas transplants and influence of rejection episodes. Transplantation 1991; 51:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/61\">",
"      Benedetti E, Najarian JS, Gruessner AC, et al. Correlation between cystoscopic biopsy results and hypoamylasuria in bladder-drained pancreas transplants. Surgery 1995; 118:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/62\">",
"      Munn SR, Engen DE, Barr D, et al. Differential diagnosis of hypoamylasuria in pancreas allograft recipients with urinary exocrine drainage. Transplantation 1990; 49:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/63\">",
"      Kuhr CS, Davis CL, Barr D, et al. Use of ultrasound and cystoscopically guided pancreatic allograft biopsies and transabdominal renal allograft biopsies: safety and efficacy in kidney-pancreas transplant recipients. J Urol 1995; 153:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/16/7434/abstract/64\">",
"      Nakhleh RE, Sutherland DE, Tzardis P, et al. Correlation of rejection of the duodenum with rejection of the pancreas in a pig model of pancreaticoduodenal transplantation. Transplantation 1993; 56:1353.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7305 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-AE2128909E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_16_7434=[""].join("\n");
var outline_f7_16_7434=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110232793\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GRAFT SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110233780\">",
"      PATIENT SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19164686\">",
"      Insulin requirements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7105545\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19164703\">",
"      Body mass index (BMI)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cardiovascular evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110233183\">",
"      Evaluation of peripheral vascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7105596\">",
"      Pancreas transplantation without renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SURGICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Segmental pancreas donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      IMMUNOSUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Induction therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Maintenance regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Sirolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      REJECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Urinary amylase excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Biopsy of the pancreatic allograft",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment of acute rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/19/41272?source=related_link\">",
"      Benefits and complications associated with kidney-pancreas transplantation in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=related_link\">",
"      Clinical manifestations and diagnosis of acute renal allograft rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11224?source=related_link\">",
"      Dialysis issues prior to and after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=related_link\">",
"      Evaluation of the potential renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=related_link\">",
"      Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26250?source=related_link\">",
"      New onset diabetes after transplant (NODAT) in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7162?source=related_link\">",
"      Pancreas and islet transplantation in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20905?source=related_link\">",
"      Peripheral artery disease in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29703?source=related_link\">",
"      Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_16_7435="Eval cancer treatment induced diarrhea";
var content_f7_16_7435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of cancer treatment induced diarrhea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Obtain history of onset and duration of diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Describe number of stools&nbsp;and stool composition (eg, watery, blood in stool, nocturnal) and compare to baseline stool frequency/consistency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assess patient for fever, dizziness, abdominal pain/cramping, or weakness (ie, rule out risk for sepsis, bowel obstruction, dehydration)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medications profile (ie, to identify diarrhea-inducing agents)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dietary profile (ie, to identify diarrhea-enhancing foods)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Benson AB, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Onc 2004; 22:2918. Copyright &copy; 2004 American Society of Clinical Oncology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_16_7435=[""].join("\n");
var outline_f7_16_7435=null;
var title_f7_16_7436="Causes of ptosis";
var content_f7_16_7436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F63515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F63515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cardinal features of common underlying causes of ptosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cause",
"       </td>",
"       <td class=\"subtitle1\">",
"        Levator function",
"       </td>",
"       <td class=\"subtitle1\">",
"        Eyelid crease margin",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Other clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital abnormality of the levator muscle*",
"       </td>",
"       <td>",
"        Reduced",
"       </td>",
"       <td>",
"        Crease often absent",
"       </td>",
"       <td>",
"        Often unilateral",
"       </td>",
"       <td>",
"        Many patients also have amblyopia, strabismus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aponeurotic ptosis",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Often increased",
"       </td>",
"       <td>",
"        Uni- or bilateral",
"       </td>",
"       <td>",
"        Isolated finding of ptosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cranial nerve 3 palsy",
"       </td>",
"       <td>",
"        Reduced",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Usually unilateral",
"       </td>",
"       <td>",
"        Impaired extraocular movement in ipsilateral eye. If ipsilateral pupil dilated, urgent evaluation for aneurysm is required.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Horner's syndrome",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Usually unilateral",
"       </td>",
"       <td>",
"        Ipsilateral miotic pupil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myasthenia",
"       </td>",
"       <td>",
"        Reduced",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Uni- or bilateral",
"       </td>",
"       <td>",
"        Variable and fatigable. Diplopia and extraocular movement abnormalities often present.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscle disease",
"       </td>",
"       <td>",
"        Reduced",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Usually bilateral",
"       </td>",
"       <td>",
"        Orbicularis oculi, other extraocular or bulbar muscles may be affected",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Other, less common causes of congenital ptosis are discussed in text.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_16_7436=[""].join("\n");
var outline_f7_16_7436=null;
var title_f7_16_7437="DDx of syndromes after BMT I";
var content_f7_16_7437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of specific clinical syndromes after stem cell transplantation - I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preengraftment, &lt;3 weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Immediate post-engraftment, 3 weeks to 3 months",
"       </td>",
"       <td class=\"subtitle1\">",
"        Late post-engraftment, &gt;3 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start_left\" colspan=\"4\">",
"        Mucositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Infectious",
"       </td>",
"       <td>",
"        <span class=\"sublist_other\">",
"         HSV, Candida spp",
"        </span>",
"       </td>",
"       <td>",
"        <span class=\"sublist_other\">",
"         &nbsp;HSV, Candida spp",
"        </span>",
"       </td>",
"       <td>",
"        <span class=\"sublist_other\">",
"         &nbsp;HSV, Candida spp",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Other",
"       </td>",
"       <td>",
"        <span class=\"sublist2\">",
"         GVHD, drug toxicity",
"        </span>",
"       </td>",
"       <td>",
"        <span class=\"sublist2\">",
"         &nbsp;GVHD, drug toxicity",
"        </span>",
"       </td>",
"       <td>",
"        &nbsp;GVHD, drug toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        Pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Localized",
"       </td>",
"       <td class=\"sublist_other\">",
"        Bacteria, molds, pulmonary embolism, hemorrhage",
"       </td>",
"       <td class=\"sublist_other\">",
"        Bacteria, Aspergillus spp., Pneumocystis carinii (PCP), Legionella spp, Nocardia spp, Mycobacterium tuberculosis (TB), Mycobacterium avium complex (MAC), tumor relapse",
"       </td>",
"       <td class=\"sublist_other\">",
"        Bacteria, Aspergillus spp, PCP, Legionella, Nocardia, Varicella zoster virus (VZV), Epstein-Barr virus (EBV)-associated lymphoma, pulmonary calcinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diffuse",
"       </td>",
"       <td class=\"sublist_other\">",
"        Respiratory viruses, HSV, conditioning regimen, acute graft-versus-host disease (GVHD), pulmonary edema, radiation pneumonitis, alveolar hemorrhage, acute respiratory distress syndrome (ARDS), hypersensitivity drug reaction, idiopathic interstitial pneumonitis, leukoagglutinin reaction",
"       </td>",
"       <td class=\"sublist_other\">",
"        CMV, PCP, respiratory viruses, Legionella spp, Mycoplasma pneumoniae, Cryptococcus spp, adenovirus, TB, MAC, acute GVHD, radiation pneumonitis, idiopathic interstitial pneumonitis, ARDS, hypersensitivity drug reaction, pulmonary veno-occlusive disease (VOD)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Chronic GVHD, EBV-associated lymphoma, ARDS, hypersensitivity drug reaction, alveolar proteinosis, radiation pneumonitis, idiopathic interstitial pneumonitis, bronchiolitis obliterans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start_left\">",
"        Sinusitis",
"       </td>",
"       <td>",
"        Bacteria, molds, respiratory viruses",
"       </td>",
"       <td>",
"        Bacteria, molds, respiratory viruses",
"       </td>",
"       <td>",
"        Bacteria, molds, respiratory viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start_left\">",
"        Bacteremia",
"       </td>",
"       <td>",
"        Bacteria, Candida spp.",
"       </td>",
"       <td>",
"        Bacteria (especially coagulase-negative staphylococci), Candida spp",
"       </td>",
"       <td>",
"        Streptococcus pneumoniae, Neisseria meningitidis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start_left\">",
"        Shock (including septic shock)",
"       </td>",
"       <td>",
"        Bacteria (eg, alpha streptococci, Pseudomonas aeruginosa), anaphylaxis, adrenal insufficiency, cardiovascular complications",
"       </td>",
"       <td>",
"        Same as for the preengraftment period",
"       </td>",
"       <td>",
"        Same as for the preengraftment period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start_left\">",
"        Fever without localizing signs",
"       </td>",
"       <td>",
"        Bacteria, HSV, respiratory viruses, molds, chronic disseminated candidiasis, tumor fever, drug fever, adrenal insufficiency, acute GVHD, heart failure, pulmonary emboli, infarction (eg, splenic, pulmonary, cardiac)",
"       </td>",
"       <td>",
"        Bacteria, CMV, adenovirus, PCP, molds, chronic disseminated candidiasis, respiratory viruses, acute GVHD, drug fever",
"       </td>",
"       <td>",
"        CMV, VZV, EBV, PCP, molds, encapsulated bacteria, chronic GVHD, drug fever",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_16_7437=[""].join("\n");
var outline_f7_16_7437=null;
var title_f7_16_7438="Misoprostol lvls oral v vaginal";
var content_f7_16_7438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Misoprostol levels over time with oral versus vaginal administration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 404px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Khan, RU, El-Refaey, H, Sharma, S, et al. Obstet Gynecol 2004; 103:866.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_16_7438=[""].join("\n");
var outline_f7_16_7438=null;
var title_f7_16_7439="Ultrathin pancreatoscope";
var content_f7_16_7439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrathin pancreatoscope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADuAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDyVRUgXNIB+Oaeor9HR8a2AXFKB9KcBxxSgY+lUQ2CjingY+uKAO1KKZDYBelGKcBn0o56etArjccYpCKc3X+lIeKAGEUY+WnGm0FDNtAHJHFLnHegigYh9aQ9OKU9R2pKQAKBRiii4xDyOKTFLzkmkP60rjGnrSMOaD7UhAqblIQADOMetKenSig0hjT0oxzS9RRSAQjtQeaWkpXGIOaUjrij8qd29KAuN+vNL/OiigBKQ/jmlNHSgBMcU0jNPx6UzmkxoaBSU4+lN9KhlIQjJppGBTjjmkbnPWkUhCO5PFJ2pxo4pWKGAdfSm45p9Iw96lxKTIyKKX1GcelFZWNEzUFOUelIM4py969E85jwOKcKQdORTvxqiGKKUY564pOBRyM5oJHDr0oPp/OkOcYFHr3oEIcdqTp2xilPJpjd8UDBj+lJkd6D0PrSc4+lIoQ4oBx060nOKOTQMQ9qOKDx3opDFPH4UlA6UDkZoARvpSEZzTjzSEc0hjCKMEUuP5UY7UmO40+lIR6U/FJg9eaQ7jcUnWnYopANPFFOx+dJg0rjExxTsfnRilxnvRcBneg9M04jnAFIR+VACevFHejFGOaBiY47UzHX1p5FBHFJjRGc03B9KeSPak/zikUhuKTHWnHrikIpFITA24pP4eMU76mm59OaLjEpp9cDNOPTAppqJMpCHpnpRQR6UVm2zRGkPenr1J5NRipB3rvRwMf24pQcj1poPH0pcZ9AKZDHjnNKKRenNLj0pki9MUHvSeg7fWl9+/1osIb2xzRkdTzQe2aQ9cdqBiH+VNI+tOb2pD0FIY0/rTTTu/SkPTGKBiEgHvmjj0pGP0/ClpDDPajPbmgUdqAAmkOMZ96X3oI6Hn6UANoPtSsDggcE96CO/WpbGMPrzQBT8Z5xTJnjgTfPIsadNzHGazlJRV2UlfRB+FGMHvzTIbmGc/upA2emRjP51YMZT74K59RWMa9ObtGSb9S3TlFXaIcZ6/rS4J4qbZyeKAnWruSQ7adipWXt60bOvrRzBYhK89qQr7DirBTnPb1pCmPTmncCDHtSYHGKkK/SjHNHMOxEBTGxnHfNTED/AOvTGHWlzDREc9MZpop7Dn0pmDge1HMWkBOSab057+tKaYcetK40gYegpQOeaQn14pB0wB1qblAfU9aTvR26jmg9fapbLQlFDdBRUNlJGmAKcB+FNHfPSnDqa9JHnscAMdeacOKZnApc8dsUyWSD17UcfjSA9aXPpmi4rC0E/hSZ6UHmi4hM0nag/wA6ToTmlcYMaa3vilJ5pv4UhoQ0HvR+hpD70hiGnZ44pD09KKLjFHPfrRTgBmlA4+tK4hmKdjtT8cdKUCpch2IwvXtS7efSpAM54peBkngDqSegrNyKSZSvJ/s6okSCS5lbbFFnGfc+ijuaILBElE87faLroZXHT2VegFP06Au8l9KMTTjCA/wRDoB9eprQ8sAjOB6VyqSn78vkv19X+H3nRyuPux+f+Xp+f3EAQFfmAP1FW4LmeK0ksvMdrOQhjCezDoyk9D+hrodD8E69q5Q2umzJC/InmGxMeuTXf6N8JrWHa2s3zzHHMVv8i/ix5NeZj81wdNctWV2u2rXpbZ+eh14fBV5O8VZef9anjQh+fYPmJGVwOWHrjt9KlaynAJaCYDrkxtj+VfQF94R061sIm8OR2+n6vav5trcn5gWHBSTPVWGVP1zVvStbttWsjMFME8ZMV1ayHLW0o+9G38we4IrwJcWey05Lru3Z/NWav/Wh6UcmUtb/AIHzeYSBlgVHbIIoEXpzX0ndWVtdRkTwRSJno6Aj8qxrnwloE0n73T4F948p/Kqp8Y0v+XlNr0af+RMskl9mX4HgrR4PSmlODwa9zbwB4dlyFtp19Nsx/rVW4+G+iv8A6t7yNj3Dhv6V1R4twT35l8v+CZPJa3df18jxJkx1zSeXxivVbz4X4Lm11E47CWP+orGuvh1rUJJiNrcDvsfH867KfEeAqbVEvW6/MwnleIj9m/oeflajZMn36V19x4M12IEtpzED+66t+lY17pl3aMVurWaIg/xIa9ClmNCt/Dmn6NM554SrD4otfIxGUc/SozV14/TBxVS5kjt498zBF6DIyWPoB3NdDrRSu2ZKD2ImHqaY3Tjr60yR7uX/AI94lt4z1lnHzfgn+NVZkeF4FFxPLcytxuwFCj7xwOgqJYi2qRpGnfRst9+aOcU72PIpDk8CteYkQdaQkgdDilz0pOaLjQhPHYUUfw0UmykafOKcBzSClHWvRRwMWnDpSDpQDxj1qiWOHINLx60g/GlHWmSA/wAilPekoPQ0gA9OtNPAz0pSOlNdtoySfwpNgkDdabQDkZ5/EUnelcqwdqCfWkHelpXGFOXHFJinKOalsLDh1PrTgM0qjOMCpFT2qHIpIaq5zTwh7ipljznI4rT0jRNQ1aby9Osprg55Kj5R9WPFc9SvGnHmk7I1p0ZTdoq7MhIsnmoNRh81YrbO03L7TjrsAy2Pw/nXq+j/AAuvHZW1i5jgj4zHAwdz7Z6Cu40vw/ouhKGtbaBJlGDM675ev949Pwr5nMuIsPTg4U/ev8lbrr6drnsYTKqjlzT0/Fnl3h74eavqvlyTxjTrNgCHmHz7fZOvT1r1Dw94N0Tw+UmjszcXQ4+0XJDH8F6CtZNSTCtCcls/Meuao3V7uB3ON3rXyOP4ir4lWcrLstF/wT2cPlsKT0Wvd7nQNeAjJbJHQVTurzcCAw2+vpWF9tXo0hyOfqapXV+GR1J+RRxnvmvEeN5kd8cLqXNQv/LbG5SCOueBXGT3q2Hie31DeEtNTkS0vSeFD5/dSn8RsJ9xTtf1CPyiqMMnoQMA/wCelc5DcwX3n2V1/wAe9zG1sx67dw4Ye4OD+Fcrm5Tu9up6NOglA9fuZSoHIB6bag83PzFvwzXMeFNXuL/RFGotnULN2srzA/5aJxu+jLhs+9aouVbIAz70qsveszmjSdjdt5lZAVG5RxnOalkuVVMjCk8AetZVtcqqKg+X3qSRskDKnvnvVKo1HQzdPXUsqWkbDsdpPbmgq4lwCgC8ktwBVQ3IjVjGcMe5qppt+uoTSJGN0cTYLds98mspTSst2Wqbab6GtKyYDcH0z1qvLB5kJ8zDoexGRUFlm81CQsf3MfLEd60NUnjjhypyeijsaak3F1HsiXGzUTj9b8H6bdglrVI2bkPAdhrz3Uvh8bS4aa0uTcy9vtPDKPRSOBXuYURxfNy5GAc1h6uLeGG4uLyRIbeFDJJI5wEUdSTXqYbOsXhGrTvbo9fz/Q5amDpVr3R4fceHb23ZWv41tbUuA907Bo0Hqcc/h3rm1tCl1czMxd3bYpKFSIwePlPTPU17Va2M+pzwateQNDYxnfptrIPn/wCviQdiR91T0HPWma9pNvqMZa4iDyf89Bww/Hv+NfS4fiz94liY7duj/rz0PMqZP7r9m/vPGmWo+natzW9Kl0658uQZQ8o3qKx2XmvtqFeFeCqU3dM8GpTlTk4yWqIsc+9Ie9PI9qax9etdCIQ00UHpRSLRpjpS+vvTe1KOpr1Tz2KOlOBxTR0pecUyWPHGeeaAc9qReh4oyc4/WmId2FHakzjpQelIQHtTD3p2fSmmkNCHv1ptONIe9Syg6UoptPHWpbAVRmpUU8dqag49a0NNsp766itrSFpbiVtqRr1Y1jOoormexcIuTsiFI+MnjFdN4a8Ianru17eHyrQnBuJeFP09fwr0/wAJfDuw0m3SfWES7vzgndzHF7Adz7muhvZwMRoMKvAUdv8ACvjMz4oVO8cMr+b/AEX+f3H0ODyhNp1X8v8Ag/16nLaP8PdE08rJevJqMwGSr/LHn2ArqWvYrKBYLeKKKBR8saLgD8BWTc35XKrjFZF3eMSxzz9a+Hxmb18Q71JNv+uh9Hh8BCCtFWRqXerzOxy4C9gD2rOutUbGM8isK4vRnr83YE1mXWp8EZ4xnNeNKpObPVhhkuh02n6nvvZIy+BjIzxz3qe6vl3lVf8ATrXBW96q3qkn5Tmr8+oI43YBPOMmpcZRVi3RXNc3Df8AQBs/jWdqOq7AQGwNvUVzs2oFEIyFz71kXt6z9X/KtaWHk2aeySepb1fVWKNtwDkY9+ah0adYrqCWZhvZt2wngVgTCS4k+ThF5OT1p1mojulLMPlOcHr9a9L6vFQ5UXy30PUbW5W28StLEBjVrTa4z8pnhwVI9zGT/wB81riYk/MeT6GvPNRuQ2krc2xK3thKt7Dgn5tn3lx7qSK6RdWt7kRSQTxyQSqJE+UjgjNeVWhOyfy+7/gW+5mHJaTR0kcx3YJIUHgk1aF2w4LfjXMrqIEOF259f8Kq3OpbIiWkIx1IGKxSlsh+y5jU8Qas+UtLRs3U7iOMe57/AIV1Wn2CWemRWsLERqPmbuzdz+deefDy2k1bWLnWrhD9nRvLtmbpgdWA716FfXZjHytnHetpJUrxlq+v9eX+ZlWWqpxL6SQ2VoQp2rjv/WqcKTXjfaHAWFAdue5qLS7CW6kE12/AOVj9vWk8R6mY7Z4oMKoHJx2olrHmnouiOdR97ljq+rNWRmls0wwOFzk8AD19q46x/wCKy1yPA3eHLRxKmR/x+yoeHI/55Keg/iIz0qwkE/jKNdPsC40CLi6nOV+1OP8AlmP+mY/iPc8V2EFvBo2mrZ2wAAABIH3sfyFbqDSU5f16ef5eu2Tko3S3/rUzdbCltoO5ie55NYMy5Rl6rzmtedTJJ3IJ4IFVZ4yi52gelcqbcrjskrHF+JtPW8smQEbxyD/tV5fcIUYqwwRkGvZdRXKYGeeea8t8Q23kajIo6N8w461+gcH42T5sNJ6br9T5/OaCsqq9DEYepxUZFSsKjI9a++R8+hpopSPWiixVy/nHNOBpmadxXpJnAxc9KUU3tzSgU7kj+1GTSDocUhAFFxDsmlzxzgHtTfQmg9KVxAT9KRqDSdc0rjCk/Kg0v4VLYxRT09gKjH4VKgz2qGx2JYlwQB+Fel/Bu1j/ALYu72RctbxBY/Yt1P5V5tGOldr8PdUWw1GWCQ4W5TCnOPmHQfjXiZ7zvAVfZ72/Dr+Fz0ssUfrMObv/AMMez31+AvU47Vz15fjLEsBWbc6oGTBYgqMc9aw5rx55DHBG88rdEiUsx/Kvxeti51XZH6HQwfLuaV5qOCRnJPWsS81Elm5AoGj6/czMiWKQcZH2icKT7cZ5ps3g7xG6tiG16ZDeY3P6frShRnLc7k6UOqMS5u2G5icdxWbc3wD4LDB61f1Dwl4qQkf2ekgA/wCWUo5/PFc3e6LrtuWNxpN+AvUrEXH5jNd9LDx6tGntYdGTfbgblTn5RnvVuXUMLkdPfjNcmyXfnY+zyrjghlINXI7G+cDK7fcnNdM8PBWuyPaI0JbzIYZwapzX0YG3JZumFGTVmDRnJH2lmb6cCrqWMMalUVVwcg1PPSjtqTKpfY5tLi7laQw25I7buOKRJLuB98ts2c9Rziu0tLeHzSoKjPT3rWi06JyvK8j0qJY6MdOUzUvM89GtSIMkMp9CvFQ6JrX2CT7NJ/x6liY2x9zJ+6favRZdGtJgRIiYHQis+78KWTnIUHjJ29qI4zDuLjKNrjlJvW4wavEsW7zMqR1yDVGxWbxRetawOUslbErjq5/uiuf17RRYqSm5V/uE9K9G+H9lHp+lQKqZZlDMe+481nWVPD0va03dvbyL9o+x3OmpFp2nQW8ShIo0CADsKbBcfaLtVjTzZSeAeg+tVZnRziWQIvoKhXU/shVbRF2HqAMn614id3qZ8t7tbnZxSpaW8m4mSdhyfQ+1cvaaTJ4u1S6tI3ki0uFtt/dI33m/54xn+903HtTbN73VNQ/szT3YXUoBupxyLKE9WP8AtsPuj8a9BVLDQtIjsNLjWG2gXaqjt6knuT3NenQipRVWrolsjzqs3TbhDWTIo5LTSbKLT7CFILeJdiIgwMDt9azCWup22sSG9+lPjtZtTkDKrCM/x4xWr9kjsoAqAue59/605Kdf3npFGV409PtMotaxxrnO9sYPbFY2pBc7SQxPfpWreyuQRyB0wBWHeISG7nsK5qlr2RpFO12YtwpkZhjv1rgvGlpyk45C/Kc+lehzRnYx6dvxrm9dtluIpImwVPH/ANevTybGfU8VCs9uvo9zkxlH21JwPLpRyagarl3C0Mrxv95Tg1Ufiv2SE1JJo+NcbOzIzRSnvgUVYy924peRSCjiu65wtDhTulNHApQPSqJYueoooAHakOKYh3pQBkUnpmgfSkICKQ98UvamnrSY0FA6UH2peD71DGKBkVMnIqNUJ52kigXNukgSS4gWT+40qgn8M1lOahu7Fxi5OyNC0gknlSKBGklc7VRRksfQV6Rpfw7eK3E+u3PkucEW0HLD0y3QfhV7wLFpXh7S4b1bHVtV1edMk2lhKViB6KJHCovuc1f1K+8SahxDpthosI/jvZvtU312IQgP1Jr4HOeIal3Twjsl17+nl+J9Vl2Ux0lWV3/X3mYfD1xqetQWllK0UIX97LId7BR39z2r0Gw0a0sbJYrdfKg5U4+/LjqzN6f5FYngiOW102+mu9Qlv7p5cedIix7QAAFVRwFzz+NdZcuokEYwRGBH+Q/xzXx1CEZp1JWbZ7mKrzuqa0SKjWNvtwI1KcDAHH+NSxLJFEYIyBETny25H4HtSxlGbgkYqX94xG3DA1206S3scjk9mOlgiIRiDhhn6URWsKnIjGO3GKluP3aRq44wc8VLAuEBfrUS/iOPYz5ny3M6+0TS7wH7Xp1tLu7ugJ/OsLUPAWgzIWSH7Jjq0TEY/A12MkYKjnpVSTbJLt3ZjXkipqRVrNF061RbSZ5dqnw3uUXdY3yOMcJPGVP5iuJ1rwvrdi+ZrGWSAdZLf94AD9Oa9/uHBlUHJz1wefrVS0jX7bMQTgJ2NcbajK0Tvp4uaV5anzmsqR3WwEqwxlW4I/CtyCfcgAIVuxPGa9m1PQtK1UhL+wt55G6M8eGH49axLj4c6Q/y25ubN+cGOTcv5NmlOl7TY6I42m/i0POoZisgBII7d6uLKo3blGfX0roL34bahG27T723uPRZl8s4+ozWPe+DvE0S4GnGXb3imRiR9M5rnnhZ32Oj6xRmtJI4TxtOhgKr94mur8L3cc+nW0inarxr8p65Fcf4h0PW5b+OC50fU4oi2GdrV9oHfkDFazSHSzEdrpEoCsGUjbjoa6cRQ/cxp9SrpuyOxuU8yT53CoRk881R855L2PT9JjMl7dNsiU9PdmPZQOTWVda3AbYFZQ5bCrGpBZ2PRVHcmvSPAWgNoNnLeX5Q6tcqBM2ciFOoiU/kSe5rhp0Laz2IrVvZxstzoNA0y28O6OtlbM09wWL3Fw3DTSHqxPp2A7Cr0dmjv5l2chTnb2qBGZwfKQMeztwv/wBerkKmNwFO9z0LdFPsK7IyU3drT+vvPJldddS8GSOMGQrGoGAM4/Ks+aY3D7YVYjsTxVjy49wabDuOmf6UStxjAUYrWpJzVnsYxsncyLm2YAtIwDH+52rHuwuTgDb/AFrdvG4wfujsOaw7zBJwf0rzqqSdkdcG2tTKusYIPU+nYVh3wGWHB4xj1rdukOCPu8c+9ZNxBuU56eo/lSptiZ5z4rsvKm+0KvDHa3sa5l+tepapZC6tJYpRwRgH0PY15neQNBO8Ugw6HBr9R4azD6zh/Yy+KH5dP8j5rM8N7OpzrZ/mVWxRQ/oKK+lueakXeaXJyewpg69acPxr00cDH9Bil6U0GnCqJYtJQP1oP1oJAnpRmjNB60mAZppJ+lKaT1qWhojuPPMYFq0UcmeXlBYY9gO9VhaXr/6/VHAPVYIVT9TzV08n60o9qxnRUnd3+9/lc0VRxVlb7kU10m1cETi4uT1/fzsR+QwK6v4f2FqPFWlpBbW8I84MSqAHjnr1rBBxmtfw3fDT9asbpjhYpVLfTof51yYrDr2M1SilJp/kb0Kr9rFzel0fQ97fblG6Ric9zmue1W83ROFySe3aor28Qg7WBHUHP5GsLUL7Cbcggj1r8QrVpS90/SqFBKzOm8IXwfS7mPjzIpycfkRXSmdJJNy9X+dcH1/wPFeMaf4g/sbUWkc5tpRiUDt6N+Fd9Y6uk2w28qSQtypXBGT3B/nThVdJJPYnE4a83JdTrlYkNk+nDCrdq+2QZX7vI2nNZtjHdTqGRQqk4LE8fl1rat7QxR+bMyFxyFXv9a9nDvmjzWPKq2jpcW4cNd4xxHx9T/8AWqaIErzgsetUMMZy+4Ajt61bWYKFO4dOc1jGV5OUjKUdEkPuZBGjEgAAZ69KofOsKtxliXPPaoNTuRJGRySW2YHentLI8gCsgQcAkZxWE6ilJo1jTaRBK3+lJGWG3YXOOpHYVJa5VZWVf9Y2M4xwO9VLQEXFxdNJnjylP61acnyC7AkEcAHAH4muaEk25ev+RtJW0Ftg0t0ZX+7HkdOp9KsSr5hG5SFz69PanW8Iht1G4Z65HvSYO4bF3Z7tW8VZWZk3d6Eg7Ad/Q08D+9njvUB3BlAJb6DAFPRtxYqct0PtVqaJcSwhcDCuw/HilkiDrhtp46MM1GJFOBjIFSCTgED8a1i4sh3RnzaVZuwdrO0ZwchvITKn1Bxwar3FvHgKyAc9xxWtLLheqnHY1SurhZFCleCMnAzisKyjY1pyk2Z+ZE6Sblx0YZFKbl9wyoIxj5TVSSXy5CM8fzpoly3XGK89VNbXOlx6mjDep93gnHBPepHmDAkMOmMY71k+YG+8p69hS+a8YIByPfn86arMXIiW4Ytkbjx6cVm3O7awOCMZ4HSrDSM3zHG4fkaqyEtj+HJ5PT86xbuWjPuCcAMSAw471RmUnj5h+HJrTnTgEDKjOQPX1qiXyGOWxn05zVLQHtoY9zH128MB+tcL4zsSkouIwNoJVj/WvSJowykE4JJNc3rNqs8LKy5Vgdwr2MpxrwWIjVW3X0OTFUfbU3E8tfqaKmvYWtriWGQYKHGfaiv1iFSM4qS2Z8pKLi7McpAyaeDj0qEHggdakU5+terFnA0P/GlBpopevetCB4PFGR2FNyKKLisLkZo4z0pO9KaBB6UCkNH9KAFJ/Gjg8U36UfnipbGPDDino2DUBb5fbpTgfSoeozptN8QzQWywSsWRRtRu4HpUd3rEkvKKWbvyK58N0zil3c183jOGsDiqrrSi03vZ2v52sz2sLnuKw0FTTTS7/wDDos3ktzc4zFgf74pmmSapp9wJbOdIQDkoz5U/UCmh8Y5pfM+bg1lHhjAxXK02vN/8A6JcR4uemn3P/M9b8J/ENoYki1IgSYxuVeDXZQ+MLa4UYdCD0PSvnhZMkknjrVq11CeA4ikOOuDyK8rHcLNK+Cny/wB17fJ7/fc1w2bxk/8AaY381/kfRK6rBKMxNlu+RUs2pDy1UPkZ3c84rwzT/Es0DhnyQPSuks/Fcc4AaRVbpyMV8jjMvx2Fv7Wm0u61X3o9qlVw9a3s5J/n9x6C13vJEj/uywfj2qSS7LNwrY9j1rik1YB1/ertJ4xWkL1XX5WOfrXiuUkjs5InUacT5A6bmJOB0A9K0Iz5kyBySBycnOT6Vz1rdiOPIwMDqDV62ugzZLE+uK0pz5UkzGcbts6IyAKdo5/vE4pJHXaCSCB1A4FZUV0vGD9M9qnE+4ht2WHv0rrVe5zeyaLXDjBHy9hinEhmO5QSRgDr+dVlk+bGckd884qXzAOF+Ueg/matSTE0SKBkLzwOccCiQ8HGCB2Y9foKYjhvvYJ7ljSnBOdoOeDngf8A16q99hWIpJcrg8sOox0qrM6lSGx0zgnr71Yly/8AEdg4wOMVUmORtDBcdAOc1zVZM2gkUnZWVmGcDgZOMVWzwFJJBPQVNcDaQdzL2C//AFqq7JMrv3jJ6dxXC73OpLQniUjPK8Dr2NH/ACzVgMEHHBpqKURivJ9hSsxIB4wB+GapaCaIpkyN0ZGOp7VC5Yrg8jHGe1WGYt6DvTdvBzwDTEVJlGGyCMjrVJl+YD+KtOWMEA5+XvjqKqOMNwOQOR7U0Joz51xGAOR1Ht7Vk3cPmIQeARnmtq4TA+XJDNyP61QuR/Lg1tF9SLHmfi2yYH7Sq7io5IGPl7Giuq1W1WaB0PzKyEfSivs8pz2NCh7Kr029DycVgPaT5onmecVInpnj0qLJwOtOQ89DX6XF6nybRMDkfpS0xTkev1FC9+ta3IsPB60Z9KQfl9KMnFMVhc+lHakpTzmkIO1J+lHTvR9aBiH6UH6f/XpCaSpGHH40FuOaTPHSkPJNSxjt3r+tO3YJ561Hz69KRiR7VLQWJt3p1pQ5xUHcYNAP+NQ0UkW1fPXkVIrc8cCqinHOfyp6kkj/ADmoaGi4r4we2PSn+YMVVDHHJ5pSSD7VnKJrFmhDcSRt+7kZTnIwa6HQLq+vGlLzuIogMMOu70rk1PIAI+uK9F8HWePDkD8Fp3aXP44/pXyvE0KFLByqSgnJ6J2V/wCrI9rKp1ZVlFSduxBL4iubQ4lAfHccVYtPHOnnar3Plv3V+P1qprmlHYSgOMd6891XTpVZyFJUd8V+d4alSrK0nZn2iw8ZRuj26w8RRzIGhlVge6nOa3rfUt5HBJ6Zzya+Worq50+UPaTPC47qePy6V0Vh8QNTtgq3EUM6j+Jco3+FbVMtqrWm7/gc86Vj6Rju1UEFsGporvc2CcDpn0rxbwz4+g1G48qV/s0w/hmbAb6H1rvYtWj2KDKmW56iuKoqlGVpqxjyI7OOdcA5J9MGpzPgKSfoK5myvsqdrAnHPoKufbQmcYKjkt/hSjXsS6OpstKr9+e/HWqsh5yPm9PSsv7dlmUHJJ7HNOW4d2xuAHSplX5hqnylosowACOOp6/hVZozvyAiEnoclm+lWIkVhwD757UskY+bbld3Vl61NmxqVinj5TnBK87ehH61EeHBPDEcKD1FWWjO0BBsI+6cjJ+tQOhVjtwwAznOdp+lS4lpiK2AucgnoP6U+MggqQQc5+lMKn/VsQTgsFpqkovPY59xWiB6k0+3aR0A7j1qrNErMGwVY9/WptwkAII+bOMHv/jSDlRuxgcDPejcm1jMulOFBHBPHPQ1mykFSG7mt64UCPJGccj2rIu4CDlTnJzirTsyWjEu4wyOFG1sYFFS3JKblkB4HXrxRWsZNE8p40TwakHIqEdKchPQGv3pPU/PmiUn+VOBx2/+vTA3PrSgkc5FaXIaHg/rRnpSLz3o6/8A6qdyR1Ln6U38aOefWmIU8UmTjrQc5pGz6Z9qQxD70lB6k5o46dKQxM9sZpBwScdeaOcdBn0FJk56c+9TcYueOlITTcnsRS561PMOwp96QH3NJ0ox1NQ2UiQN6U4H6gVGgyalVD/+qs5MaQ9TnH0q9Z2lxfTeVZwSTykZ2ovQep9BWzo3g/UL63WeVRaWzDIeQZJ+i9a7K0t4dFsfs1qhCn77/wAUp9Sf6V8vm/E2GwUXCk1Op26L1f6fke5gMlrYhqU1yx/E5qx8OW9oBJq829sZ+zxEgA/7Tf0Fd34eaK40yBraNFRMoscYwFIPSuI1S9Lz7XbAr0D4eRq3hy3dcjeWcn8f/rV+fY/MsVj2pV5adEtl8v6Z9VHL6WDppwWpDqVq8ikMh2/rXEa3YZ37QemPrXq+p4MWFQEdPpXDa7HGkcvzZbHBxXlRvSnoduHnzHj+uWRgkyFPTPtWDLhSfSu816IyKeOcYOa4TUF2qUA+bOK+pwdT2kUmPERtqURcKMnYSfc10XgjxmdDnm+32gvbCVs7SfniI7oT+orl5lMcLsew4qN18uAL6CvQqUKdaLjNXTPNlzX3PqLQ9eTXrJJtGiimg4XesgG3joV6g+1btvp9w6g3cjknnYBwK+cvhtrx8P6qjTlvsNxiOcKeV9HHuP5V9I2KS3Uam01QxuRlVkUMp+hHUV8pi8F7Gry7roVztLsWoNMmz8g8qMdB0zVsR29oCC6lhweMkVTl0bxFMCV1SyUHj7p5Hr1qBPCN7K2691vj+7Cg5rFYea+GP3sTkpfFJFqXVIV4UjAyME8//Wp1vPLc/cGFPcc1Na6HpVhg4e5lz96Q5/Q1YnvVRdsQVE9FAxWbptfHL5Inmj9lDQu3g5zjoahYDb82fqD8x/ClR5JCcEBfzp6xMcAg/wAqPQLlWVeAAjlcHJbr+VRvA0iEhGIU/J2Jq95SMCpXHHJB5oKR7ceWxYjBK8YArWMbj57FEr5ZUMMccDvmoiWByxyVParksY2s2Bn+EA81SfYnL/LnA9Tn3pSjYadyF5kOVLc5wR/hVaYK27aOh24NWZsb2AIL7QQvoKpT71CnYcH7w7j6+tQJmXeQjEgzyBRTrqR3DFegP3sdBRTUrDszwynD60wdKeD0r99Pz1jhTgevFMBpfWqIY/d8+OcgZz2+lOyevemKeDSnPfn8apMmw9SPWlz3JqIHPGacCfWnzCsPz6/hTCaRjnFN7YpNjSFD9cnmkJA/L1pD0GaaOn1qWx2HE80m78aaTx1oP+c1LHYdketNzx70E00k1LGkPB/WhTmm7vwoBwaljsaGlWM+o38NpaIZLiZgiKK948PfD7TtFs4ZpYkudRUfNPJkqD/sr0ryv4TXEcXjS1aUDPluEz/exXu11qKiEFSMV8PxRmNSnU+rJtRtd263uvu02Po8mwsXD2tru9vQxb2IRuytk8da47V5ZY5Cn3l6r7V0l9qab2bHQZrg9d1NZJXcHgjgV+d8nPP3T7LDpr4jmdevvLumVWJPUj09q9j+EStqHhDT2LHaEdSR6hjgGvnrU5907sfXrX0b8FtNudN+Hunm4O17xnuEXukbHj8/617UsNHkhzdH+j/Wxlj6loWRr6rC/kgKV49TXBeIWKuVC9elel6w0ZBRTgYxXnfiAqB8xwAe9eRiYKNXQjBSutTgdbGVOR8wBxj0rzjUDm7lPbdxXp2uEGJ89gfxrzi6tZGnkby35PHFe9lUJTT5U2a4urGEVzOxk3Y3JGg/ikH41Denkj3q89rO17DEsbbgjSYPHHTNWP7EaRGaSQBwMqijP519BTwtZq/K7LU8ipi6EXy8yu7Ijs12qAfSvbPhZrBvdFNlMVaezO0bzyYz9059uleSw2oWMZArW8O6k+jatHdRBmUfLIv95D1H9a8LGRVaLtujucOaOh9EQS/dV57qHjoTuUfQ1qR2iyBWj1Bip75/pXMaTrEc9pHIDvikUMrdmFbtvPZyj5kKOMfd4z714cVF6NHNK6NBdLtwv7yVpGPq/WpktLWIgrGhGPSoYUhXG1zj3I4qYsOCpLfj0rRU10ijPnfce7BeAAB2AFRE5bDnr3pJJAw4HHsc1XklAJJaoku4JkkrFSQQQcdarvKVyNwOfeoJ7zewxxVR5fmO4/TFQ2k9ClruWjIMhc4HXrTWVGbcWGMdPeqolXdgcn1zViFwwwFHPbFSpI0IztUsgTaFAG8981VvFwT8rHaO3Vq1NgK5I68EVSlhUMzB3Ytxz0FVJaCuYDwYR+W3HkAdPpRWhcxgA7VHXp0opJJBzHzvTwefeogaepyBX7umfAtEmfxpQaZn8qXPPFaXIsSD60U0Ec4opkjs0Z9+abTu1FwAnjGSaQtSHnrTTQFhSeOtBPSkyKTNIqwo560d+tITSE/jSAUk+tHemk5HFGaQxe1FNOfSl71Iy1Y3UtndQ3MD7JomDq3oRXo0HjSO9tVJcxT4+dD2PtXlwPAwadnH5V4+a5PQzOKVXRrZr+tUd+BzCrgpNw1T6M7XVPETZZdxORkAdK5m/wBSeYABHYkcgCqQc04uQa8alwlRpaubfy/4J674kqPaH4/8ApyWtxcH95hEYgEk9ATyfyr6v/tGOC3t0iOI44Y4otvTaqgDFfLpbKkdMivZdB8QW+paNbyggOiLFImeVZRivK4ky36nRhUo3au7/odGXZg8dUca1l2/U6HU9UYyEuy/hzg1xurX6ylg+GTuGqHW9TCb9jbWHTNcje6j8rkPx6mvkMPhamImlFNtn0l6dGHM3ZFnWb5Crggfdwa5V2LFvQ067uWnbHOPeq5PT0r9QyPK/qFC0vilv/kfD5vmCxlVKHwx2/zKu7OuPk/ctAPzarwb5gQcYNZ0ZP8AbF0QOkCD9auFvr9K9emt/VnmT6eiL0O24kEbYSQ9D0BNJJD5KMX69aphuevFXfNa9EdvIfnJCh89R7187mmTc373DK3dfqv8j3ctzVx/d136M6jwNqd3YacglcyW0rFkQ/8ALMZ7fzr0K11GOfaysFce+PwrhreNY40QLgKMAfStSxnWBwssZaMjJ55U1+f1ZKc2z35Rv7yO/trptmSx69Rg1oR3JC5D579K5WxKy/8AHvOCp5KP/jWpGsoyuxTz2ahXSujklZs03vDt44PSqM9y+RuOAepNIyOOArjvgHNQm0kc5ZDj/aPSpabVwTSGSXOCdp3CkBd1y5IX0FTraRqgMjDJGMA1IZLSFCuc47msnHuWpdiBABjHJPFX7TGwHHPrVEXiM+IoyR9MCpoZG25Ybe+c1DSWxV31NRWyPkwe2DUFxkg857cVHA4ClmOW9M0ssylSuOauLutRvRmbdcEA5I4G4daKmkIJy+0nHpRV2RLZ82hvzpwI4qEHgD1p4NfuEWfDtEoPHtTg2aizSg9a1TIaJQaXPIqNT2pynNUmS0Oz/kUpNMzmjPOKdxWHZ4NITx603NHekOwueaQtx/jSZ5FNJ6ZpXHYcW4pM8mkzxSZ5pMdh2euaTPHNNJo96VwsOzjFJn1/KmgignFTcdhwPNLu9TTN2O1GcUrhYk3Y4Jo3HtUZPOKM46VIWJC2PSrNlfT2UpktpCjkYOOhHvVLcD2oJ5rKcI1IuM1dPoXGTg+aLszSuNUnn5kIOfSqTyFyNxziogcg00msKODoYf8AhQUfRG1XE1q2lSTY8n14oB4xTAe3rR9fpXQYleMn+1rv3hQ/rVzPI9fSqCnGsSf7Vsv/AKEKuDr9KzpvR+rLmtvRfkPzyc/yp6sUYFThwcg+hqHcOmKcrcDHpVshHomjzre2sM/GSvzAdiOtaB6xsPpXCeG9Sa0vUibcYZmC4HZuxrv4AskYJr8szzL/AKliGo/DLVenb5H2GX4r29JN7rRk1qREwL8KT2roI5ZY0DEytFjiSM7sfhWLZgGI7ucHFXo45UwYZNkn6Z+leJGpy6M7alJT1W5aN6SxC3xGf7y4NMVLmchTfcH0qlH4iVJzFc2iPJ0ypBH8qvxeKFjUbbRQenBA/pW3uv4v6/E5mmtkXYtFkY5e6unPfAwKtw6JCozKGPuz5NY58SXs7fukjUf7RJqvPc3twCZbt1HpGMUuWL1SHzSWj0OlNrbRgjqR71XMkBfC4wOtYP2TzBzcXB7HLVLFZKnCyOM+9Q03pZDTW9zbknQ98D6dKYHLMW/AVnCIqAQ7dccmnuXTGG5PApWGmWpJxyqjc3tRUCN5aADqen1oq0wP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrathin pancreatoscopes with an external diameter of 5 mm have been developed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jurgen F Riemann, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_16_7439=[""].join("\n");
var outline_f7_16_7439=null;
